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  v 
ABSTRACT 
 
CD23, the low affinity IgE receptor, is expressed by various cell types and has 
numerous functions depending on the form of the protein, its interaction with 
various ligands and the type of cell involved.  CD23 is pivotal in the regulation of 
IgE, with the soluble form involved in up-regulation, while the membrane bound 
form is involved in the down-regulation.  It is clear why it is believed to be a 
central molecule in allergic responses, and a therapeutic target for the treatment 
of allergic disease.  In this study a recombinant form of the entire extracellular 
domain of the protein, exCD23, was produced by PCR cloning and expressed in 
E. coli.  His•Tag™s were introduced onto the C-terminus and N-terminus, 
respectively, in order to simplify the purification procedure.  After renaturation 
and purification, the recombinant exCD23 bound IgE, indicating its activity.  From 
the IgE binding studies it was established that the position of the tag did not 
influence the binding.  GST•Tagged™ exCD23 was also produced in an attempt 
to increase the solubility of the recombinant protein, but this proved 
unsuccessful.  Butyrate differentiated EoL-1 cells were treated with the N-
terminal His•Tagged™ exCD23, and the protein appeared to suppress the 
secretion of the constitutively expressed cytokines, especially IL-8 and IFN-γ, 
when compared to untreated cells.  In addition, treatment of the EoL-1 cells with 
exCD23 had a significant proliferative effect, but could not induce differentiation 
of this cell line into mature eosinophilic-like cells.   
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CHAPTER ONE – LITERATURE REVIEW 
 
1.1  INTRODUCTION 
Immunity can be defined as the ability to resist disease (Lawrence, 2000).  All 
vertebrates have an immune system capable of distinguishing between ‘self’ and 
‘nonself’ molecules, with the detection of nonself molecules resulting in their 
destruction (Nelson and Cox, 2000).  Most animals show innate immunity, it is 
genetically determined, potentially fully developed at birth and is not altered by 
subsequent exposure to antigens (Ag), where an Ag is defined as any molecule 
or pathogen able to elicit an immune response (Hickman et al., 1997).  Innate 
immunity includes mechanisms to protect the host against invasion by a foreign 
body or infectious agent.  Examples include physical barriers, high stomach 
acidity and the ability to rapidly repair damaged tissues.  In addition, vertebrates 
have a specialised system of nonself recognition that results in increased 
resistance to a specific foreign substance, known as adaptive immunity (Hickman 
et al., 1997).  Adaptive immune responses consist of two components: the 
production of antibodies circulating in the blood, known as the humoral immune 
response, and the production of cytotoxic and helper T cells, known as the cell-
mediated, or cellular immune response (Lawrence, 2000).  The humoral immune 
response is directed at bacterial infections and extracellular viruses, but can also 
respond to individual proteins introduced into the host.  The cellular immune 
system destroys host cells infected by viruses, and also destroys parasites and 
foreign tissues (Nelson and Cox, 2000).   
 
At the heart of the humoral immune response are soluble proteins called 
antibodies or immunoglobulins (Ig).  These proteins bind bacteria, viruses or 
large molecules identified as foreign and target them for destruction.  The basic 
antibody molecule consists of four polypeptide chains, two identical light chains, 
and two identical heavy chains, held together by hydrogen and disulphide bonds 
in a Y-shape (Hickman et al., 1997).  The heavy and light chains are made up of 
two regions – a constant region, which does not vary significantly between 
  2 
antibodies of the same subclass, and a variable region, which contains varying 
sequences between antibodies.  Each branch of the top of the Y contains a 
single antigen-binding site, able to bind compatible antigenic determinant sites.  
These branches are referred to as the Fab regions as they are the antigen-
binding fragments (Nelson and Cox, 2000), while the stalk of the Y is the 
crystallisable fragment (Fc), and contains the site where the antibody molecule 
binds to host cells.  Five subclasses of human heavy chains exist called gamma 
(γ), alpha (α), mu (µ), delta (δ) and epsilon (ε).  The properties of these five 
heavy chains determine the five Ig classes – IgG, IgA, IgM, IgD and IgE.  Each 
subclass differs in its half-life, distribution and interaction with the other 
components of the host’s defence system (Prescott et al., 1996).  The class of 
the antibody determines its role in the immune response, but not the antigen that 
it recognises (Hickman et al., 1997). 
 
1.2  IgE AND HYPERSENSITIVITY 
IgE makes up only 0.00005% of the serum antibody pool and contains the classic 
skin-sensitising and anaphylactic antibodies.  The crosslinking of IgE antibodies, 
bound to its receptors on tissue mast cells or blood basophils, initiates an 
immediate reaction in allergic individuals, when exposed to only minute amounts 
of allergen.  Cell bound IgE molecules crosslink by binding to the same Ag, and 
this reaction causes the cells to degranulate, releasing histamine and other 
mediators promoting an immediate inflammatory response (Prescott et al., 1996).  
A late-phase response associated with the influx of T cells, monocytes and 
eosinophils may follow some hours after the initial immediate response (figure 
1.1).  Examples of common allergies caused in this way are hayfever, asthma, 
eczema and more dangerously, manifestation of systemic anaphylaxis (Gould et 
al., 2003).  
 
IgE only exerts its biological function through its interaction with cell surface 
receptors that are specific for its Fc region.  The release of mediators by the 
degranulation of Fc receptor (FcR)-bearing cells or the synthesis of newly formed 
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active molecules is an essential component of many antibody-dependent 
reactions that are involved in pathogen defence or allergic disorders.  The 
resultant dramatic release of a number of potent proinflammatory mediators 
triggered by FcR aggregation is recognised as anaphylaxis and allergic disease 
(Dessaint et al., 1990). 
               
Figure 1.1 – The role of IgE in Type I hypersensitivity.  Permanent binding 
of IgE through its high affinity receptor leads to permanent sensitisation of 
mast cells.  The release of mast cell mediators results in the influx of 
inflammatory cells, causing the late-phase response.  Figure taken from 
WHO (1999).   
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Allergen-specific IgE antibodies that are permanently bound to their high affinity 
receptors (FcεRI) result in permanent sensitisation of the mast cells and are 
therefore responsible for the immediate hypersensitive response.  A number of 
factors contribute to such enduring sensitisation, including homing of mast cells 
to mucosal tissues, local synthesis of IgE, induction of FcεRI expression on mast 
cells by IgE, and the exceptionally slow dissociation of IgE from its high affinity 
receptor (Ka ~ 1010M-1).  The mast cell mediators, released after initiation, also 
result in the influx and activation of inflammatory cells, directing the late-phase 
response to these sites (Gould et al., 2003).  In vivo studies on mice have 
revealed that IgE also upregulates FcεRI on basophils, thereby further increasing 
the sensitisation of these cells (Lantz et al., 1997). 
 
FcεRI was the first IgE receptor identified, and is abundant on mast cell and 
basophil membranes (200 000 molecules/cell).  It is expressed at much lower 
levels on Langerhans cells, monocytes, platelets and eosinophil membranes 
(Gould et al., 2003).  A second IgE receptor, FcεRII, was later discovered on B 
cells, which binds the antibody with a lower affinity (Ka ~ 107 M-1).  This 
interaction is involved in both IgE regulation and allergen presentation (Sutton et 
al., 2000).  FcεRII, also referred to as CD23, was first described as an activation 
marker on B cells stimulated with Epstein-Barr virus (EBV), and was later shown 
to be identical to the low affinity receptor for IgE (Kolb et al., 1993).  Multiple 
biological functions have been reported to involve CD23 (Kolb et al., 1994), but 
understanding the functional roles of this molecule is complicated by the fact that 
it exists in two isoforms (a and b), and furthermore, can be present in both 
monomeric and oligomeric states (Sutton et al., 2000).  
 
1.3  CD23 
1.3.1  STRUCTURE 
The two IgE receptors have very different molecular structures.  FcεRI belongs to 
the immunoglobulin superfamily and shares a number of attributes with most 
other FcRs (Sutton et al., 2000).  FcεRI is expressed as an αβγ2 heterotetramer 
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on mast cells, basophils and possibly eosinophils, and as an αγ2 heterotrimer on 
monocytes and platelets (Gould et al., 2003).  CD23 on the other hand is a type II 
integral membrane glycoprotein with a molecular mass of 45 kDa and is a 
member of the C-type (calcium dependant) lectin superfamily (Mossalayi et al., 
1992), with four highly conserved and two partially conserved cysteines 
(Bonnefoy et al., 1995).  It is also closely homologous, and genetically linked on 
human chromosome 19, to the C-type lectin DC-SIGN (Hibbert et al., 2005).   
CD23 binds IgE in an unusual non-lectin-like manner, requiring calcium but not 
carbohydrate (Wurzburg et al., 2006).  The lectin domain is found at the distal, C-
terminal end of the extracellular sequence.  The lectin domain is separated from 
the cell membrane by a heptad hydrophobic repeating sequence, containing a 
hydrophobic amino acid, usually leucine, which forms a three-stranded, 15nm 
long α-helical coiled coil stalk, sometimes referred to as the leucine zipper.  A C-
terminal tail extends from the lectin domain (Gould et al., 2003).  Figure 1.2 
shows a diagrammatic representation of the structure of the CD23 membrane 
bound protein.  The coiled coil stalk region leads to trimer formation and is 
important for binding IgE.  The long stalk is necessary for proper orientation of 
the lectin heads to interact with IgE (Sancho et al., 2000).  CD23 contains a 
reverse RGD motif near the C-terminus, a common recognition site in integrin 
receptors, and one consensus sequence for N-glycosylation.  Although these 
sequences may not be essential for cytokine activities, they may be important in 
membrane CD23 linkage with appropriate carbohydrates to the extracellular 
matrix (Mossalayi et al., 1992).  
 
CD23 has a short cytoplasmic domain containing 21 amino acid residues, and a 
long extracellular domain.  A hydrophobic stretch of 26 amino acids is located 
between positions 21 and 47 at the transmembrane region (Mossalayi et al., 
1997), as shown in figure 1.2.   
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Figure 1.2 – Diagrammatic representation of the CD23 protein structure 
(modified from Shakib et al., 1998).  The arrow marked with an asterisk 
indicates the first amino acid used for cloning of the CD23 protein in this 
study.   
 
X-ray crystallography of related C-type lectin-like domains has shown one to 
three calcium binding sites per domain (Zelensky and Gready, 2003).  Ca2+ site 2 
in CD23 is reasonably well conserved, but Ca2+ site 1 is poorly conserved.  In 
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other related C-type lectin-like domains, site 2 is directly involved in binding 
carbohydrates.  However, nuclear magnetic resonance (NMR) spectra confirmed 
occupation of only Ca2+ site 1 of CD23 (Hibbert et al., 2005).  Since site 2 is 
involved in carbohydrate recognition in other C-type lectin-like domains, these 
results suggested that glycosylation was not required in binding IgE or CD21, two 
important ligands of CD23 (see section 1.3.5).  Hibbert et al. (2005) therefore 
concluded that calcium was not required to stabilise the configuration of CD23 for 
binding to these ligands, but that it affected the conformation of certain loops.  
The crystal structure of human CD23, determined by Wurzburg et al. (2006) 
differs from the NMR structure determined by Hibbert et al. (2005).  The crystal 
structures show that calcium binding occurs at the principle binding site, but not 
at an auxiliary site that appears to be absent in human CD23.  Conformational 
differences between the apo and Ca2+ bound structure suggest how IgE-Fc 
binding can be both calcium dependent and carbohydrate-independent 
(Wurzburg et al., 2006).    
 
1.3.2  DIFFERENT FORMS OF CD23 
CD23 exists in two forms; a membrane bound CD23 (mCD23) molecule, and a 
soluble form (sCD23).  mCD23 is found in the cell membrane as an equilibrium 
mixture of a 45 kDa monomer and a trimer, with the formation of trimers leading 
to a 10-fold greater affinity for IgE (Gould et al., 2003).  The efficient interaction 
with IgE is permitted by the trimer formation mediated by the α-helical coiled coil 
stalk (Sancho et al., 2000); it is this α-helical coiled coil stalk that promotes self-
association of the molecule (Hibbert et al., 2005).  mCD23 is cleaved in the stalk 
region by proteolysis into soluble forms of various molecular sizes (Armant et al., 
1994).  These fragments have differing trimerisation tendencies, depending on 
the length of the residual stalk (Hibbert et al., 2005).  The proteolytic cleavage of 
intact, cell-bound human CD23 results in the formation of soluble fragments with 
molecular masses of 37, 33, 29, 25 and 16 kDa, the first three of which show 
potent cytokine-like activities (Bailey et al., 1998).  The 37, 33 and 25 kDa sCD23 
molecules retain the ability to bind IgE (Letellier et al., 1990).  The cell surface 
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CD23 is cleaved in the stalk region by an endogenous membrane-bound 
metalloprotease (Sutton et al., 2000).  The soluble fragment released after 
cleavage is 37 kDa in size and still contains the lectin domain with an intact tail 
and part of the stalk.  Further cleavage of sCD23 at specific sites yields a 
relatively stable 16 kDa fragment, containing the lectin domain and the proximal 
part of the C-terminal tail.  Digestion by Der pI protease, from the house dust 
mite, Dermatophagoides pteronyssinus, also yields the 16 kDa fragment (Shakib 
et al., 1998). 
 
1.3.3  mCD23 
There are two isoforms of membrane bound CD23 differing by 6 amino acids in 
the N-terminal cytoplasmic region (see figure 1.2), and these two forms 
determine different signalling properties (Sancho et al., 2000).  The two isoforms 
occur as a result of alternative splicing (Kolb et al., 1994), with different cell 
specific transcriptional start sites leading to distinct 5’ leader sequences in the 
corresponding mRNA (Mossalayi et al., 1997).  CD23a is expressed on isolated 
B cells, while CD23b has been detected on B and T lymphocytes, monocytes 
and eosinophil cell lines only after induction with interleukin 4 (IL-4) (Kolb et al., 
1993).  
 
1.3.3.1  Functions of CD23a 
CD23a facilitates antigen presentation in human B cells and is involved in the 
control of IgE synthesis (Yu et al., 1994).  CD23a mediates IgE dependant Der pI 
allergen presentation to Der pI-specific T cell clones in vitro (Van der Heijden et 
al., 1993).  Antibodies against either CD23 or CD21 inhibit antigen presentation 
(Gould et al., 2003).  It has been shown that ligation of human B cells by specific 
monoclonal antibodies activates G protein pathways through a rapid increase in 
calcium influx, followed by the generation of inositol triphosphate after 
phospholipase C dependant hydrolysis of phophatidylinositol (4,5)-bisphosphate 
(Kolb et al., 1990).  It has been suggested that a G protein couples membrane 
CD23 to a phospholipase C (PLC) in human B cells (Mossalayi et al., 1997).  
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Another study showed the tight association between CD23a and the src-related 
kinase p59fyn following transfection into an NK-cell line (Mossalayi et al., 1997).  
Kolb et al. (1993) also showed that crosslinking of CD23 on either resting or IL-4 
stimulated B cells results in an accumulation of cAMP, showing a functional 
relationship between IL-4 receptor and CD23a at the level of adenylyl cyclase 
activation.   
 
Signalling through CD23a therefore involves the triggering of two different 
pathways.  Firstly, the main pathway involved in serotonin release and tumour 
necrosis factor α (TNFα) production involves a G protein and src-related kinase 
Fyn that results in PLC activation.  The second pathway triggered by CD23 
ligation leads to the generation of cAMP (Sancho et al., 2000). 
  
1.3.3.2  Functions of CD23b 
CD23b mediated functions are strictly dependant on CD23 crosslinking by IgE 
immune complexes, intact CD23 monoclonal antibodies or F(ab’)2.  Therefore, 
high surface density of CD23b is required for optimal signalling (Mossalayi et al., 
1997).  CD23b triggers an increase in cAMP (Sancho et al., 2000).  An 
accumulation of intracellular cGMP and cAMP was found to occur in human 
monocytes and macrophages after induction by IgE immune complexes, in 
agreement with the fact that cyclic nucleotides directly stimulate TNFα production 
by these cells.  In contrast to CD23a, crosslinking of CD23 on all other human 
cells had no significant effect on calcium influx and the phosphoinositide pathway 
(Mossalayi et al., 1997). 
 
The role of nitric oxide (NO) in the generation of cGMP was proposed in various 
cellular models.  NO is a short lived biological mediator produced by nitrogen 
hydroxylation of L-arginine in many cell types.  This reaction is catalysed by NO 
synthase (NOS), and plays an important role in vasodilatation and 
neurotransmission (Mossalayi et al., 1997).  Induction of NO production through 
the activation of NOS II was followed by the generation of cGMP and nitriles, end 
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products of the NO pathway, in human monocytes/macrophages, eosinophils, 
myeloid leukemias and epithelial cells (Mossalayi et al., 1997).  These data 
indicate the importance of NO and cyclic nucleotides in membrane CD23b signal 
transduction.   
 
CD23 ligation led to activation of NF-κB and the modulation of proto-oncogene 
expression in promonocytic U937 cells (Mossalayi et al., 1997).  The nuclear 
factor NF-κB was found to be the main transcription factor involved in signal 
transduction by CD23 in monocytes and the promonocytic cell line U937 (Ten et 
al., 1999a).  NF-κB is a transcription factor that activates transcription of genes 
responsible for mediating immune functions.  NF-κB is inactivated in the 
cytoplasm by inhibitory protein IκB.  However, IκB is phosphorylated and 
degraded after cell activation, allowing NF-κB to be released, hence allowing 
transcription of multiple genes important for immune responses (Ten et al., 
1999a).   The results obtained in this study showed that phosphorylation of IκBα 
did not occur directly after CD23 crosslinking on monocytes, suggesting a key 
role of a tyrosine kinase (TK) in the CD23 initiated transduction pathway, 
ultimately resulting in IκBα phosphorylation and NF-κB activation.  It was later 
found that phosphorylation of IκBα occurred at Ser32 and Ser36 residues, and that 
CD23 crosslinking in monocytes induced the activation of tyrosine kinase, 
followed by the activation of IκB kinase (IKK) which phosphorylates IκBα, causing 
its degradation and resultant NFκB activation and gene transcription (Ten et al., 
1999b). 
 
The ability of CD23 to transmit signals to various cells, together with its short 
intracytoplasmic domain, strongly suggests that it may be associated with other 
molecules involved in signal transduction (Mossalayi et al., 1997). 
 
Membrane bound CD23 ligation induces the release of various inflammatory 
mediators from human macrophages, eosinophils and epithelial keratinocytes.  In 
addition to NO and peroxides, CD23 ligation induced rapid TNFα gene 
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transcription and the release of TNFα, IL-1 and IL-6 by human macrophages and 
keratinocytes (Mossalayi et al., 1997). 
 
1.3.4  sCD23 
The soluble fragments of human CD23 are generally produced by the cleavage 
of the cell surface membrane CD23, but a small fraction may also be found 
intracellularly (Mossalayi et al., 1997).  Several different forms of sCD23 exist, 
ranging in size from 25 to 37 kDa, and retain IgE binding ability.  The cleavage of 
membrane CD23 also generates poorly characterised smaller fragments that do 
not bind IgE (Mossalayi et al., 1997).  Membrane CD23 and sCD23 may have 
opposite effects on the regulation of IgE synthesis (Gould et al., 2003), with 
sCD23 responsible for the up regulation of IgE, but only in its trimeric form, not 
as a monomer.  Membrane bound CD23 is responsible for the down regulation of 
IgE synthesis (Sutton et al., 2000). 
 
sCD23 may exert several regulatory effects, either alone or in conjunction with 
other cytokines, on a large variety of cells, especially those derived from bone 
marrow.  Signal transduction by sCD23 depends on the type of cell, the ligands, 
and the co-factors required for its functions (Mossalayi et al., 1997).  The sCD23 
domain necessary for cytokine activity is distinct from the IgE binding domain, 
with the presence of Cys288 essential for the former (Mossalayi et al., 1992).  
However, the role of Cys288 in cytokine activity may not act through the free SH 
group, but it may form a disulphide bridge with another Cys residue, and thus, 
sCD23 may function as a dimer (Mossalayi et al., 1992). 
 
It has been shown that sCD23 promotes differentiation of germinal centre B cells 
into plasma cells in vitro, possibly interacting with CD21 and thus extending the 
lifetime and capacity of these cells to proliferate.  It also promotes the growth and 
differentiation of basophils and T cells from their respective precursor cells 
(Gould et al., 2003).  CD23 fragments have also been found to stimulate the 
synthesis of IgE in B cells after incubation with IL-4 and anti-CD40, allowing 
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greater proliferation and hence facilitating class switching to IgE (Aubry et al., 
1992).  sCD23 produced by epithelial cells has been shown to potentiate 
histamine release, and may also act as a co-factor for inducing TNFα, IL-1 and 
soluble IL-1 receptors from activated human monocytes (Mossalayi et al., 1997). 
 
Although sCD23 is involved in the regulation of IgE, most of the activities of 
sCD23 are pleiotropic and IgE independent.  Armant et al. (1994) investigated 
the effect of sCD23 on cytokine production in human peripheral blood 
mononuclear cells (PBMC).  It was demonstrated that sCD23 enhanced the 
production of induced interferon γ (IFNγ), by acting as a costimulator to IL-2 and 
IL-12, and acted directly as a potent inducer of TNFα.  In addition, sCD23 
triggered the release of other inflammatory mediators such as IL-1α, IL-1β and 
IL-6 (Armant et al., 1994).  Thus sCD23 appears to act as a proinflammatory 
cytokine, and may play an important role in controlling the immune system 
response, with the ability to enhance IFNγ and trigger TNFα underlying its 
potential role in controlling the immune response (Armant et al., 1994). 
 
sCD23 has been shown to influence myeloid cells in a number of ways, and 
results in the differentiation and proliferation of these cells, as well as initiating 
histamine synthesis.  sCD23 was also found to induce tyrosine phosphorylation 
of a 38 – 40 kDa substrate (Mossalayi et al., 1997). 
 
sCD23 has also been shown to influence the action of IL-7 (Jeannin et al., 1998).  
IL-7 is a B cell growth factor produced by bone marrow stroma cells and follicular 
dendritic cells in primary lymphoid follicles and germinal centres.  IL-7 was found 
to play a role in the regulation of human isotype switching, by synergising with IL-
4 to induce IgE synthesis.  The presence of T cells is required for this effect to 
occur and is caused by an enhancement of sCD23 and IL-9 production (Jeannin 
et al., 1998). 
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The role of nitric oxide (NO) in the accumulation of cGMP was described in 
human monocytes by Aubry et al. (1997).  As previously mentioned, NO is a 
biological mediator that activates cGMP production, a known second messenger 
molecule in various systems, and its importance in mCD23 signal transduction 
has already been discussed.  However, Aubry et al., (1997) showed that soluble 
CD23 triggered an early increase in cGMP accumulation through NO generation.  
This reaction was found to be calcium dependant and sCD23 was shown to 
induce a calcium influx in the monocytes (Aubry et al., 1997).   
 
Expression of sCD23 by human monocytes was investigated by Alderson et al. 
(1992).  This study showed that IL-3, IL-4 and granulocyte-macrophage colony 
stimulating factor (GM-CSF) increased the expression of both mCD23 and 
sCD23 by human monocytes, as well as increasing the sCD23 levels in cultures 
of whole human blood.  IL-4, GM-CSF and IFNγ were found to increase surface 
and soluble CD23 expression by the monocytic cell line U937 (Alderson et al., 
1992).  
 
In short, several biological activities have been ascribed to both sCD23 and 
mCD23 by numerous authors.  An attempt to summarise these multiple functions 
is shown in table 1.1.  
 
Table 3.1 – Summary of the various cytokine-like effects of CD23 on a 
variety of immune system cells 
Cell type CD23 species 
responsible 
Effect 
sCD23 induces IgE production4 
16 kDa sCD23 inhibits IgE release3 
CD23 
activation, proliferation, cell adhesion and antigen 
presentation to T cells4 
 
 
 
 
B cells 
crosslinking CD23 
phosphoinositide hydrolysis5 
Ca2+ mobilization5 
cAMP accumulation5 
G-protein in PIC (phosphoinositidase C) activation5 
CD4+ T cells sCD23 and IL-1 increases response to CD2 ligation3 
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Cell type CD23 species 
responsible 
Effect 
CD7+ thymocytes sCD23 
induces CD3/TcRαβ expression4 
deletion of TcRδ4 
CD7+ CD3- thymic/ bone 
marrow precursors sCD23 and IL-1 
differentiation3 
down regulates apoptosis3 
CD34+ bone marrow 
precursors sCD23 
generates myeloid colonies4 
induces basophil development4 
sCD23 differentiation and proliferation3 
sCD23 tyrosine phosphorylation of 38 – 40  kDa substrate3 Myeloid cells 
sCD23 stimulates IL-3 histamine synthesis3 
Germinal centre 
centrocytes sCD23 
stops apoptosis, thereby allowing differentiation into 
plasmocytoid cells4 
sCD23 
generates NO, increased cGMP2 
increases Ca2+ influx2 
sCD23 (co-factor with 
IL-2 and IL-12) 
increases TNFα, IL-1α, IL-1β, soluble IL-1 
receptors3 
CD23 
cell adhesion and Ag presentation to T cells4 
cAMP accumulation5 
Monocytes 
crosslinking CD23 
activates TK, activates IKK, phosphorlyates IκBα, 
activates NF-κB, increases IL-1β, TNFα6 
CD23 cell adhesion and Ag presentation to T cells4 
mCD23 release of various inflammatory mediators4 Macrophages 
CD23 ligation releases NO, peroxides, TNFα, IL-1, IL-64 
Alveolar macrophages CD23 ligation 
secretes arachidonic acid metabolites6 
releases oxygen radicals6 
releases multiple monokines6 
sCD23 increases TNFα, IL-1α, IL-1β, IL-61 
PBMC sCD23 (co-stimulated 
IL-2/IL-12) increases IFNγ1 
mCD23 releases various inflammatory mediators4 
Keratinocytes CD23 ligation releases NO, peroxides, TNFα, IL-1, IL-64 
Eosinophils mCD23 releases NO, peroxides, TNFα, IL-1, IL-64 
1Armant et al., 1994  2Aubry et al., 1997  3Mossalayi et al., 1997  4Mossalayi et al., 1992  5Kolb et al., 1994  
6Ten et al., 1999b 
 
As table 1.1 shows, the regulation of expression of CD23 on cell types other than 
B cells is less well understood (Alderson et al., 1992), and this needs to be 
investigated in order to better understand the role of IgE and its receptors in 
allergic responses. 
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1.3.5  THE INTERACTION OF CD23 WITH ITS LIGANDS 
The lectin domain and tail of the CD23 molecule contain the binding sites for all 
the known ligands of CD23.  The molecule displays the ability to bind various 
biological ligands, including IgE, complement receptors CR2, CR3 and CR4, also 
called CD21, CD18-CD11b, and CD18-CD11c, respectively, and vitronectin 
(Mossalayi et al., 1997).  The interactions of CD23 with IgE and CD21 are pivotal 
in IgE regulation.  The NMR structure of derCD23, the Der pI fragment, was 
determined by Hibbert et al. (2005).  They found a marked polarity in its 
electrostatic character.  The surface was highly charged, but the positive and 
negative charges were found on opposite faces of the molecule.  The highly 
charged character affects how CD23 interacts with ligands and appears to be 
particularly important in self-association (Hibbert et al., 2005).     
 
The IgE binding domain is present in a region of 128 amino acids, residues 160 – 
287.  Calcium ions must be present in the conserved carbohydrate recognition 
sites in order to maintain the native structure of the lectin domain and for the 
recognition of the carbohydrate substituents on the complement receptors (Gould 
et al., 2003).  The binding sites on IgE for FcεRI and CD23 are located close to 
one another, explaining why high concentrations of soluble CD23 are able to 
block the binding of IgE to mast cells or basophils (Mossalayi et al., 1997).  The 
fact that CD23 has various functional epitopes makes it possible to bind a range 
of different ligands, thereby providing exciting prospects for possible mechanisms 
of cellular interactions between CD23+ cells and other haematopoietic cells 
(Mossalayi et al., 1992). 
 
Despite the fact that CD23 is a lectin-like molecule, meaning that it binds to sugar 
residues (Lawrence 2000), it does not bind to the carbohydrate component of 
IgE, and only recognises protein epitopes in IgE.  CD23 binding to galactose 
residues plays a role in cell aggregation of EBV-transformed B cells (Mossalayi 
et al., 1997).  CD23 interacts with another B cell surface molecule, CD21 (Sutton 
et al., 2000).  CD21 is a coreceptor for CD23 and is a type I integral membrane 
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protein.  CD21 plays a role in B cell survival and specification of IgE (Gould et al., 
2003).  Both the binding of IgE to CD23 and the interaction of CD23 with CD21 
are calcium dependant (Bonnefoy et al., 1995), and occur at independent sites 
on the CD23 molecule (also independent from the trimerisation interface), 
allowing the formation of a tri-molecular complex of IgE-CD23-CD21 (Hibbert et 
al., 2005). 
 
T cells and thymocytes ligate sCD23 through CD21 expressed on the cell 
surface.  This enables them to mediate CD21 related signal transduction 
(Mossalayi et al., 1997).  CD21 contains a cytoplasmic domain that has potential 
protein kinase C (PKC) and tyrosine kinase sites (Mossalayi et al., 1997).  CD21 
comprises a tandem array of 15-16 short consensus repeat domains.  CD23 
binds to domain 1-2 (D1-2) and domains 5-8 (D5-8) via protein-protein and 
protein-carbohydrate interactions, respectively (Aubry et al., 1994).  
 
Hibbert et al. (2005) showed that a single lectin domain of CD23, with a complete 
tail region, contains the complete binding site for the CD21 region D1-2.  sCD23 
enhances IgE synthesis by binding to CD21 (figure 1.3b).  However, in the 
membrane form when CD23 binds IgE, further IgE synthesis is suppressed 
(figure 1.3a). 
 
Hibbert et al. (2005) found that B cells express membrane IgE and CD21 before 
differentiating into IgE-secreting plasma cells.  The up-regulation of IgE by 
sCD23 may therefore be explained by co-crosslinking of membrane IgE and 
CD21 on these transitional cells, causing selective proliferation of these cells and 
subsequently higher levels of IgE synthesis (Hibbert et al., 2005).  mCD23 on the 
other hand is associated with the down-regulation of IgE synthesis.  The binding 
of mCD23 to IgE prevents cleavage of CD23 and the release of sCD23 
fragments that stimulate IgE synthesis.  Since IgE has been shown to 
cooperatively bind two lectin domains of CD23 and appears to promote 
oligomerisation of CD23 (Hibbert et al., 2005), IgE might stabilise the trimeric 
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form of mCD23 on the cell surface, making it less susceptible to proteolytic 
cleavage. 
   
 
 
 
 
 
 
 
 
 
Figure 1.3 – Competition between CD23 and CD21 for membrane IgE on the 
B cell surface.  (a) shows how co-crosslinking of membrane CD23 and IgE 
by an Ag-IgE complex leads to suppression of IgE synthesis, while (b) 
shows how the co-crosslinking of trimeric sCD23, membrane IgE and CD21 
leads to increased IgE synthesis.  Figure taken from Hibbert et al. (2005). 
    
1.4.  EOSINOPHILS 
Eosinophils are actively motile, terminally differentiated leukocytes derived from 
the bone marrow and have been identified in many mammalian and non-
mammalian species (Lynch et al., 1999).  A hallmark of allergic disease is the 
infiltration of the tissues with increased numbers of eosinophils, known as 
eosinophilia (Gould et al., 2003).  In humans, eosinophils were initially thought to 
be primarily involved in immune defence against parasites, with disease 
characterised by elevated IgE levels, including IgE specific for schistosomes, and 
blood and tissue eosinophilia.  Studies have found that eosinophils bearing 
cytophilic IgE are crucial in protection against schistosomiasis (Gould et al., 
2003).  However, it is now recognised that eosinophils are involved in a number 
of allergic and non-allergic diseases, including hypereosinophilic syndromes, 
eosinophilic pneumonia, atopic dermatitis, asthma and rhinitis (Lynch et al., 
1999).   
 
(a) (b)
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Activation of eosinophils is thought to cause localised tissue damage through the 
release of specific molecules from the eosinophilic cells.  The relatively 
eosinophil-specific basic proteins stored in granules and released by these cells 
include major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil 
peroxidase (EPO), and eosinophil neurotoxins (Gould et al., 2003).  All these 
proteins are toxic to helminthic parasites, but also to the bronchial epithelial cells, 
causing tissue injury, contraction of the smooth muscle of the airways and 
bronchial responsiveness to a wide range of spasmogens (Lynch et al., 1999).  
The release of leukotriene C4 (LTC4), EPO, eosinophil-derived neurotoxin (EDN), 
IL-3, GM-CSF and superoxide ions from eosinophils are regulated by integrins, 
and will only be released when attached to counter ligands in the extracellular 
matrix or plasma proteins (Lynch et al., 1999).  Therefore, eosinophils do not 
release these products in suspension, and the respiratory burst (production of 
toxic oxygen metabolites, namely superoxide ions) will only occur when the cells 
are adhered, and in culture this would be to an albumin-coated plate (Lynch et 
al., 1999).   
 
Hypodense eosinophils, defined by lower than normal density in Percoll 
gradients, have been isolated from patients with hypereosinophilic syndromes or 
from hosts infected with Schistosoma mansoni (Owen et al., 1987).  These 
hypodense eosinophils show enhanced antibody-dependant cytotoxicity and 
generate more LTC4 when stimulated with calcium ionophore (Owen et al., 
1987), indicating the importance of the hypodense phenotype in the allergic 
response.     
 
1.4.1  EOSINOPHILS AND INFLAMMATORY REACTIONS, ESPECIALLY 
ASTHMA 
In inflammatory disorders like asthma, eosinophils become activated and migrate 
to airway mucosa, with eosinophilopoiesis modulated by T cell factors (Owen et 
al., 1987).  Bronchial asthma is characterised pathologically by an infiltration of 
eosinophils into the airway submucosa.  Studies suggest that CD4+ T cells of the 
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T helper 2 (Th2) phenotype play a critical role in the development of eosinophil 
accumulation, mediated by IL-5 (Coyle et al., 1996).  They are recruited to the 
tissues by adhesion of very late antigen (VLA)-4 to vascular cell adhesion 
molecule (VCAM)-1 (Gould et al., 2003).  IL-5, in addition to being a strong 
chemoattractant to eosinophils, is an important cytokine in the development and 
function of these cells.  In the bone marrow, it is responsible for the expansion of 
eosinophil precursors, and is a late differentiation factor for eosinophils.  IL-5 has 
the ability to prime eosinophils, increasing their responsiveness to mediators that 
stimulate degranulation, respiratory burst and chemotaxis.  Finally, it is important 
for eosinophil survival as it inhibits apoptosis in these cells (Palframan et al., 
1998).  
 
IL-5 is a well known endogenous eosinophilic chemoattractant (Wang et al., 
1989), and acts systemically to mobilise eosinophils from the bone marrow, 
involving adhesion interactions with the α4 (CD24d) and β2 (CD18) integrins 
(Palframan et al., 1998).  Another chemokine, eotaxin, was also found to play an 
important role in eosinophil mobilisation from the bone marrow.   
 
Chemokines are a superfamily of chemotactic cytokines that mediate leukocyte 
trafficking by binding to specific G-proteins linked to seven transmembrane 
spanning receptors.  Chemokines can be divided into three groups, depending 
on the primary sequence of the first two cysteines: the C-X-C, C-C and C families 
(Rothenberg et al., 1997).  The C-X-C and C families are active towards 
neutrophils and lymphocytes respectively, while the C-C chemokines are active 
towards macrophages, lymphocytes, basophils and eosinophils.  Eosinophil 
active chemokines include macrophage chemotactic protein 2 (MCP-2), MCP-3, 
MCP-4, macrophage inflammatory protein 1α (MIP-1α) and eotaxin (Rothenberg 
et al., 1997). 
 
Eotaxin is the main eosinophil chemotactic chemokine released in the lung in the 
guinea pig, and its mRNA is induced in multiple models of eosinophilic 
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inflammation and in human tissue in response to allergen challenge (Rothenberg 
et al., 1997).  Unlike many other chemoattractants, eotaxin is eosinophil specific.  
IL-5 and eotaxin were found to act cooperatively (Palframan et al., 1998), with 
eotaxin enhancing the magnitude of the early eosinophil recruitment after antigen 
challenge in asthma.  Eotaxin definitely shows a contributory role in the 
generation of peripheral blood and antigen-induced eosinophilia (Rothenberg et 
al., 1997). 
  
Eosinophilia in the airways thus occurs as a result of eosinophil infiltration 
caused by the chemotactic effects of IL-5 and eotaxin.  These cytokines are 
released after induction of a Th2 immune response, indicating the importance of 
Th2-derived cytokines in the initiation of bronchial asthma (Coyle et al., 1996).  
IL-5 was identified in eosinophilic granules, and blood eosinophils have been 
shown to secrete IL-5 after stimulation with IgE immune complexes (Dubucquoi 
et al., 1994).  Therefore, eosinophils can release significant amounts of IL-5 
themselves.  Thus they may be able to participate in local recruitment and 
activation during inflammatory diseases associated with eosinophilia (Dubucquoi 
et al., 1994). 
 
1.4.2  EOSINOPHILS AND IgE RECEPTORS 
Recently considerable new information concerning the functions of eosinophils 
and their role in disease has been obtained.  Correlations between the number of 
infiltrating eosinophils and the severity of asthma have been observed, while in 
allergic diseases there is also a close correlation between serum IgE levels and 
the prevalence and severity of the disease.  Thus it is reasonable to speculate 
that IgE is involved in the activation of eosinophils in these diseases (Kita and 
Gleich, 1997).  Indeed, Lantero et al. (2000) showed that IgE binding to the 
eosinophil surface receptors resulted in activation of the cells.  CD23 stimulation 
induced functional changes in blood eosinophils from atopic patients, 
characterised by increased eosinophil migration, with enhanced expression of 
late function antigen (LFA)-1 and macrophage antigen (Mac)-1.  
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There has, however, been some controversy in providing evidence of IgE 
receptors on eosinophils, exacerbated by the discrepancy between human and 
mouse eosinophils, the latter lacking IgE receptors (Kita and Gleich, 1997) and 
are often used as models for human disease.  IgE receptors were first 
characterised on human eosinophils by binding and functional assays (Capron et 
al., 1981, 1984).  The inhibitory effects of anti-CD23 antibodies on IgE-dependent 
functions of these cells then indicated that eosinophils could express this 
receptor (Capron et al., 1986), with flow cytometric analysis indeed revealing the 
expression of CD23 on human eosinophils, with large variability according to 
individual patients (Capron et al., 1991).  Soussi Gounni et al. (1998) showed 
molecular data to confirm the synthesis of CD23 by eosinophils, with a 
preferential expression in the hypodense population.  Both the CD23a and b 
isoforms were detected in human eosinophils as well as EoL-3 cells, an 
eosinophilic leukaemia cell line, with the CD23b isoform previously only detected 
on eosinophil cell lines, after induction with IL-4 (Kolb et al., 1993).  Thus there is 
now definitive proof that the low affinity IgE receptor synthesised and expressed 
by human eosinophils is identical to the CD23 molecule expressed by B cells.  In 
a study by Saini et al. (2000), it was found that CD23 expression on eosinophils 
was detected from a patient suffering with IgE myeloma, but no correlation was 
found between CD23 expression and circulating serum IgE levels in this patient, 
as was seen for basophils. 
 
The effects of IFNα, IFNγ, TGFβ (transforming growth factor β) and 
dexamethasone on CD23 expression on human eosinophilic cells was 
investigated by Watanabe et al. (1990).  This study demonstrated that CD23 
expression on the eosinophils was enhanced by both IFNα and IFNγ, and 
suppressed by TGFβ and dexamethasone, with the reagents influencing 
expression from mRNA level.  IFNγ appeared to preferentially enhance the 
release of surface CD23, which resulted in an increase of sCD23.  These 
molecules therefore play important regulatory roles in allergic and parasitic 
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responses by influencing CD23 expression on eosinophils (Watanabe et al., 
1990). 
 
The high affinity IgE receptor, on the other hand, is expressed on human and rat 
(Dombrowicz et al., 2000) eosinophils, but not on mouse eosinophils (Kita and 
Gleich, 1997) and is involved in degranulation as well as eosinophil-mediated 
cytotoxicity against parasites (Soussi Gounni et al., 1994). 
 
Although CD23 is a pluripotent molecule with pleiotropic effects on cell activation 
and proliferation (Soussi Gounni et al., 1998), literature is only available on the 
expression of CD23 by eosinophils, while the cytokine effects of sCD23 on these 
cells remains unknown. 
 
1.4.3  KNOWN CYTOKINE ACTIVITIES 
The major function of eosinophils in inflammatory or infectious responses was 
thought to be restricted to degranulation and release of highly cytotoxic proteins.  
However, in addition to being cytotoxic mediators, they have the ability to 
produce a large number of cytokines, including pro- and anti-inflammatory 
cytokines, growth factors and chemokines (Woerly et al., 1999a).  As already 
mentioned, eosinophils are known to release a number of molecules important in 
an immune response, including MBP, ECP, EPO, eosinophil neurotoxins, LTC4,  
IL-3, GM-CSF, superoxide ions and IL-5. However, there are a number of other 
molecules also released by these cells. 
 
Transforming growth factor α (TGFα) is a pleuripotent cytokine with diverse 
biological effects.  Most malignant tumours have been found to express TGFα, 
but it has been shown that normal tissue and cell types express TGFα as well, 
suggesting its ability to influence the proliferation of normal cells or neoplastic 
epithelial cells (Wong et al., 1990).  These authors also showed that human 
eosinophils express TGFα, with expression dependant on the microenvironment.  
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TGFα expression by tissue-infiltrating eosinophils indicates their contribution to 
physiological, immunological and pathological responses (Wong et al., 1990). 
 
The demonstration that eosinophils synthesise and release IL-5, IL-4 and IL-10 
suggested that they were able to participate in the regulation of the Th2 pathway 
of the immune response.  Eosinophilia is frequently associated with increased 
IgE levels, and appears to be mainly linked with the Th2 response.  However, it 
has been shown that IFNγ, IL-2 and IL-12, which are Th1 pathway cytokines, are 
present within eosinophils, indicating that they could play an important role in the 
modulation of the immune response in both type 1 and type 2 pathways (Woerly 
et al., 1999b).  However, the eosinophils used in this study were isolated from 
venous blood of patients with hypereosinophilia using immunomagnetic beads, 
with the purity of the eosinophil preparations usually greater than 97%.  
Therefore, T cells were possibly also present in the eosinophil preparations and 
their influence on this study should be kept in mind. 
 
Moqbel (1996) reviewed the synthesis and storage of regulatory cytokines in 
human eosinophils.  The cytokines associated with allergic inflammation and 
asthma, synthesised, stored and released by eosinophils include IL-1, IL-2, IL-3, 
IL-4, IL-5, IL-6, IL-8, TGFα and β, GM-CSF, and TNFα, as well as the 
chemokines RANTES and MIP-1α (Moqbel, 1996).  Thus eosinophils synthesise, 
store and release a broad range of cytokines as well as basic granule-derived 
proteins and lipid mediators, illustrating the capacity of this cell to participate in 
effector functions during allergic type reactions.  
 
Very few studies have reported the secretion of various cytokines by eosinophils, 
and since they are able to function as immunoregulatory cells involved in the 
release of both type 1 and type 2 cytokines, their functioning in the immune 
response needs to be investigated further. 
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1.5.  THERAPEUTIC APPLICATIONS  
IgE plays a central role in allergic disease, and since CD23 appears to be 
involved in the regulation of IgE synthesis (Kolb et al., 1994), its importance in 
the manifestation of allergies is apparent.  CD23 specifically binds IgE-allergen 
complexes thus playing an important part in pathogenesis of IgE mediated 
immunity (Ten et al., 1999a).  The interactions between IgE and its receptors 
have been studied over the years not only in order to elucidate the molecular 
mechanisms underlying allergic responses, but also in order to identify molecular 
targets for therapeutic intervention.  The extensive network of interactions 
between IgE, its receptors and their co-receptors offer numerous opportunities 
for molecular intervention (Sutton et al., 2000). 
 
Healthy individuals have stable sCD23 serum levels (0.2 – 3 ng/ml), which are 
not correlated with serum IgE concentrations.  Serum sCD23 levels are clearly 
influenced by age however, with children having higher values than adults 
(Mossalayi et al., 1997).  High levels of serum sCD23 were detected in patients 
with parasitic infections associated with high serum IgE levels.  Infection of 
human monocyte-derived macrophages or dendritic cells promoted expression of 
CD23 on these cells and CD23 expression on eosinophils and platelets was also 
reported (Mossalayi et al., 1997). 
 
The reaction of IgE with its receptors is a central phenomenon of allergy (Gould 
et al., 2003), hence some work has already begun investigating therapeutic 
intervention for allergic responses by examining IgE and its receptors.  For 
example, digestion by Der pI protease, from the house dust mite, D. 
pteronyssinus, as previously mentioned yields the 16 kDa sCD23 fragment 
(Gould et al., 2003).  This may promote IgE synthesis by simultaneously 
removing the down regulatory signal, via the membrane bound CD23, and 
promoting the up regulatory signal, through sCD23 (Sutton et al., 2000).  
Inhibitors of Der pI are therefore being developed to combat house dust mite 
allergies.  It has been shown that antibodies to CD23 alleviate rheumatoid 
  25 
arthritis, asthma and chronic lymphoblastic leukaemia, CLL (Hibbert et al., 2005).  
In fact, an anti-CD23 antibody, IDEC-152, is currently in clinical trials for asthma 
and CLL (Rosenwasser et al., 2003; Mavromatis and Cheson, 2004).  The 
inhibition of mCD23 cleavage or sCD23 binding to either IgE or CD21 also offers 
potential targets for therapy (Hibbert et al., 2005), with the structure for the 
design of the inhibitors based on the data presented by these authors.   
  
IgE plays a critical role in the production of Th2 cytokines and hence in the 
development of eosinophil infiltration into the airways after antigen provocation.  
Therefore, an approach to treating asthma may include not only preventing IgE 
binding to mast cells to inhibit bronchoconstriction, but also inhibiting the 
activation of the Th2 cytokine producing cells and the recruitment of eosinophils 
in the lungs, thereby preventing localised tissue damage and the exaggerated 
allergic response (Coyle et al., 1996).  
 
The most studied and best characterised interaction is between IgE and its high 
affinity receptor, FcεRI, and some success has been made in inhibiting this 
interaction by using an anti-IgE antibody (Sutton et al., 2000).  The functioning of 
CD23 and its interactions is not as well understood as that of FcεRI, but it 
obviously plays an important role in the regulation of IgE levels and is hence a 
central target for therapeutic intervention (Sutton et al., 2000), but a better 
understanding of this molecule is required.  Obviously, a better understanding of 
the key factors in IgE regulation will increase the chances of developing more 
effective medicines. 
   
World-wide, parasitic and allergic diseases cause enormous morbidity and 
mortality.  Despite being closely involved in the pathogenesis of both these 
diseases, eosinophils remain understudied in relation to other white blood cells 
(Hansel et al., 1990). 
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1.6  AIMS AND OBJECTIVES OF THIS STUDY 
Due to the diverse functions of CD23, such as its roles in cellular adhesion, 
growth and differentiation of B and T cells, rescue of B cells from apoptosis and 
the release of cytotoxic mediators, it is clear why this molecule is believed to play 
a central role in allergic response.  Due to its important function in the regulation 
of IgE production, CD23 may be the primary cause of certain allergic conditions.  
Although there is much speculation, the function of the soluble form of CD23 is 
not precisely known. 
 
The main objectives of this study were to express and purify tagged versions of 
recombinant human CD23 protein, consisting of the entire extracellular domain, 
termed exCD23.  Figure 1.2 shows the structure and sequence of the protein 
portion to be cloned, with the first amino acid, aspartate, marked with an asterisk.  
In the cloning scheme, the previous amino acid, the tryptophan present as the 
last residue in the transmembane region of the protein, was substituted for a 
methionine to act as the translational start site.  The protein and DNA sequences 
for CD23 are shown in annexure A in the appendix.  The vector maps used for 
construction of the recombinant plasmids are also shown.  The aims and 
objectives are discussed in more detail below: 
 
• Construction of a recombinant plasmid for the expression of a GST•Tagged™ 
CD23 protein construct by subcloning into the pET42 vector using the Bam HI 
and Mun I restriction sites (see annexure A), in order to investigate the solubility 
of the protein; 
 
• Subsequent expression and purification of the translated GST•Tagged™ protein 
product, exCD23 (figure 1.4); 
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Figure 1.4 – Schematic design showing the expression of the 
GST•Tagged™ exCD23.  The position of the tags and cleavage sites are 
shown, as well as the restriction sites used for cloning the CD23 gene into 
the vector. 
 
• Construction of a recombinant plasmid for expressing a His•Tagged™ CD23 
protein construct with an N-terminal His•Tag™ by subcloning into the pET28 
vector using the Bam HI and Nde I restriction sites present in the multiple cloning 
sites (see annexure A); 
 
• Construction of a recombinant plasmid for expressing a His•Tagged™ CD23 
protein construct with a C-terminal His•Tag™ by subcloning into the pET28 
vector using the Nde I and Xho I restriction sites (see annexure A); 
 
• Subsequent expression and purification of the two His•Tagged™ CD23 protein 
constructs, N-terminal His•Tagged™ exCD23 and C-terminal His•Tagged™ 
exCD23 (figure 1.5); 
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Figure 1.5 - Schematic design showing the expression of the His•Tagged™ 
exCD23.  (a) shows the N-terminally tagged protein, while (b) shows the C-
terminally tagged protein.  The position of the tags and cleavage sites are 
shown, as well as the restriction sites used for cloning the CD23 gene into 
the vector. 
 
• Investigation of the effect of the recombinant CD23 on eosinophilic cells, 
especially concerning the cytokine properties of the protein.  
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CHAPTER 2 – DNA CLONING AND PROTEIN EXPRESSION 
 
2.1.  INTRODUCTION 
DNA cloning involves the isolation and manipulation of a specific piece of DNA, 
typically a gene of interest, by incorporating it into modified vectors and 
introducing it into a bacterial cell.  The DNA of interest is then replicated along 
with the vector DNA and can subsequently be recovered from the bacterial 
culture in large amounts (Lawrence, 2000), as well as the expressed protein 
product of the cloned gene.  The pET system was developed for the cloning and 
expression of recombinant proteins in Escherichia coli.  It offers high expression 
levels with tight control over basal expression, as well as a choice of N-terminal 
and C-terminal fusion tags for detection and purification of the recombinant 
protein.  In addition, the E. coli system is advantageous for rapid results with 
convenient restriction sites for subcloning from other vectors, as well as a choice 
of methods for one-step purification of target proteins (Novagen Catalog, 
2004/2005). 
 
2.1.1  DNA INSERT 
In order to obtain sufficient amounts of target gene DNA to use in 
experimentation, the gene of interest can be amplified using the polymerase 
chain reaction (PCR).  Traditional methods used for cloning a DNA sequence into 
a vector and replicating it in a living cell often require days or weeks of work, but 
amplification of DNA sequences by the polymerase chain reaction requires only 
hours. Most biochemical analyses require the input of significant amounts of 
biological material, but the PCR process requires very little. Thus, PCR can 
achieve more sensitive detection and higher levels of amplification of specific 
sequences in less time than previously used methods. These features make the 
technique extremely useful, not only in basic research, but also in commercial 
uses, including genetic identity testing, forensics, industrial quality control and in 
vitro diagnostics (Taylor, 1991). 
 
  30 
The polymerase chain reaction is a technique used for amplification of specific 
DNA sequences by the simultaneous primer extension of complementary strands 
of DNA.  This method was initially described and named by Mullis and Faloona 
(1987), but had limited applications until the use of a heat-stable DNA 
polymerase (Lawyer et al., 1989) became widely available.  DNA polymerases 
used in DNA replication synthesise a complementary strand of DNA in the 5’ to 3’ 
direction starting from a double stranded region with a primer.  The polymerase 
chain reaction is based on the same principle as DNA replication.  However, two 
primers, each complementary to opposite strands bracketing the region of the 
target DNA, are used.  The primers are arranged so that each primer extension 
directs DNA synthesis towards the other (Taylor, 1991). 
 
The specific amplification is achieved in a three-step cycling process, 
denaturation, annealing and polymerisation, as shown in figure 2.1.  The target 
DNA sequence to be amplified is usually a double stranded fragment.  The DNA 
polymerase enzyme used for DNA synthesis requires a single stranded template 
in order to replicate it and make a complementary copy.  The dsDNA template 
must therefore first be denatured into two complementary single strands before 
the reaction can proceed (Eeles and Stamps, 1993).  This is most easily 
achieved by rapidly heating and cooling the DNA, as figure 2.1 shows. 
 
Taq polymerase extends the 3’ end of a primer but can only carry out this activity 
when the primer is annealed in a complementary fashion to the template DNA 
strand.  Therefore, after denaturation, the mixture is quickly cooled to prevent 
immediate reannealing of the long DNA strands.  Because of the small size of the 
primers, they rapidly anneal to the ssDNA at specific positions in the template 
where their sequences are complementary.  In this position the primers are 
available to the DNA polymerase for elongation (Eeles and Stamps, 1993).  
Annealing of the primers to the template is highly temperature and salt 
dependant. 
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Figure 2.1 – Diagrammatic representation of the polymerase chain reaction 
(taken from www.roche-applied-science.com). 
 
Polymerisation or extension is the final step in the PCR cycle, where the 
temperature of the reaction is adjusted to the optimum temperature for 
polymerase activity.  During this step, the enzyme incorporates nucleotides into 
the new, growing DNA strand, forming a complementary copy of the DNA 
template (Eeles and Stamps, 1993).   
 
PCR differs from other DNA synthesis reactions in that the specific sequence is 
copied repeatedly to produce logarithmic amplification.  This is achieved by using 
the two primers complementary to opposite strands and by repeating the PCR 
cycle many times (Eeles and Stamps, 1993).  During the synthesis phase of the 
first cycle, the newly synthesised strand is extended beyond the point of the 
sequence that is complementary to the second primer.  These long templates 
that are produced will be amplified in the second cycle. 
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During the second cycle, the original DNA strands as well as the new strands 
synthesised in the first cycle are denatured and hybridised to the primer 
sequences.  The second cycle of strand synthesis produces more long templates 
as well as some DNA strands that have a primer sequence at one end and a 
sequence complementary to the other primer at the other end.  These strands 
are known as short templates (Glick and Pasternak, 1994). 
 
During the third cycle, the short templates, long templates and original DNA 
strands are denatured to ssDNA and anneal to the primers, allowing replication.  
In subsequent cycles, the short templates are preferentially accumulated and the 
number of these fragments is doubled during each PCR cycle, while the original 
template strands are copied only once.  The DNA fragments of the desired length 
therefore become the major reaction product and accumulate logarithmically 
(Eeles and Stamps, 1993). 
 
After the production of large amounts of insert, the DNA fragment can then be 
cloned into an appropriate vector, allowing transformation of a bacterial cell and 
subsequent production of the recombinant protein of interest.  
 
2.1.2  PLASMID VECTOR 
2.1.2.1  T7 promoter and RNA polymerase 
The primary reason for the success of the pET system is that the target gene is 
cloned into the plasmid under the control of the T7 promoter, which is not 
recognised by E. coli RNA polymerase.  The RNA polymerase of bacteriophage 
T7 has a stringent specificity for its own promoters, which are highly conserved 
nucleotide sequences long enough to make it unlikely to occur by chance in any 
DNA unrelated to T7 DNA (Studier and Moffatt, 1986).  More importantly, no T7 
promoters are known to be present in the DNA of E. coli, a natural host of this 
phage.   
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Transcription by T7 RNA polymerase is very active and very selective.  T7 RNA 
polymerase initiates RNA chains very efficiently and elongates chains about five 
times faster than E. coli RNA polymerase (Studier et al., 1990), and is extremely 
selective for a relatively large and specific promoter sequence (Rosenberg et al., 
1987).  Efficient termination signals for T7 RNA polymerase also appear to be 
rare thereby making the enzyme capable of efficiently producing complete 
transcripts from almost any DNA linked to a T7 promoter (Rosenberg et al., 
1987).  This enzyme is so active and so selective that almost all of the cell’s 
resources are converted to target gene expression after induction.  The 
recombinant protein can comprise more than 50% of the total cell protein a few 
hours after induction (Novagen, 2003).  The selectivity, activity and ability to 
produce complete transcripts make the T7 RNA polymerase enzyme attractive to 
use in directing high level expression of selected genes in E. coli.   
 
T7 expression systems can be completely selective if the RNA polymerase of the 
host cell and the T7 RNA polymerase recognise completely different promoters, 
and if the host cell DNA contains no T7 promoter sequences.  Therefore, any 
DNA cloned into the cell can be placed under control of the T7 promoter, and 
since these promoters are not used by the host cell’s RNA polymerase, the 
presence of the T7 promoter in the cell should have little effect on gene 
expression (Studier and Moffatt, 1986).  T7 RNA polymerase introduced into 
such a cell would actively and selectively transcribe only the DNA under control 
of the T7 promoter, and in some cases transcription by the T7 RNA polymerase 
is so active that transcription by the host cell RNA polymerase cannot compete, 
and almost all transcription in the cell rapidly becomes due to the T7 RNA 
polymerase (Studier et al., 1990).  The problem in such a system of high level 
expression is how to deliver active T7 RNA polymerase to a cell containing a T7 
promoter. 
 
Initially, infection of the host cell with T7 phage was the only method of delivering 
active T7 RNA polymerase into the E. coli cell.  This method was effective for 
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directing expression of genes under control of T7 promoters in plasmids, but was 
not ideal as the gene products could not accumulate to high levels due to 
competition with T7 promoters in the phage DNA, and rapid death of the cell from 
the T7 infection (Studier and Moffatt, 1986).  A better method of introducing the 
active T7 RNA polymerase into the E. coli cell involved cloning the gene for the 
enzyme, thus providing a convenient source of the T7 RNA polymerase, 
independent of T7 infection and free from competing T7 promoters, which is able 
to direct the selective production of large amounts of specific RNAs and proteins 
(Rosenberg et al., 1987).  
 
2.1.2.2  λDE3 lysogen 
Once the plasmid has been established in a non-expression host, it is 
transformed into a host bearing the T7 RNA polymerase gene, a λDE3 lysogen, 
for expression of the target protein.  Bacteriophage DE3 is a λ derivative that 
carries a DNA fragment containing the lacI gene, the lacUV5 promoter, the 
beginning of the lacZ gene, and the gene for T7 RNA polymerase (Studier and 
Moffatt, 1986).  Once a DE3 lysogen is formed, the only promoter known to direct 
transcription of the T7 RNA polymerase gene is the lacUV5 promoter, which is 
inducible by isopropyl-β-D-thiogalactopyranoside (IPTG).  Figure 2.2 shows how 
the addition of IPTG induces expression of the recombinant protein in bacterial 
cells.  The T7 RNA polymerase is produced from its own translation start and not 
as a fusion to the beginning of the lacZ protein (Studier et al., 1990).  Therefore, 
addition of IPTG to a growing culture of DE3 lysogen host cells induces T7 RNA 
polymerase, which in turn transcribes the target DNA cloned into the plasmid.   
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Figure 2.2 – IPTG induction used for expression of the recombinant protein 
in the host bacterial cell.  Addition of IPTG to a growing culture induces T7 
RNA polymerase production, which in turn transcribes the target DNA in 
the plasmid.  Taken from Novagen (2003). 
 
2.1.2.3  pET vectors 
The pET vectors (Novagen, USA), the name derived from the term plasmid for 
expression by T7 RNA polymerase, are plasmid vectors developed for cloning 
and expressing target DNA under control of a T7 promoter.  The pET system has 
a higher stringency option at the level of the T7 promoter itself, with a T7lac 
promoter (Novagen Catalog, 2004/2005).  These plasmids contain a lac operator 
sequence just downstream of the T7 promoter, as well as the natural promoter 
and coding sequence for the lac repressor (lacI) (Studier et al., 1990).  In the 
presence of appropriate levels of lac repressor, transcription from this T7lac 
promoter is greatly reduced.  However, normal transcription can be restored with 
the addition of IPTG (figure 2.2).  In order to provide enough lac repressor to 
occupy the operator sites on a multicopy plasmid vector, and thereby block 
transcription from the T7lac promoter, a DNA fragment containing the natural 
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promoter and coding sequence for lacI was placed upstream of the T7lac 
promoter, orientated so that the lacI and T7lac promoters diverge (Studier et al., 
1990). 
 
When this type of vector is used in λDE3 lysogens, the lac repressor acts in a 
double repression to significantly reduce basal expression of the target protein in 
uninduced cells, however little effect is seen on the level of expression after 
induction (Studier et al., 1990).  This is achieved by the lac repressor acting both 
at the lacUV5 promoter in the host chromosome to repress transcription of the T7 
RNA polymerase gene by the E. coli polymerase, and at the T7lac promoter in 
the vector to block transcription of the target gene by any T7 RNA polymerase 
that is produced.  The double repression of this system is important as any 
recombinant protein expressed in E. coli may interfere with the normal 
functioning of the bacterial cells, and could therefore be toxic to the E. coli.  If the 
target gene products are sufficiently toxic to the bacteria, the basal expression 
level of the protein may be enough to prevent vigorous growth and the 
establishment of plasmids in λDE3 lysogens (Novagen, 2003). 
                                            
2.1.3  EXPRESSION OF RECOMBINANT PROTEIN IN E. COLI 
In some cases, especially when the target protein is harmless and non-toxic to 
the bacteria, it may be possible to clone directly into an expression host, but this 
approach is not ideal as even low levels of basal expression of the target can 
lead to difficulties in growth of the bacteria and plasmid instability due to 
transcription from the T7 promoter in the pET plasmids (Novagen, 2003).  For 
this reason, suitable cloning hosts like E. coli strains JM109 and DH5α are 
recommended.  These strains are used for initial cloning of target DNA into pET 
vectors and for maintaining these vectors as they are recA- endA- and have high 
transformation efficiencies, with good plasmid yields (Hanahan, 1983).  DH5α 
cells are recA-, meaning that there is a complete deletion of the recA gene in 
their genetic material.  This gene is central to general recombination and DNA 
repair, therefore the absence of the gene makes this E. coli strain deficient in 
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homologous recombination (Hanahan, 1983).  DH5α cells are also endonuclease 
deficient (endA-).  This strain contains a complete deletion of the endA gene, 
encoding the DNA specific endonuclease I, thus improving the yield and quality 
of DNA obtained from plasmid isolations (Hanahan, 1983). 
 
In order to produce the target protein, the recombinant plasmid is transferred to 
an E. coli strain containing a chromosomal copy of the gene for T7 RNA 
polymerase, a λDE3 lysogen.  These strains can be chosen for protease 
deficiency, amino acid auxotrophy, solubility enhancement, rare codon 
supplementation or other features (Novagen, 2003).  Rosetta™ (Novagen) cells 
are derived from the BL21 E. coli strain and are deficient in the lon and ompT 
outer membrane proteases, both of which degrade proteins during purification.  
Therefore, target proteins should be more stable in these strains than other host 
strains containing these proteases (Grodberg and Dunn, 1988).  In addition, the 
Rosetta™ strain is a lacY1 deletion mutant of BL21.  This mutation allows 
uniform entry of IPTG into all cells in the culture, producing a concentration 
dependent, homogenous level of induction.  By adjusting the IPTG concentration 
used for induction (figure 2.2), expression can be regulated from very low level 
expression up to strong, fully induced expression levels commonly seen in pET 
vector systems.  Lower level expression may enhance the solubility of difficult 
target proteins (Novagen, 2003).              
 
All cells use a specific subset of the 61 available amino acid codons for the 
production of most mRNA molecules.  In addition, the tRNA population closely 
reflects the codon bias of the mRNA population in that particular organism.  
Major codons are those that occur in highly expressed genes, and are therefore 
used often, whereas minor or rare codons are found in genes expressed at a low 
level (Kane, 1995).  Problems may arise when translating target genes 
containing a distribution of codons different to that normally encountered by the 
host E. coli cell.  If the mRNA from the cloned gene contains rare codons, or if 
the amino acid distribution is very different to typical E. coli proteins, then it is 
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likely that problems will occur when producing the target protein, leading to a 
reduction in the quantity or quality of the synthesised protein (Kane 1995).  For 
example, insufficient tRNA pools can lead to translational stalling, premature 
translation termination, translation frameshifting and amino acid misincorporation 
(Novy et al., 2001).   
 
A subset of the codons for Arg, Ile, Gly, Leu and Pro are very rarely used in 
highly expressed E. coli genes.  Problems of rare codon usage can be overcome 
by elevating the corresponding tRNA levels in the host cell, which can be 
achieved by increasing the copy number of the respective tRNA gene (Novy et 
al., 2001).  This is done by inserting the wild type tRNA gene on a multiple copy 
plasmid, either into the expression vector itself, or on a compatible plasmid.  
Novagen created a plasmid containing tRNA genes for all of the problematic 
rarely used codons encoding Arg, Ile, Gly, Leu and Pro and transformed this 
plasmid into various strains to create the Rosetta™ series of expression hosts 
(Novy et al., 2001).  Rosetta™ strains supply tRNAs for the codons AUA, AGG, 
AGA, CUA, CCC and GGA on a compatible chloramphenicol resistant plasmid 
(Novagen, 2003).  These strains are therefore used to enhance the expression of 
eukaryotic proteins containing codons rarely used in E. coli that would otherwise 
be limited by rare codon usage.      
 
2.1.4  FUSION TAGS 
Fusion tags can facilitate detection and purification of the target protein, or may 
increase the probability of biological activity by affecting the solubility of the 
protein (Novagen, 2003).  The GST•Tag™ fusion tag is a highly soluble 
polypeptide that can potentially enhance the solubility of target proteins.  The 
pET-42 series of expression vectors is designed for cloning and high-level 
expression of peptide sequences fused with a 220 amino acid GST•Tag™ 
protein.  Although the Schistosomal glutathione-S-transferase (GST) fusion 
partner was not initially designed for this purpose, the GST•Tag™ sequence has 
been shown to enhance the solubility of its fusion partners (Novagen, 2003).  The 
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His•Tag™ sequence (found in a variety of pET vectors) is a very useful fusion 
partner for target proteins as it is small in size and binds specifically to metal 
ions, allowing for easy experimentation with the tagged protein.  pET vectors also 
provide protease cleavage sites enabling the optional removal of the fusion tag 
after protein purification (Novagen Catalog, 2004/2005). 
 
2.2.  MATERIALS AND METHODS 
The target gene, exCD23, was amplified using PCR and cloned into two different 
pET vectors, namely pET-28 and pET-42, resulting in His•Tagged™ and 
GST•Tagged™ protein sequences, respectively.  All molecular cloning 
procedures were performed according to standard techniques, as described by 
Sambrook et al. (1989).  The cloning strategy used to construct the desired 
expression vectors is shown in figure 2.3. 
 
2.2.1  PCR OF TARGET GENE 
The gene for the target protein, CD23, was available in the laboratory in a pET-
22 vector.  The CD23 sequence used in this project was obtained by using PCR 
to amplify the target stretch of DNA using specific primers, shown in table 2.1, 
with the primer sequences given in table 2.2. 
 
Table 2.4 – Primers used for the PCR amplification of the CD23 gene 
Primer combination Tagged protein 
Forward Reverse 
N-terminal GST•Tag™ exCD23FLF 3CD23 
N-terminal His•Tag™ VO-1 3CD23 
C-terminal His•Tag™ VO-1 CD23RHis 
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Table 5.2 – Primer sequences used for PCR 
Primer Sequence 
exCD23FLF 5’ GCT ACA ATT GAC ACC ACA CAG 3’ 
VO-1 5’ AAA GTG GCA TAT GGA CAC CAC ACA G 3’ 
3CD23 5’ TGG CTG GAT CCA TGC TCA AG 3’ 
CD23RHis 5’ TCA AGA CTC GAG AGG GGC AGA G 3’ 
 
 
PCR of target gene sequence 
         ↓ PCR clean-up 
Ligation into TA cloning vector 
 ↓ 
Heat shock transformation into chemically competent DH5α cells 
        ↓ Colony PCR to confirm 
Plasmid isolation 
             ↓ Restriction enzyme digest to confirm 
Restriction enzyme digest of recombinant TA cloning vector and of expression vectors 
         ↓ Gel purification 
Ligation into pET expression vectors 
↓ 
Electroporation into electro-competent DH5α cells 
      ↓ Colony PCR to confirm 
Plasmid isolation 
            ↓ Restriction enzyme digest to confirm 
Electroporation into electro-competent Rosetta™ cells for expression 
↓ 
Expression 
Figure 2.3 – Schematic overview of the cloning strategy used in the 
construction of the recombinant expression vectors. 
 
The template DNA used in the PCR reactions was initially diluted 10X with sterile 
ddH2O, and heated at 95°C for 5 minutes to denature the double helix, facilitating 
annealing of the primers to the template. 
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The PCR reaction mixture consisted of the following components: 
Forward primer (100 pmol/µl stock solution)  1 µl 
Reverse primer (100 pmol/µl stock solution)  1 µl 
Template DNA (10X dilution)    2 µl 
dNTPs (10 mM each dNTP, Roche, Germany)  0.5 µl 
Buffer (10X PCR Buffer with MgCl2, Roche)  2.5 µl 
Enzyme (Taq DNA polymerase, 5 U/µl, Roche)  0.3 µl 
Sterile ddH2O      17.7 µl 
TOTAL VOLUME   25 µl 
  
Each primer pair was initially screened to obtain the ideal annealing temperature 
for the reaction, using a gradient PCR protocol, with the optimum annealing 
temperature seen as that producing the most specific PCR product in the highest 
concentration.   
 
The PCR protocol used for amplification of the target gene sequence is shown 
below in figure 2.4. 
Initial denaturation: 95°C for 2 minutes 
    Denaturation: 95°C for 45 seconds 
    Annealing: 55°C for 45 seconds 
    Elongation: 72°C for 90 seconds 
Polishing step: 72°C for 10 minutes 
Hold step: 4°C for 5 minutes 
Figure 2.4 – PCR protocol used in amplification of the target gene 
sequence. 
 
2.2.2  AGAROSE GEL ELECTROPHORESIS 
Gel electrophoresis is commonly used in the purification of specific fragments of 
DNA.  Agarose gels are used for separating DNA fragments ranging in size from 
a few hundred base pairs to about 20 kb (Old and Primrose, 1994).  Agarose is a 
complex network of polymeric galactopyranose molecules extracted from 
seaweed, whose pore size depends on both the buffer composition and 
X 30 cycles 
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concentration of agarose.  The movement through the gel was originally thought 
to resemble snake-like motion; however it has been revealed that DNA 
molecules display elastic behaviour by stretching in the direction of the applied 
field and then contracting into dense balls.  The larger the pore size, the greater 
the ball of DNA which can pass through and therefore the larger the molecules 
that can be separated (Old and Primrose, 1994). 
 
The DNA samples need to be loaded onto the gel with a buffer containing 
bromophenol blue and glycerol.  The bromophenol blue is a tracking dye which 
shows the progress of the samples through the gel, thus allowing the voltage to 
be stopped before the samples are lost off the gel.  Glycerol increases the 
density of the sample solution, causing it to sink to the bottom of the well and 
therefore move through the gel and not along the top of the gel through the buffer 
(Andrews, 1991).    
 
A particular advantage of gel electrophoresis is that the DNA bands can be easily 
detected at high sensitivity (Old and Primrose, 1994).  Ethidium bromide is the 
most popular method for detecting nucleic acid bands in gels, and is added 
directly to the gel before it is poured.  Ethidium bromide is an intercalating dye 
that displays enhanced fluorescence when intercalated between stacked nucleic 
acid bases and viewed under UV light (Boyer, 1993).  Either long or short 
wavelength UV light can be used as the excitation wavelength, and an emission 
wavelength of 590 nm results, with the DNA bands showing up as orange-red 
fluorescence.  
 
The agarose gels run in this experiment were all 1% gels, made by dissolving 0.5 
g agarose in 50 ml warm 1 X TAE buffer (diluted 50X from the TAE stock solution 
containing 2 M Tris, 0.05 M EDTA and 57.1 ml acetic acid at pH 8, in 1ℓ).  Before 
polymerisation of the agarose, 5 µl of ethidium bromide (0.5 µg/ml final 
concentration) was added to the solution to allow visualisation of the DNA in the 
agarose.  The liquid solution was poured into the gel tray and allowed to set at 
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room temperature for 20 minutes.  The DNA samples to be run on the gel were 
diluted with a 6X loading buffer, consisting of 30% glycerol, 0.25% bromophenol 
blue and 0.25% xylene cyanol FF in water, and loaded into the wells.  The gels 
were run at 100 V (constant voltage) and 64 mA for about an hour, until the 
bromophenol blue tracking dye had travelled at least ¾ of the way down the 
length of the gel. 
  
2.2.3  PCR CLEAN UP AND DNA PURIFICATION 
The development of recombinant DNA research has made the importance of 
obtaining high-quality, purified DNA essential.  The basic steps of DNA isolation 
are disruption of the cellular structure to create a lysate, separation of the soluble 
DNA from cell debris and other insoluble material and purification of the DNA of 
interest from soluble proteins and other nucleic acids.  This process was 
traditionally lengthy and time consuming involving the use of a variety of 
hazardous reagents, including cesium chloride banding, ribonuclease treatment, 
phenol extraction, ethanol precipitation and dialysis (Marko et al., 1982).  
However, these days a number of commercial kits are readily available for the 
rapid and reliable purification of nucleic acids from a cleared lysate. 
 
In this project Promega (USA) Wizard® Plus DNA Purification Systems were 
used to isolate plasmid DNA and clean up PCR products from the remaining 
reaction mixture, or to purify the DNA fragments from agarose gels.  The Wizard® 
system is based on the purification of the nucleic acids by silica because DNA 
binds silica in the presence of high concentrations of chaotropic salts (Chen and 
Thomas, 1980; Marko et al., 1982; Boom et al., 1990).  The binding of DNA to 
silica seems to be driven by three forces, namely, the dehydration of the DNA 
and silica surfaces, and hydrogen bond formation between the DNA and silica, 
both of which compete against weak electrostatic repulsion of these two 
negatively charged entities (Melzak et al., 1996). A high concentration of salt will 
help drive DNA adsorption onto silica, while a low concentration will release the 
DNA. 
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The purification of DNA fragments from amplification reactions and agarose gels 
is often required in a cloning experiment.  Promega provides several systems for 
DNA fragment purification, and in this project the Wizard® SV Gel and PCR 
Clean-Up System, based on silica membrane technology, was used.  This 
system provides a reliable method to purify double-stranded, PCR-amplified DNA 
either directly from the reaction or from agarose.  The PCR products are purified 
from contaminants in the reaction mixture, including primer dimers, PCR 
additives and amplification primers.  The PCR product can be separated from 
non-specifically amplified products by agarose gel electrophoresis with the 
agarose subsequently dissolved by a chaotropic buffer, freeing the DNA for 
binding to the silica membrane (Chen and Thomas, 1980). After removal of 
contaminants by alcohol-based washes (Wilcockson, 1975), the DNA that is 
bound to the silica is eluted in a solution with a low salt concentration like water 
or TE buffer (Melzak et al., 1996).  The Wizard® SV Gel and PCR Clean-Up 
System can also be used to purify DNA from enzymatic reactions such as 
restriction digestion and alkaline phosphatase treatment. 
 
2.2.4  LIGATION OF INSERT INTO TA CLONING VECTOR 
Taq DNA polymerase was used during PCR as this enzyme inserts multiple 
adenylate residues at the end of the PCR fragment, allowing it to be easily 
inserted into the Promega pGEM®-T Easy Vector TA cloning vector.  The ligation 
reactions were set up following the manufacturer’s protocol: 
Buffer (2X Rapid Ligation Buffer)    5 µl 
Vector (pGEM®-T Easy Vector, 50 ng/µl)  1 µl 
PCR product       1 µl 
Ligase (T4 DNA Ligase, 3U/µl)    1 µl 
Sterile ddH2O      2 µl 
TOTAL VOLUME     10 µl 
For this reaction, a positive control using 2 µl of a control insert (4 ng/µl), as well 
as a negative control, with no PCR product or control insert added to the reaction 
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mixture was used.  For these two reactions, the volume was adjusted to a total of 
10 µl by changing the amount of water used in each case. 
 
The ligation reaction was allowed to proceed at room temperature for one hour, 
after which half of the mixture was used for chemical transformation, while the 
remainder of the reaction was allowed to proceed overnight, and this half of the 
reaction mix was then used to transform chemically competent DH5α cells. 
 
2.2.5  CHEMICALLY COMPETENT CELLS 
Chemically competent DH5α cells were prepared using the calcium chloride 
method described by Sambrook et al. (1989). 
 
2.2.6  HEAT SHOCK TRANSFORMATION 
Chemical transformation was performed by mixing 5 µl of the ligation mixture and 
20 µl of chemically competent DH5α cells in an Eppendorf tube, and this was 
mixed by gently flicking the tube.  The tube was incubated on ice for 15 minutes, 
heated to 42°C for 30 seconds, followed by cooling on ice for 2 minutes.  Warm 
LB broth (100µl) was added to the cells, and they were incubated at 37°C, with 
shaking at 180 rpm for 45 minutes.  This cell suspension (100µl) was plated onto 
LB plates (100 µg/ml AMP, 0.5 mM IPTG, 80 µg/ml X-gal), and grown overnight 
at 37°C.  Successful transformants were identified by resultant antibiotic 
resistance and blue/white screening. 
 
2.2.7  COLONY PCR 
Colony PCR was used as a quick alternative to plasmid isolation and restriction 
enzyme digestion to confirm the presence of the desired fragment in the vector.  
A single colony from the plate of transformants was chosen.  Half of the bacterial 
colony was streaked onto another plate, while the other half was added to 50 µl 
sterile ddH2O, which was boiled for 5 minutes.  The solution (2 µl) was used as 
the template DNA in a PCR reaction, as described in section 2.2.1. 
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2.2.8  PLASMID ISOLATION    
Midi-prep plasmid isolations were performed using the Promega Wizard® Plus 
Midipreps DNA Purification System, in order to obtain enough DNA, in sufficiently 
high concentrations, to use in subsequent experiments.  Midi-prep plasmid 
isolations were used to isolate both the TA cloning vectors containing the desired 
inserts, and the pET vectors used for insertion of the target sequences. 
 
The main consideration for plasmid DNA purification is separating it from the 
chromosomal DNA and cellular RNA of the host bacteria.  A number of methods 
have been developed to generate a cleared lysate that not only removes protein 
and lipids but efficiently removes contaminating chromosomal DNA while leaving 
plasmid DNA free in solution.  Methods for the preparation of cleared lysates that 
enrich for plasmid DNA include SDS-alkaline denaturation (Birnboim and Doly, 
1979; Birnboim, 1983), salt-SDS precipitation (Hirt, 1967) and rapid boiling 
(Holmes and Quigley, 1981).  The SDS-alkaline denaturation method, which is 
used in all Promega plasmid isolation systems, is a popular procedure for 
purifying plasmid DNA because of its overall versatility and consistency.  This 
technique uses the difference in denaturation and renaturation characteristics of 
covalently closed circular plasmid DNA and chromosomal DNA fragments.  Both 
plasmid and chromosomal DNA are efficiently denatured under alkaline 
conditions (at pH 11).  Rapid neutralization with a high-salt buffer such as 
potassium acetate in the presence of SDS has two effects that contribute to the 
success of this method.  Firstly, the rapid neutralization causes interstrand base-
pairing in the chromosomal DNA, resulting in an insoluble aggregate that 
precipitates out of solution.  The covalently closed nature of the circular plasmid 
DNA promotes intrastrand rehybridization, allowing the plasmid to remain in 
solution.  Secondly, the potassium salt of SDS is insoluble so the protein 
precipitates and aggregates, which assists in trapping the high-molecular-weight 
chromosomal DNA and precipitating it out of solution.  The soluble and insoluble 
materials are separated by centrifugation or filtration (Birnboim, 1983).   
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Promega products like the Wizard® Plus SV Minipreps DNA Purification System 
combine the benefits of alkaline lysis with the rapid and easy purification by silica 
(Chen and Thomas, 1980; Marko et al. 1982; Boom et al. 1990).  This is done by 
using a silica-based membrane in a column format to bind the plasmid DNA in 
the soluble fraction of the cleared alkaline lysates (Birnboim and Doly, 1979; 
Birnboim, 1983).  Purification is based on selective adsorption of DNA to the 
silica membrane in the presence of high concentrations of chaotropic salts, 
washes to efficiently remove contaminants, and elution of the DNA with low-salt 
solutions such as TE buffer or water.  The plasmid isolation protocol was carried 
out according to the manufacturer’s kit instructions. 
 
2.2.9  RESTRICTION DIGESTIONS 
Restriction digests were used to confirm the insert in the isolated vectors, as well 
as to clone the fragments into the respective pET vectors.  The components of 
the restriction digestion are shown below: 
 
      Single digest  Double digest 
Buffer (10X concentration with BSA)  1 µl   1 µl 
Restriction enzyme 1 (10 U/µl)   0.3 µl   0.3 µl 
Restriction enzyme 2 (10 U/µl)   -   0.3 µl 
DNA (~ 300 µg/ml)    5 µl   5 µl 
Sterile ddH2O     3.7 µl   3.4 µl 
TOTAL VOLUME     10 µl  10 µl 
 
The combinations of restriction enzymes (all from Fermentas, Lithuania) used in 
the various reactions are shown in table 2.3.  The target fragment was released 
from the TA cloning vector with the same combinations, relevant to each clone, 
as shown in the table. 
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Table 2.3 – Expression vectors and restriction enzymes used for 
construction of the three tagged recombinant proteins.  The buffer used for 
the restriction digest is also shown. 
Fusion protein Vector 
digested 
Restriction enzymes 
used 
Buffer used 
N-terminal 
GST•Tag™ 
pET-42 Bam HI and Mun I Buffer G 
N-terminal 
His•Tag™ 
pET-28 Bam HI and Nde I Buffer R 
C-terminal 
His•Tag™ 
pET-28 Xho I and Nde I Tango Buffer 
 
The digestion reaction was allowed to proceed for 90 minutes at 37°C, after 
which the vector was treated with 1 unit calf intestine alkaline phosphatase 
(Roche) per 20 µl reaction volume, at 37°C for 60 minutes to remove the free 5’ 
phosphate group, in order to prevent the re-circularisation of the vector in the 
ligation reaction.  
 
After restriction, the entire sample was loaded and electrophoresed on a 1% 
agarose gel to visualise the desired bands.  The appropriate bands were excised 
from the gel with a sterile scalpel and purified using a Promega Wizard® SV Gel 
and PCR Clean-Up System.   
 
2.2.10  LIGATION OF INSERT AND VECTOR 
The restriction-enzyme digested, gel purified insert of interest was ligated into 
similarly restricted vector, as described for the PCR product ligation into the TA 
cloning vector (section 2.2.4).  The DNA concentration of the insert and vector 
was estimated from ethidium bromide staining of the agarose gel in relation to 
markers of known DNA concentration, as well as by the absorbance at 260 nm.   
The DNA concentration was calculated using the following formula: 
A260 x dilution factor x 50 (for dsDNA) = [ DNA ] in µg/ml 
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Once the DNA concentration was estimated, the amount of insert : vector was 
calculated so that there was a molar ratio of at least 3 : 1 in the ligation reaction. 
 
2.2.11  ELECTROPORATION 
The ligation mixture was used to transform electrocompetent DH5α cells, which 
were plated onto LB plates containing the appropriate vector-specific antibiotic.  
Electroporation was carried out by adding 1 µl of the ligation reaction to 40 µl of 
cells in a chilled Eppendorf tube.  This was mixed by pipetting up and down or 
gentle flicking of the tube.  The mixture was transferred to a chilled 
electroporation cuvette and electroporated at 12 500 V/cm (EquiBio, EasyjecT 
Plus).  Pre-warmed LB broth (460 µl) was added to the cells and incubated at 
37°C for 45 minutes.  This cell suspension (100 µl) was spread onto an LB plate.  
The antibiotics used for the various combinations of vectors and cells used are 
shown in table 2.4. 
 
Table 2.4 – Type and concentration of the antibiotics used in the bacterial 
culture of both the cloning and expression strains of E. coli.   
E. coli 
strain 
Vector Antibiotic Concentration 
(µg/ml) 
TA cloning vector Ampicillin 100 
pET 28 Kanamycin 15 
DH5α 
pET 42 Kanamycin 15 
pET 28 Kanamycin 
chloramphenicol 
15 
36 
Rosetta™ 
pET 42 Kanamycin 
chloramphenicol 
15 
36 
 
2.2.12  ELECTRO-COMPETENT CELLS 
Electro-competent cells were made by inoculating a single colony in 50 ml SOB 
medium overnight at 37°C with shaking at 180 rpm.  SOB (1ℓ) was inoculated 
with 5 ml of the overnight culture.  This culture was grown to mid-log phase 
(OD600 ~ 0.6 – 0.8) at 37°C with shaking at 180 rpm on an orbital shaker.  Once 
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the cells reached mid-log phase, they were chilled on ice and decanted into 
sterile centrifuge bottles and centrifuged at 3 000 x g for 15 minutes at 4°C.  The 
cell pellet was loosened and washed with ice cold wash buffer (sterile 10% (v/v) 
ultra-pure glycerol, 90% (v/v) ddH2O).  The cells were centrifuged at 3 000 x g for 
25 minutes at 4°C, washed again, and centrifuged as before.  The pellet was 
resuspended in about 4 ml wash buffer and 90 µl aliquots of the cells were 
transferred into sterile Eppendorf tubes and snap frozen in liquid nitrogen.  After 
freezing the cells were stored at -80°C.   
 
2.2.13  PROTEIN EXPRESSION 
Single colonies of the relevant clones were inoculated into 10 ml LB medium, 
with the appropriate antibiotics (Table 2.4) and grown overnight at 37°C with 
shaking at 180 rpm.  The overnight culture (5 ml) was used to inoculate 50 ml LB 
medium containing antibiotics for a test expression, or 1 ℓ for a preparative 
expression.  The culture was allowed to grow at 37°C with shaking until an 
optical density at 600 nm of between 0.6 and 0.8 was reached.  Protein synthesis 
was induced by addition of IPTG to a final concentration of 1 mM.  However, for 
expression of the GST•Tagged™ protein lower concentrations of IPTG were also 
used, namely 0.8, 0.6 and 0.4 mM.  The cells were grown as before, with 500 µl 
aliquots removed for specific time intervals.  The aliquots were centrifuged at 
maximum speed in a microfuge (Eppendorf miniSpin) for two minutes to pellet 
the cells.  The supernatant was removed and the remaining pellet frozen and 
stored at -80°C for further analysis by SDS-PAGE. 
 
For preparative protein expression, after three hours of expression, the cells 
were harvested by centrifugation (Beckman Avanti™ J-20) at 5 000 x g for half 
an hour, at 4°C.  The cell pellet was resuspended in 10 ml sonification buffer 
containing 50 mM Tris-HCl, 0.3 M NaCl and 0.2% NaN3 at pH 7.8.  The 
centrifuge bottles were rinsed with another 5 ml of the buffer and added to the 
cell suspension.  This mixture was stored at -80°C. 
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2.2.14  SDS-PAGE 
Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis was carried 
out as described by Laemmli (1970) using 15% polyacrylamide resolving gels. 
 
2.2.15  SEMI-DRY BLOTTING 
Protein samples separated by SDS-PAGE were transferred to an Immobilon 
PVDF membrane (Roche, Germany) for Western blotting and amino acid 
sequencing.  Protein transfer onto the solid support was achieved using a 
Transblot® SD Semi-Dry Electrophoretic Transfer Cell System from Biorad 
(USA). 
 
Duplicate gels were run, with one stained for SDS-PAGE analysis and the other 
used for blotting.  After electrophoresis, the acrylamide gel was equilibrated by 
placing it in transfer buffer (48 mM Tris, 39 mM glycine, 20% methanol) for 20 
minutes.  A piece of Immobilon PVDF membrane was cut to the same size as the 
gel and briefly pre-wet in methanol.  It was immediately transferred into distilled 
water for at least 5 minutes, to remove all the methanol.  The membrane was 
then equilibrated in transfer buffer.  Two pieces of extra thick blotting paper were 
also equilibrated in the transfer buffer. 
 
The semi-dry blotting cassette was assembled according to the manufacturer’s 
instruction manual.  A piece of extra thick blotting paper was placed on top of the 
anode, followed by the PVDF membrane.  The equilibrated gel was placed on top 
of the membrane, and another piece of extra thick blotting paper was stacked on 
top of it.  Any air bubbles trapped between the layers were gently removed by 
rolling a clean pipette tip between each layer of the sandwich.  The cathode was 
connected on top of the stack.  Protein transfer was carried out for three hours 
using a voltage of 25 V, with a constant current of 5 mA/cm2.  
 
If the membrane was used for Western blotting, it was rinsed a few times with 
PBS then transferred into blocking solution (5% (w/v) Elite fat-free milk powder in 
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PBS) and incubated at room temperature for one hour with constant agitation.  
The membrane was then stored at 4°C overnight in blocking solution.  For 
Western blot detection, the membrane was removed from the blocking solution 
and washed twice, for ten minutes each, with 20 ml TBS-T (25 mM Tris, 150 mM 
NaCl at pH 7.5, containing 0.05% (w/v) Tween 20).  The membrane was then 
washed for ten minutes with 15 ml TBS (25 mM Tris, 150 mM NaCl at pH 7.5).  
The membrane was incubated with the primary antibody, a monoclonal anti-
glutathione-S-transferase (clone GST-2) mouse IgG2b isotype (Sigma), diluted 
1:1 000 in blocking solution, for one hour at room temperature.  After the hour 
incubation, the membrane was washed twice for ten minutes each with 20 ml 
TBS-T, and once for ten minutes with 15 ml TBS.  The alkaline phosphatase 
conjugated secondary antibody, goat anti-mouse IgG AP conjugate from 
Novagen (8 ml), diluted 1:5 000 in blocking solution, was then added, and 
incubated at room temperature for an hour.  The membrane was washed five 
times, for ten minutes each with 20 ml TBS-T, and incubated for ten minutes with 
NBT/BCIP solution for detection of the protein bands.  To stop the reaction, the 
blot was thoroughly washed in deionised water and allowed to air dry. 
 
If the membrane was used for protein sequencing, it was stained with Coomassie 
(0.1% Coomassie Blue R-250 in 40% methanol, 10% acetic acid) for ten minutes, 
and destained with destain solution (40% methanol, 10% acetic acid and 50% 
distilled water).  Once a clear background was obtained the membrane was 
allowed to air dry and was stored at room temperature.   
 
2.3.  RESULTS AND DISCUSSION 
2.3.1  PCR OF TARGET GENE 
The target CD23 gene was amplified using PCR with the pET 22 vector 
containing the gene of interest as the template DNA.  A range of temperatures 
was used for this initial PCR reaction in order to optimise the annealing 
temperature for each primer set.   
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Figure 2.5 shows the agarose gel electrophoresis of the PCR products for the 
three primer sets, used to construct the three different recombinant proteins.   
 
 
Figure 2.5 – Agarose gel electrophoresis (1%) of the PCR reaction 
products, using the original pET22 recombinant plasmid as the template 
DNA.  A range of annealing temperatures was used and each PCR product 
represents a different annealing temperature for each primer set.  (a) shows 
the amplified product for the N-terminal GST•Tagged™ protein, i.e. primers 
exCD23FLF and 3CD23 were used.  Lanes 2 to 7, excluding lane 4 which 
was empty, represent annealing temperatures 50°C, 52.4°C, 57.7°C, 59.9°C 
and 62°C respectively.  (b) shows the amplified product for the N-terminal 
His•Tagged™ protein, i.e. primers VO-1 and 3CD23 were used, lanes 3 to 8 
representing annealing temperatures of 50°C, 52.4°C, 54.6°C, 57.7°C, 59.9°C 
and 63°C respectively.  (c) shows the amplified product for the third primer 
set, VO-1 and CD23RHis used for construction of the C-terminal 
His•Tagged™ protein.  Lanes 2 to 4 show reaction products for the 50°C, 
52.4°C and 54.6°C reactions.  The reaction was also carried out at 57.7°C 
and 62°C, but as the gel shows, no reaction product is seen in lanes 5 and 
6.  Lane 1 in (a) to (c) contains the DNA marker, with sizes shown in 
kilobases (Fermentas GeneRuler™ 1 kb DNA Ladder). 
 
As figure 2.5 shows, annealing temperature had an influence in the quantity of 
PCR product produced in the amplification reaction, but was dependent on the 
primer set.  This is particularly evident in Figure 2.5 (c), where no PCR product is 
seen for annealing temperatures greater than 54.6°C.  This phenomenon is 
expected as the annealing temperature is crucial to the specificity of the reaction 
(Rolfs et al., 1992).  Annealing temperature is dependant on the sequences of 
the primers and the ionic strength of the buffer.  If the annealing temperature is 
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too high, no annealing will occur at all, however, if the temperature is too low, 
non-specific annealing might drastically increase.  All primers that anneal at their 
3’ terminal, regardless of whether they are specifically bound or not, will be 
elongated from the free 3’ OH.  Therefore, specificity through annealing 
temperature is vital and must be empirically optimised for each PCR reaction 
(Rolfs et al. 1992). 
 
As figure 2.5 (a) shows, any of the five annealing temperatures investigated 
resulted in substantial reaction product with annealing at 57.7°C showing a 
particularly strong band, and thus a large amount of product.  For the second 
primer set, used to produce the N-terminal His•Tagged™ protein, shown in figure 
2.5 (b), there appeared to be an increase in the amount of PCR product 
produced with increasing annealing temperatures.  However, annealing at 54.6°C 
showed a very bright band.  As figure 2.5 (c) shows, the optimum annealing 
temperature for the third primer set appears to be 52.4°C, as the strongest DNA 
band is obtained at this temperature. 
 
As figure 2.4 shows, the annealing temperature used for the PCR amplification of 
the target gene was 55°C.  This temperature was chosen as large amounts of 
PCR product were obtained for all three primer sets using this temperature, and it 
lay in the middle of the range of optimum temperatures for the three primer sets, 
allowing the same PCR protocol to be used for all three reactions. 
 
The expected band sizes for the target DNA fragments were calculated to be 
approximately 800 bp.  As figure 2.5 shows, the PCR products obtained for all 
three primer sets lie between the 750 bp and 1 000 bp markers, in all three 
cases, just above the 750 bp marker.  Thus the size of the amplified DNA 
fragment can be estimated to be about 800 bp, which is the same as the 
expected size.  Hence these fragments were assumed to be the correct PCR 
products, and since no non-specific PCR products are seen, as indicated by the 
sole bright band in each lane on the gels, it can be concluded that the primer sets 
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are specific and will ensure the amplification of only the desired product under 
the experimental conditions. 
 
2.3.2  COLONY PCR VERIFICATION OF THE INSERT IN THE TA CLONING 
VECTOR 
After the appropriate amplification reaction produced the desired DNA fragment, 
the PCR product was purified and ligated into a TA cloning vector from Promega.  
The resultant recombinant plasmid was introduced into chemically competent 
cells and the transformants, identified by blue/white colony selection, were used 
for colony PCR to confirm the presence of the insert in the TA cloning vector 
(figure 2.6). 
 
As figure 2.6 shows, positive results for the colony PCR were obtained for all 
three primer sets, however, not every colony selected gave positive results, as 
lane 2 in figure 2.6 (a) shows.  Therefore, not every colony grown after 
transformation can be considered a transformant, and thus the importance of 
confirming the presence of the insert in the plasmid is essential.  The DNA band 
sizes correlate to the expected size of ~800 bp, when compared to the DNA 
marker.  From these results, in addition to plasmid isolation and restriction 
digestions to reconfirm, it was assumed that the correct insert was present in the 
TA cloning vector.  The fragment was digested out of this vector and subcloned 
into the desired pET vector to construct the appropriate recombinant protein 
constructs (table 2.4).   
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Figure 2.6 – Agarose gel electrophoresis (1%) of the PCR reaction products 
after colony PCR was used to amplify the recombinant TA cloning vector.  
(a) shows the amplified insert for the N-terminal GST•Tagged™ protein 
present in the TA cloning vector, (b) for the N-terminal His•Tagged™ 
protein, and (c) for the C-terminal His•Tagged™ protein in the TA cloning 
vector.  Lane 1 in (a) to (c) contains the Fermentas 1 kb DNA ladder, with 
the sizes shown in (c).  Lanes 2 – 4 in (a), 2 – 8 in (b) and 2 – 4 in (c) each 
represent a single colony from the plate of transformants used for colony 
PCR.  
 
2.3.3  COLONY PCR VERIFICATION OF THE INSERT IN THE EXPRESSION 
VECTOR 
After ligation of the pGEM-T digest fragment into the appropriate expression 
vector and successful transformation, colony PCR was performed to confirm the 
presence of the insert in the vector.  Figure 2.7 shows the agarose gel 
electophoresis of the PCR products after colony PCR was performed. 
 
As figure 2.7 shows, recombinant plasmids containing the correct size (± 800 bp) 
of amplified product were constructed for the three desired recombinant proteins.  
After electroporation using the ligated vector and insert reaction mixture, random 
colonies were picked off the plate of transformants and used for colony PCR.  
Not all the colonies tested contained the plasmid with the desired insert as lanes 
2 and 3 in Figure 2.7 (a) show no amplified product, while lanes 4 to 6 show a 
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clear positive result.  The same can be seen in lanes 2 and 4 in Figure 2.7 (b).  
Only the colonies giving positive results were used in further experiments. 
 
 
Figure 2.7 – Agarose gel electrophoresis (1%) of the PCR reaction products 
after colony PCR was used to amplify the cloned insert in the different 
expression vectors.  (a) shows the amplified insert for the N-terminal 
GST•Tagged™ protein present in the pET 42 vector, (b) for the N-terminal 
His•Tagged™ protein in the pET 28 vector, and (c) for the C-terminal 
His•Tagged™ protein in the pET 28 vector.  Lane 1 in (a) to (c) represents 
1kb DNA Ladder; the remaining lanes represent random colonies picked. 
 
2.3.4  DNA SEQUENCING 
Once the three recombinant vectors were constructed, they were sequenced to 
completely ensure the presence of the insert in the vector, as well as confirming 
the correct orientation and reading frame of the insert.  A representative example 
of each sequencing run can be seen in figure 2.8.  As this figure shows, clear 
resolution was obtained, with distinct peaks for each nucleotide base, making the 
sequencing simple and comprehensible.  The sequences obtained for the 
forward and reverse reactions were aligned with each other, using the ClustalW 
alignment tool on the EMBL-EBI webpage, available at http://www.ebi.ac.uk/ 
clustalw/index.html.  Any discrepancies between the two sequences were 
eliminated by referring back to the sequence file.  These differences could occur 
due to the poor resolution obtained at the beginning and end of each sequencing 
run.  Thus unclear, poorly resolved peaks are usually seen in these regions.  
However, when compared to the known DNA sequence, any discrepancies can 
be clarified by referring to the original chromatogram.  Once the sequence was 
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corrected, it was aligned with the known CD23 sequence obtained from an NCBI 
Blast search (http://130.14.29.110/BLAST/ index.shtml), accession number 
BC064417.  Once again, if any discrepancies were seen between the two 
sequences, the original sequence file was checked in order to ensure that the 
correct nucleotide base was reported.  The DNA sequence was then translated 
into a protein sequence, using the ExPASy translate tool, available at 
http://www.expasy.org/tools/dna.html.  The resultant protein sequence was then 
aligned with a published CD23 protein sequence, accession number AAH62591.  
The aligned DNA and protein sequences are shown in annexures B, C and D 
respectively for the N-terminal GST•Tagged™ protein, N-terminal His•Tagged™ 
protein and the C-terminal His•Tagged™ protein constructs.  
 
 
 
 
 
 
 
 
Figure 2.8 – Example of DNA sequencing runs for the three recombinant 
plasmids.  (a) represents a short section of the DNA sequence obtained for 
the N-terminal GST•Tagged™ exCD23, (b) for the N-terminal His•Tagged™ 
exCD23, and (c) for the C-terminal His•Tagged™ exCD23. 
 
The aligned sequence for the N-terminal GST•Tagged™ protein, seen in 
annexure B, appears to have a single amino acid substitution at the alanine 
residue at position 80 in the reference sequence.  This residue has been 
replaced by a threonine residue.  This amino acid replacement involves the 
substitution of a nonpolar CH3 group with a polar uncharged R-OH group.  The 
substitution includes the addition of a hydroxyl group, but will hopefully not affect 
the structure of the protein and its functioning.  Unfortunately due to the large 
size of the GST•Tag™ and the primers available, the sequence of the complete 
protein was impossible to obtain.  Thus three of the first amino acids in the 
(a) (b) (c)
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recombinant protein are missing (indicated by question marks in annexure B).  
The T7 promoter was used as a sequencing primer, and the end of this 
sequence shows the first five amino acids of the recombinant protein are indeed 
the same as those of the reference sequence.  But unfortunately the second 
primer used for sequencing does not overlap with the end of the first, thus three 
amino acids are missing for the translated product.  The isoleucine residue at the 
start of the recombinant sequence is as a result of the Mun I restriction site used 
in the cloning strategy.  The translational start site is a methionine residue at the 
beginning of the GST•Tag™.  The protein sequence is very similar to the human 
CD23 sequence, besides the addition of the GST•Tag, and can thus be assumed 
to be suitable for use as a substitute for human CD23 into the functioning of this 
protein.   
 
As annexure C shows, the translated sequence for the N-terminal His•Tagged™ 
protein, aligned with the known CD23 protein sequence, shows no amino acid 
substitutions.  The only change from the human sequence is the use of a 
methionine residue in place of tryptophan (W47), the last membrane amino acid in 
the human CD23 protein structure (figure 1.1).  This substitution is due to the 
Nde I restriction site used for the cloned gene and was part of the cloning 
strategy.  Thus the entire extracellular domain of human CD23 is encoded in the 
recombinant N-terminal His•Tagged™ protein sequence.  In addition to this 
sequence, a short N-terminal sequence has been included containing the six 
histidine residues making up the N-terminal His•Tag™.  The sequence adjacent 
to the CD23 sequence is obtained from the vector and contains a thrombin 
cleavage site for optional removal of the His•Tag™ (not used in this study).    
 
The alignment of the reference CD23 sequence with the translated C-terminal 
His•Tagged™ protein sequence, seen in annexure D, shows two amino acid 
differences when compared with the reference sequence.  These substitutions 
are present at A80 and L141.  The replacement of an alanine residue by a 
threonine residue is the same as that seen in the GST•Tagged™ protein.  This 
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indicates that the change in sequence may be present in the template DNA used 
for PCR.  The L141 substitution on the other hand, involves the replacement of 
leucine 141 in the reference sequence with a phenylalanine.  In this case the 
nonpolar leucine side chain (CHCH3CH3) is substituted with an aromatic benzene 
ring.  These amino acid substitutions may influence the folding and tertiary 
structure of the protein.  These changes are a result of the misincorporation of 
the correct nucleotides by the Taq polymerase used for PCR.  Other high fidelity 
polymerase enzymes are available but in this study the use of Taq was essential 
for the incorporation of multiple A residues at the end of the PCR product in order 
to ligate the fragment into the TA cloning vector. 
 
In addition to the two changes described above the incorporation of the 
methionine residue in place of W47 is again part of the cloning strategy as 
described for the N-terminal His•Tagged™ protein.  The end of the protein has 
also been altered in order to achieve the addition of the C-terminal His•Tag™, 
with the presence of a glutamate residue just before the six histidines, a product 
of the Xho I restriction site used in the cloning scheme.  Ultimately the addition of 
the His•Tag™s require a few modifications of the protein sequence, but these will 
hopefully not influence the structure and biological activity of the recombinant 
protein.  The results of the changes in protein sequence can only be investigated 
by examining the folding, structure and IgE binding ability of the proteins once 
they have been expressed and purified.  
 
2.3.5  EXPRESSION OF RECOMBINANT PROTEIN 
All the cloning experiments were performed in DH5α cells, as these cells have 
high transformation efficiencies and good plasmid yields (Hanahan, 1983).  
However, this is not an expression strain and hence the recombinant protein can 
not be produced by these cells.  For this reason the recombinant plasmid was 
isolated and transformed into Rosetta™ cells, a λDE3 lysogen, for expression 
(figure 2.3).  Protein production was induced with the addition of IPTG to the 
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cultures and cell aliquots after specific time intervals were taken and tested for 
protein expression by SDS-PAGE (figure 2.9).   
 
 
Figure 2.9 – SDS-PAGE analysis of the test expression of the three 
recombinant proteins, (a) N-terminal GST•Tagged™ protein, (b) N-terminal 
His•Tagged™ protein and (c) C-terminal His•Tagged™ protein.  In all three 
gels, a pre-induction sample was loaded in the first lane after the marker, 
followed by an half hour post induction sample, 1 hour post induction, 2 
hours post induction and finally 3 hours post induction, as indicated on the 
gels.  The lanes labelled ‘M’ contain the protein marker (peqGOLD Protein 
Marker II), with the sizes shown in (b) in kDa.  The dashed boxes in the post 
induction samples show the induced protein bands of interest. 
 
The protein from all three cloned plasmids is produced in large amounts by the 
Rosetta™ cells, and all three correspond to the predicted sizes expected from 
Vector NTI calculations.  These are approximately 37 kDa for the two His•Tagged 
proteins and about 63 kDa for the GST•Tagged protein.  As Figure 2.9 (a) shows, 
the recombinant protein bands are roughly in line with the 70 kDa protein marker.  
The expected size for the GST•Tagged™ protein is 63 kDa, thus corresponding 
well with the banding pattern shown on the gel.  The slight difference in 
experimental and expected size estimations could be due to the inherent error in 
the technique, which is accepted to be approximately 10%.  Thus the expected 
size is well within the limits of sensitivity of this method.  The His•Tagged™ 
proteins’ sizes are expected to be approximately 37 kDa, and as Figure 2.9 (b) 
and (c) show, the recombinant protein bands lie between the 30 kDa and 40 kDa 
protein markers, closer to the bigger band.  Thus, the estimated and 
experimental molecular weights are very similar.  This is expected as the addition 
of a His•Tag™ involves only a few extra amino acid residues (about 6) on the 
end of the protein, which should not drastically influence the size, and therefore 
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the migration of the protein in the gel.  Thus the molecular mass estimated from 
SDS-PAGE should be very close to the theoretical mass and this is seen in 
Figure 2.9.  Estimation of the exact molecular mass from calibration with the 
marker proteins was not used as the software used did not always yield accurate 
results, due to nonlinearity of the calibration curve.  
 
From these test expression experiments, it was concluded that three hours was 
the best induction period, therefore preparative expression of the proteins was 
carried out for three hours after induction of the culture. 
 
2.3.6  SOLUBILITY OF THE N-TERMINAL GST•TAGGED™ PROTEIN 
E. coli is still the preferred expression host of recombinant proteins due to its 
advantages in ease of use, high growth and production rates, cost effectiveness, 
and availability. It has some disadvantages though, including low success rates 
for expressing eukaryotic proteins, the absence of most post-translational 
modifications, and the production of the target protein is often in the form of 
inclusion bodies (Baneyx, 1999).  Inclusion bodies are insoluble aggregates of 
the recombinant proteins expressed in E. coli.  The process used to refold 
proteins from inclusion bodies is difficult, and any improvements in the solubility 
of recombinant proteins in E. coli are therefore beneficial (Hammarström et al., 
2001).  One commonly used strategy to increase solubility is to make a fusion to 
a protein that is known to have high solubility.  There are several fusion proteins 
that have been shown to increase solubility in E. coli, one of them being 
glutathione-S-transferase (Smith and Johnson, 1988). 
 
Although some proportion of the target protein may be present in the soluble 
fraction of a cell lysate, even when inclusion bodies are formed, when using the 
pET system, with its very high expression levels, most of the target protein is 
present in aggregates (Novagen, 2003).  In general, the percentage of target 
protein found in the soluble form can be increased using conditions that decrease 
the rate of protein synthesis, like lower induction temperatures. 
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It has been shown that growth at 37°C causes some proteins to accumulate as 
inclusion bodies, while incubation at 30°C leads to the production of soluble, 
active protein (Schein and Noteborn, 1989).  Therefore, growth and induction at 
temperatures lower than 37°C can be used to increase the yield of soluble 
protein. 
 
The IPTG concentration used for induction can be adjusted to regulate 
expression of the recombinant protein from very low level expression to the fully 
induced high level expression associated with pET vectors.  Lower level 
expression may enhance the solubility and activity of some target proteins 
(Novagen, 2003).  Thus, lower IPTG levels may enhance the solubility of the 
target protein. 
 
The GST•Tag™ was added to the CD23 protein as a fusion partner in an attempt 
to increase the solubility of the protein which is usually insoluble and aggregates 
in inclusion bodies (Daniels et al., 2005).  Therefore, expression conditions were 
adjusted in an effort to express soluble exCD23.  This was achieved by lowering 
the induction temperature to 26°C as opposed to the standard use of 37°C for 
protein expression.  In addition, lower concentrations of IPTG were used.  Figure 
2.10 shows the SDS-PAGE gel for these samples, while the Western blot of a 
duplicate gel is shown in figure 2.11. 
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Figure 2.10 – SDS-PAGE analysis of the GST•Tagged™ protein expressed 
under conditions favouring solubilisation of the recombinant protein.  
Three different culture conditions were used; 1 was induced using 0.8 mM 
IPTG and grown at 26°C, 2 was induced using 0.6 mM IPTG and grown at 
26°C, and 3 was induced using 0.4 mM IPTG and grown at 26°C.  For all 
three cultures, 3 hours after induction, the cells were harvested by 
centrifugation and lysed with lysozyme treatment and sonification.  The 
resultant lysate was centrifuged at 20 000 rpm for 40 min at 4°C, and both 
the pellet and supernatant were analysed by SDS-PAGE.  Lane 1 contains 
the protein marker, peqGOLD Protein Marker II, with the sizes shown in 
kDa.  Lane 2 contains the pre-induction sample.  Lanes 3 and 6 contain the 
pellet and supernatant, respectively, of the culture grown under culture 
condition 1.  Lane 4 and 7 contain the pellet and supernatant respectively 
of the culture grown under culture condition 2, and lanes 5 and 8 contain 
the pellet and supernatant samples of the culture grown under culture 
condition 3.  The dashed box shows the recombinant protein. 
 
As figure 2.10 shows, the recombinant protein is present in the pellet of all three 
culture conditions, representing the insoluble form of the protein, present in 
inclusion bodies.  A faint band of the same size can be seen in the soluble 
fraction present in the supernatant, loaded in lanes 6, 7 and 8.  However, there is 
a similarly sized band in the pre-induction sample, seen in lane 2.  Due to the 
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uncertainty of the presence of the recombinant protein in the supernatant, a 
Western blot was performed on a duplicate gel to that shown in figure 2.10, with 
the primary antibody specific for the GST•Tag™.  The blot is shown in figure 
2.11.    
 
                                  
 
 
 
 
 
 
 
 
 
Figure 2.11 – Western blot for identification of the GST•Tagged™ protein.  
Lane 1 contains the protein marker (peqGOLD Prestained Protein Marker IV 
was used), the band sizes are shown in kDa.  A pre-induction sample was 
loaded in lane 2, while lanes 3 to 5 contained the pellet and lanes 6 to 8 the 
supernatant after 3 hours of induction, cell lysis with lysozyme treatment 
and sonification, and centrifugation.  Lanes are as for figure 2.10.  The 
dashed white box indicates the tagged recombinant protein.  
 
As discussed in section 2.3.5, the expected mass of the GST•Tagged™ protein 
is 63 kDa.  As figure 2.11 shows, the recombinant protein bands are seen 
approximately in line with the 55 kDa protein marker.  However, for the Western 
blot, prestained protein markers were used, in order to visualise the bands after 
transfer.  These proteins are covalently coupled to a chromophore, which affects 
the mobility of the protein.  The prestained markers are therefore only used for 
approximate molecular weight determinations and a more accurate estimate of 
the mass of the protein can be obtained from the duplicate gel, run with 
unstained protein markers (see figure 2.10).  From the duplicate gel, the 
recombinant protein bands can be seen slightly above the 60 kDa protein 
marker, very close to the expected size of 63 kDa.  Thus the protein bands 
indicated can be assumed to be the target protein. 
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GST has a theoretical average molecular mass of 27 000 Da (Brockwell et al., 
2000), and the bacterial glutathione-S-transferase protein can be seen in the pre-
induction sample (lane 2 in Figure 2.11), as well as the pelleted fractions in lanes 
3 – 5, indicated by the solid white box.  These protein bands lie adjacent to the 
33 kDa protein marker.  Taking into account the shift in mobility due to the 
coupled chromophore of the prestained marker, it falls within the expected size 
range for GST.  Due to the high solubility of GST, it is not expected to be in the 
pelleted, insoluble fraction, as seen in figure 2.11.  One explanation could be that 
the aggregated mass of insoluble protein present in the inclusion bodies trapped 
the GST in the insoluble fraction.  Alternatively, the cells may not have been 
properly lysed; however, there is no other evidence to further support this option.  
The same lysis procedure was used for all the protein preparations, and since 
inclusion bodies were isolated as expected from the His•Tagged™ exCD23 
expressions, which resulted in high yields of target protein, there is no evidence 
suggesting that cell lysis was incomplete.   
 
Although the recombinant protein is present in the insoluble fractions after 
induction (lanes 3, 4 and 5 in Figure 2.11), no detectable GST•Tagged™ protein 
is found in the soluble fraction (lanes 6, 7 and 8).  The addition of the GST•Tag™ 
was therefore not successful in increasing the solubility of recombinant exCD23, 
as even under conditions favouring solubility, i.e. lower temperature and IPTG 
concentrations, no target protein was present in the soluble fraction. 
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CHAPTER THREE – PROTEIN PURIFICATION AND BINDING STUDIES 
 
3.1  INTRODUCTION 
Proteins are the most abundant biological macromolecules, occurring in all cells 
and all parts of cells.  There is a great variety of proteins, with thousands of 
different kinds ranging in size from small peptides to huge polymers, all found in 
a single cell.  Proteins exhibit great diversity in their biological functions and 
include such varied products as enzymes, hormones, antibodies and transporters 
(Nelson and Cox, 2000).   In order to study an individual protein in any detail it 
must be separated from all other proteins and once a pure protein preparation is 
available its properties, amino acid composition and sequence can be 
determined. 
 
3.1.1  PROTEIN PURIFICATION 
A fundamental step for studying individual proteins is the purification of the 
protein of interest.  A variety of strategies have been developed for purifying 
proteins, depending on the different requirements of downstream applications.    
There are four basic steps required for protein purification and they are firstly cell 
lysis, secondly interaction of the protein with a matrix, washing, and finally 
elution. 
 
The source of a protein is generally tissue or microbial cells which need to be 
lysed in order to release their proteins into solution.  Cell lysis can be achieved in 
a number of ways including non-enzymatic methods, like sonication or French 
press by use of a detergent, or by using hydrolytic enzymes such as lysozyme. 
 
There are various methods for purifying a particular protein of interest in the 
extract obtained from cell lysis.  The extract is usually subjected to treatments 
that separate the proteins into different fractions based on some property of the 
protein, allowing it to be separated from the other proteins present in the solution 
(Nelson and Cox, 2000).  The most powerful methods for fractionating proteins 
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make use of column chromatography which takes advantage of differences in 
protein size, charge, binding affinity or other properties, permitting separation.  A 
porous solid matrix with the appropriate chemical properties is held in place in a 
column format (stationary phase), equilibrated in a buffered solution (mobile 
phase).  A solution containing the protein is applied to the column, which 
percolates through the solid matrix, with individual proteins moving at different 
rates through the column depending on their properties (Nelson and Cox, 2000).  
Although separation can be achieved using gravity flow, FPLC (Fast Protein 
Liquid Chromatography) makes use of high precision pumps to drive the mobile 
phase through the system resulting in high resolution and impressive versatility, 
with a high degree of automation which facilitates reproducible chromatography 
(Sheehan, 2000). 
 
Numerous modes of chromatography are available, each differing in the chemical 
basis fundamental to the interaction between the protein sample and the 
stationary phase.  In this study three different types of column chromatography 
were utilised, namely gel filtration, ion exchange and affinity chromatography. 
 
3.1.1.1  Gel filtration chromatography 
Proteins differ greatly in their size and shape, and gel filtration chromatography, 
also known as size exclusion chromatography, takes advantage of these 
differences to separate proteins in sample.  The stationary phase is made up of a 
gel consisting of beads with pores of a defined and narrow size range.  Only 
molecules below a particular mass can diffuse into the pore, where it will be 
retained momentarily.  Larger molecules will not be able to enter the beads and 
will therefore move freely through the column eluting in a single unresolved peak 
(Sheehan, 2000).  The smaller molecules will be retained depending on their 
mass, with the smallest molecules retained the longest.  Gel filtration 
chromatography can be used in protein purification, separating proteins based on 
differences in their molecular mass.  This approach is however limited in the 
  69 
loading volume and is often used as a polishing step, since alone it is unable to 
achieve complete purification of proteins (Sheehan, 2000). 
 
3.1.1.2  Ion exchange chromatography 
Proteins have a net charge on their surface at any given pH, resulting from the 
charged amino acid side chains.  At acidic pH, most proteins carry a net positive 
charge, while at alkaline pH they have a net negative charge.  Since the surface 
charge of a protein is dependant on the amino acid sequence, it can be regarded 
as a characteristic property of a particular protein and can therefore be used to 
separate proteins from each other (Sheehan, 2000).  Ion exchange 
chromatography is a form of adsorption chromatography in which charged 
proteins are exchanged for small ions of similar charge, like Na+ or Cl-, coming 
from salts.  The ions are attached to the stationary phase and are charged with 
counterions, which have a similar charge to the protein to be purified.  These 
counterions are exchanged in favour of the protein.  It is very important that the 
sample is free of any similarly charged species, since these will also bind to the 
column and are usually present in large molar excess relative to the protein 
concentration.  Desalting should therefore always be carried out before ion 
exchange chromatography (Sheehan, 2000).  Elution of the protein from the 
column is achieved by reversing the binding process and exchanging the protein 
for a counterion. 
 
3.1.1.3  Affinity chromatography 
Affinity chromatography is based on the principle of biospecific recognition, 
where a small ligand is immobilised on the stationary phase and the sample 
containing the protein to be purified is passed over the column.  Due to the highly 
specific nature of this biological recognition, only the molecule of interest will bind 
to the stationary phase, with all other molecules passing freely through the 
system (Sheehan, 2000).  Immobilised metal affinity chromatography (IMAC) is 
an example of affinity chromatography in which metal ions are immobilised onto 
the stationary phase and bind to metal-binding regions of proteins.  It has been 
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shown that proteins have an affinity for metal ions, and in 1975 a new concept for 
affinity purification was presented based on the interaction between amino acid 
side chains, particularly histidines, on the surface of a protein and immobilised 
transition metal ions (Porath et al., 1975). 
 
A greater specificity of binding can be obtained by using six or more histidine 
residues (Sheehan, 2000).  Advances in genetic engineering have enabled the 
construction of gene fusion products resulting in fusion proteins with the 
combined properties of the original gene products (Nilsson et al., 1997).  Genetic 
engineering has made a powerful purification technique possible, by genetically 
fusing an affinity fusion partner to the target protein.  These fusion proteins can 
often be purified to near homogeneity from crude biological mixtures by a single 
affinity chromatography step (Nilsson et al., 1997).  Fusion tags consisting of 
consecutive histidine residues were first described in 1988 by Hochuli et al., and 
are now the most commonly used tag for purification and detection of 
recombinant expressed proteins (Yip et al., 1989).  Poly-histidine tagged proteins 
adsorb to the metal-chelate adsorbent at neutral or slightly alkaline pH, as the 
imidazole group of the histidines is not protonated.  The target protein can then 
be eluted from the Ni2+-nitriloacetic acid (NTA) adsorbent at low pH or by 
competitive elution using imidazole (Nilsson et al., 1997). 
The interaction between proteins tagged with six consecutive histidine residues 
and Ni-NTA provides remarkable selectivity and strong affinity (Yu et al., 2005).  
As figure 3.1 shows, the affinity interaction is believed to be a result of the 
coordination of nitrogen in the imidazole side chain of the poly-histidine tagged 
protein with an empty coordination site on the metal ion.  The metal is 
immobilized to a support by forming a complex with a chelate that is covalently 
attached to the support.  NTA occupies four of the six ligand binding sites in the 
coordination sphere of the nickel ion, leaving the other two sites free to interact 
with the poly-histidine tag of the protein (Ho et al., 1998).  This interaction 
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provides strong binding at the terminal amine and the nitrogen of the imidazole 
ring (Ho et al., 1998). 
                                                                                                   
Figure 3.1 – Schematic representation of the interaction between 
immobilised Ni2+ ions and poly-histidine tagged recombinant proteins 
(taken from Yu et al., 2005). 
Poly-histidine tags offer several advantages for protein purification. The small 
size of the polyhistidine tag renders it less immunogenic than other larger tags. 
Therefore, the tag usually does not need to be removed for downstream 
applications following purification. A large number of commercial expression 
vectors that contain polyhistidine are available. The polyhistidine tag may be 
placed on either the N- or C-terminus of the protein of interest. And finally, the 
interaction of the polyhistidine tag does not depend on the tertiary structure of the 
tag, making it possible to purify otherwise insoluble proteins using denaturing 
conditions (Novagen, 2003). 
3.1.2  INCLUSION BODIES  
Major advances in genetic engineering have resulted in the development of 
bacterial expression systems, especially in E. coli, that are able to produce large 
amounts of proteins from the cloned genes (Misawa and Kamagai, 1999).  The 
abundance of protein expression systems makes efficient bacterial production of 
most proteins possible, however, high level expression of these recombinant 
proteins often leads to inclusion body formation (Lilie et al., 1998).  Inclusion 
bodies are dense, amorphous protein deposits found in the cytoplasmic and 
periplasmic spaces of bacteria (De Bernardez Clark, 2001), and are seen as 
large spherical particles containing up to 50% or more of the total cell protein, 
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often almost entirely the overexpressed protein (Lilie et al., 1998).  The 
recombinant protein found in inclusion bodies is insoluble and inactive.  
Therefore to obtain biologically active recombinant proteins from the inclusion 
bodies it is necessary to develop a simple and efficient procedure for renaturation 
(Misawa and Kamagai, 1999).  A three step strategy is generally used for the 
recovery of active protein from inclusion bodies, firstly inclusion body isolation 
and washing, solubilisation of the aggregated protein and finally refolding of the 
solubilised protein (De Bernardez Clark, 2001). 
 
3.1.2.1  Inclusion body isolation and solubilisation 
Cells containing inclusion bodies are disrupted by a combination of mechanical, 
chemical and enzymatic methods (De Bernardez Clark, 2001).  Inclusion bodies 
are characterized by a relatively high specific density and can therefore be 
harvested by centrifugation at moderate rotor speeds (Misawa and Kamagai, 
1999).  Major contaminants of inclusion body preparations are outer membrane 
proteins which are not part of the inclusion body particles, but co-purify as non-
solubilised protein in the inclusion body fraction (Lilie et al., 1998).  It is very 
important that complete cell lysis is achieved as intact cells sediment together 
with the inclusion bodies, contaminating them with host protein.  Separation of 
the contaminants from the inclusion body material can be achieved by extensive 
washing with detergents (Lilie et al., 1998).  The purified inclusion bodies must 
then be solubilised, and a variety of methods may be used.  The most commonly 
used solubilising agents are denaturants like guanidinium chloride and urea (De 
Bernardez Clark, 2001).  A key to the solubilisation process is the addition of a 
reducing agent to maintain cysteine residues in their reduced state, thereby 
preventing non-native disulphide bond formation in the protein solutions.  
Typically used reducing agents include β-mercaptoethanol and dithiothreitol, 
which should be added in excess to ensure complete reduction of all the cysteine 
residues (De Bernardez Clark, 2001), and to cleave any non-native disulphide 
bonds formed during preparation (Lilie et al., 1998).  Addition of these thiol 
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reagents in combination with chaotrophs allows reduction of the disulphide bonds 
by thiol-disulphide exchange (Misawa and Kamagai, 1999). 
 
3.1.2.2  Renaturation of inclusion body proteins  
In order to obtain correctly folded proteins after solubilisation of the inclusion 
bodies, excess denaturants and reducing agents must be removed and the 
reduced proteins transferred to oxidizing conditions.  Renaturation is initiated by 
the removal of the denaturant by either dilution or dialysis (Misawa and Kamagai, 
1999).  Due to the simplicity, dilution of the solubilised protein into renaturation 
buffer is the most commonly used method in small scale refolds (De Bernardez 
Clark, 2001).  The efficiency of renaturation depends on the competition between 
correct folding and aggregation, and to slow down the aggregation process 
refolding is usually performed at low protein concentrations, typically between 10 
and 100 µg/ml (Lilie et al., 1998).  The key to successful dilution is to control the 
rate of addition of the denatured protein to the renaturation buffer, and to ensure 
good mixing to maintain low local protein concentrations during refolding and 
thereby prevent aggregation (De Bernardez Clark, 2001). 
 
For disulphide-bonded proteins, the renaturation buffer must promote disulphide 
bond formation, i.e. oxidation.  This is achieved by supplementing the 
renaturation buffer with a redox system.  A mixture of the reduced and oxidized 
forms of a low molecular weight thiol reagent is added to the buffer, and provides 
the appropriate redox potential to allow formation and reshuffling of disulphide 
bonds.  These redox systems increase the rate and yield of 
renaturation/oxidation by aiding in rapid reshuffling of incorrect disulphide bonds 
(Misawa and Kamagai, 1999).  The most commonly used reagents in a redox 
system for this purpose are reduced (GSH) and oxidized (GSSG) glutathione (De 
Bernardez Clark, 2001). 
 
In addition to controlling factors such as temperature, pH and redox conditions, 
the presence of low molecular weight additives in the renaturation buffer have a 
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marked effect on the yield of renaturation (Lilie et al., 1998).  The most popular 
additive is L-arginine, usually used at a concentration between 0.4 and 1 M 
(Misawa and Kamagai, 1999).  Although the mechanism of action of the low 
molecular weight additives is still unclear, it appears that they play a role in 
suppressing aggregation by inhibiting the intermolecular interactions that lead to 
aggregate formation.  These additives may influence the stability and solubility of 
the native, denatured and intermediate states of the protein, they may act by 
changing the ratio of the rates of proper folding and aggregate formation, or they 
may merely solubilise the aggregates (De Bernardez Clark, 2001). 
 
3.1.2.3  Advantages of inclusion body formation 
Although the recovery of biologically active proteins from inclusion bodies is a 
complex process that needs to be optimized on a case by case basis, expression 
of the target protein in inclusion bodies can be advantageous.  Large amounts of 
highly enriched proteins can be found in the inclusion bodies, making up about 
50% or more of the total protein (Misawa and Kamagai, 1999).  The recombinant 
protein may be unstable in the cytoplasm of the E. coli host cell but because it is 
trapped in insoluble aggregates, it is generally protected from proteolytic 
cleavage (De Bernardez Clark, 2001).  The recombinant protein may also be 
toxic to the host cell in its native form, thereby making inclusion body expression 
the best available production method (Misawa and Kamagai, 1999).  And since 
inclusion bodies have a relatively high density, they can be separated from other 
cellular proteins by centrifugation with a purity of up to 90% under ideal 
conditions (Misawa and Kamagai, 1999).  
 
3.2  MATERIALS AND METHODS 
3.2.1  INCLUSION BODY ISOLATION 
E. coli cells from preparative expression of recombinant CD23 (section 2.2.1.3) 
were thawed on ice.  Lysozyme was added to thawed cells to 1 mg/ml and was 
incubated at room temperature for one hour, with end-over-end mixing.  The cells 
were chilled on ice and sonicated for 6 bursts of 30 seconds, pulsing at 50% duty 
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cycle and 40% power.  At least one minute was allowed between bursts for the 
cells to cool and the cells were kept on ice at all times.  The lysate was 
centrifuged at 47 500 x g for 40 minutes at 4°C, and the resultant pellet was 
resuspended in 15 ml IB wash buffer (50 mM Tris-HCl, pH 7.8, containing 0.3 M 
NaCl, 0.5 % LDAO, 0.2 % NaN3).  A Potter-Elvejham homogeniser was used to 
resuspend the inclusion bodies, using 6 – 7 strokes on ice.  The homogenate 
was transferred back into a centrifuge tube, while the Potter tube was rinsed with 
another 10 ml IB wash buffer, using 5 – 6 strokes on ice.  This wash step was 
added to the resuspended inclusion bodies and centrifuged as before at 47 500 x 
g for 40 minutes at 4°C.  Washing of the inclusion bodies was continued for eight 
wash steps.  After each wash, the supernatant was retained for analysis.  After 
all the washing steps were completed the inclusion body pellet was resuspended 
in 4 ml sonification buffer (50 mM Tris-HCl, 0.3 M NaCl and 0.2 % NaN3 at pH 
7.8), and stored at 4°C. 
 
3.2.2  SDS-PAGE ANALYSIS 
Electrophoresis was carried out as described in Chapter 2, section 2.2.14 to 
determine the purity of the protein samples (Laemmli, 1970). 
 
3.2.3  BCA PROTEIN CONCENTRATION DETERMINATION 
The most common method of determining protein concentrations in samples is 
protein assays based on the conversion of reagents to products with 
characteristic absorption spectra (Lorenzen and Kennedy, 1993).  The Lowry 
method has been used extensively for protein quantification in a number of 
biological samples (Brown et al., 1989).  However, due to the instability of the 
Folin-Ciocalteau reagent in alkaline medium, the complexity of the two step 
nature of this method, and the interference of non-ionic detergents and some 
buffer salts, another method may be preferable (Smith et al., 1985).  One such 
method which maintains the high sensitivity and low protein-to-protein variation 
associated with the Lowry technique is the bicinchoninic acid (BCA) assay.    
 
  76 
This assay is dependent on the biuret reaction, with production of a coloured 
complex between peptide bonds and copper atoms when protein is placed in an 
alkaline environment containing Cu2+.  The BCA assay uses the sodium salt of 
bicinchoninic acid to enhance the colour of the biuret reaction (Brown et al., 
1989).  The water soluble sodium salt of BCA is a sensitive, stable and highly 
specific reagent for Cu+ (Smith et al., 1985).  The BCA assay measures the 
reduction of Cu2+ in an alkaline medium at sites within the peptide (Hill and 
Straka, 1988).  It is thought that the reduction of Cu2+ to Cu+ occurs at the 
complexation site within the protein molecule, allowing the BCA to form a stable 
complex with the Cu+ ions, forming a highly coloured chromophore with an 
absorbance maximum at 562 nm (Smith et al., 1985).  The colour intensity is 
representative of the protein concentration present. 
 
Protein content of the unknown sample was determined spectrophotometrically 
using the BCA assay.  Sample (10 µl) was reacted with 200 µl reagent A (0.03 M 
sodium bicinchoninate, 0.2 M sodium carbonate, 0.007 M sodium tartrate, 0.1 M 
sodium hydroxide and 0.1 M sodium bicarbonate, at pH 11.25) and B (0.25 M 
copper sulphate) in a ratio of 1 : 50, in a microtitre plate.  The reaction was 
incubated at 37ºC for an hour and the absorbance was read at 540 nm using a 
Multiskan microtitre plate reader.  A BSA standard curve ranging from 3 mg/ml to 
0.1875 mg/ml was constructed to determine the protein content.  The protein 
samples were diluted appropriately in order for the absorbance values to fall 
within the range of the standard curve, shown in figure E.1 in annexure E.  
Double distilled water was used in place of the protein solution for the blank. 
 
3.2.4  PROTEIN REFOLDING BY RAPID DILUTION 
The protein concentration of the inclusion bodies was determined using the BCA 
assay, and the appropriate volume, corresponding to 50 mg of protein, was 
dissolved in the minimal volume of IB solubilisation buffer (6 M guanidinium, 20 
mM Tris, 0.02% NaN3 at pH 8) necessary to dissolve the protein, with ß-
mercaptoethanol added to a final concentration of 100 mM.  GSH and GSSG 
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were added to the refold buffer (1.5 M arginine, 100 mM Tris, 150 mM NaCl and 
10 mM CaCl2) to final concentrations of 5 and 0.5 mM respectively.  Once the 
GSH and GSSG were dissolved in the refold buffer, the dissolved inclusion 
bodies were added dropwise at 4°C to the refolding buffer, with continuous 
stirring.  Addition of the inclusion bodies to the refold buffer was done very slowly 
(about one drop per minute), and the progression of the refold was monitored 
using a redox potential assay.  The solution was allowed to continue stirring at 
4°C until the redox potential had dropped and stabilised.  After all the protein had 
refolded the solution was concentrated down to a smaller volume and purification 
was continued. 
 
3.2.5  REDOX POTENTIAL ASSAY 
The refolding process was monitored by following the redox potential of the 
solution over time.  This redox potential assay is based on the determination of 
sulfhydryl groups using the water-soluble aromatic disulfide compound 5,5′-
dithiobis(2-nitrobenzoic acid), DTNB (Ellman, 1959).  A reading was taken before 
the addition of the protein, then another after all the protein was added to the 
refold buffer.  Thereafter a reading was taken until the redox potential had 
stabilised.  The assay was performed in triplicate using 25 µl 1M Tris (pH 8.0), 2 
µl 100 mM DTNB made up in ethanol, 2 µl of the protein solution, and making the 
total volume up to 500 µl using double distilled water in a sterile Eppendorf tube.  
This solution (100 µl) was transferred into a well of a 96 well microtitre plate, and 
the absorbance was measured at 412 nm.  Double distilled water was used in 
place of the protein solution for the blank. 
 
3.2.6  CONCENTRATION OF REFOLDED PROTEIN SAMPLES 
In many of the steps during the purification procedure a large volume of liquid 
had to be concentrated down to a much smaller volume for subsequent 
experiments, without any loss of protein sample.  This was achieved in a number 
of ways depending on the initial volume of the solution and the volume required 
after concentration. 
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For large initial volumes (greater than 100 ml), an Amicon stirred ultrafiltration 
cell was used.  This apparatus allows for rapid concentration of macromolecular 
solutions by forcing the solution through a membrane under pressure, with 
continuous stirring.  The reservoir of the cell is magnetically coupled to a stirring 
bar which maintains fluid movement during the operation when placed on top of a 
magnetic stirrer.  This results in the reduction of negative effects of concentration 
polarization, especially the build up of concentrated solutes on the membrane.  In 
this study Millipore polyethersulfone ultrafiltration membranes were used with a 
molecular weight cut off of 10 000 Da, and N2 gas pressure of 75 psi. 
 
For smaller volumes Amicon Ultra centrifugal filter devices were used containing 
a regenerated cellulose filter, with a molecular weight cut off of 5 000 Da.  Two 
different sizes were used, 15 ml and 4 ml, depending on the volume of liquid to 
be concentrated.  These centrifugal filter devices are intended to be used for 
concentrating fluids prior to analysis.  The concentrated sample is recovered 
from the filter unit sample reservoir, while the ultrafiltrate is collected in the 
provided centrifuge tube.  It allows fast separation of solutes from low molecular 
weight compounds.  These filter devices were centrifuged at 3 500 x g at 4°C for 
as long as was necessary to obtain the desired amount of concentrated product. 
 
3.2.7  PURIFICATION OF N-TERMINAL HIS•TAGGED™ exCD23 
Fast Protein Liquid Chromatography with a variety of columns was used for the 
purification of the N-terminal His•Tagged™ recombinant protein, initially following 
the method described by Askew (2006). 
 
3.2.7.1  Gel filtration chromatography 
For preparative purification of the recombinant protein, it was passed through a 
HiLoad™ 26/60 Superdex™ 75 pg (Amersham Pharmacia Biotech, USA) gel 
filtration chromatography column using an Äkta FPLC (Amersham Pharmacia 
Biotech).  The protein sample was injected onto the column in 2 ml fractions, and 
run through the system at 2 ml/min using a 100 mM Tris, 150 mM sodium 
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chloride and 10 mM calcium chloride buffer at pH 8.  Fractions (5 ml) were 
collected and the relevant peaks were pooled and concentrated using Amicon 
Ultra centrifugal filters.  The protein content was determined using the BCA 
assay, while purity of the sample and the molecular weight of the protein was 
estimated using 10 µl for SDS-PAGE analysis. 
 
3.2.7.2  Ion exchange chromatography  
A QHyperD 10 (Beckman, USA) anion exchange column was used for further 
purification of the recombinant N-terminal His•Tagged™ protein.  Ion-exchange 
chromatography was performed by injecting 2 ml of the protein sample onto the 
column at a flow rate of 0.5 ml/min in a 50 mM Tris buffer at pH 8.  Once a stable 
baseline was established after the fall through peak had been collected, the 
protein of interest was eluted from the column using 1 M sodium chloride in a 50 
mM Tris buffer at pH 8.  A linear gradient was used for elution over 30 ml to 350 
mM sodium chloride.  Thereafter the gradient was increased to 1M sodium 
chloride.  Fractions (1 ml) were collected and the peaks were analysed using 10 
µl of the sample by SDS-PAGE.  Once again the tubes containing the relevant 
peaks were pooled and concentrated using Amicon Ultra centrifugal filters. 
 
3.2.7.3  Affinity chromatography   
The final step in the purification of the N-terminal His•Tagged protein was Ni-IDA 
affinity chromatography.  The protein sample (2 ml) was injected onto a 1 ml 
HiTrap™ Chelating HP affinity column (Amersham Biosciences, USA) charged 
with NiSO4 (0.1 M) at a flow rate of 1 ml/min.  The column was initially rinsed with 
ddH2O for more than 5 ml, followed by 2 ml 1 M NiSO4.  Another rinse step with 
ddH2O was performed, followed by equilibration of the charged column in 
equilibration buffer (50 mM Tris, 250 mM NaCl at pH 8).  Once a stable baseline 
was achieved the protein solution was injected onto the column.  Once a stable 
baseline was established, the column was rinsed with 50 mM imidazole (in 50 
mM Tris, 250 mM sodium chloride buffer at pH 8) to wash off any non-specifically 
bound proteins.  The His•Tagged™ protein was eluted from the column using 
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250 mM imidazole in the same buffer.  Fractions (3 ml) were collected and the 
peaks were analysed by SDS-PAGE.  Once more the relevant peaks were 
pooled and concentrated, with protein concentration determined using the BCA 
assay. 
 
3.2.8  PURIFICATION OF C-TERMINAL HIS•TAGGED™ exCD23  
3.2.8.1  Affinity chromatography 
Injections (2 ml) of the concentrated refolded protein solution were loaded onto a 
1 ml HiTrap™ Chelating HP affinity column as described in section 3.2.7.3.  
Equilibration buffer was run through the system until a stable baseline was 
reached after the fall through peak was collected.  Approximately 5 ml of wash 
buffer (50 mM Tris, 250 mM NaCl, 50 mM imidazole at pH 8) was used to elute 
non-specifically bound proteins, followed by elution of the recombinant protein 
using a 250 mM imidazole elution buffer (50 mM Tris, 250 mM NaCl, 250 mM 
imidazole at pH 8).  Fractions (3 ml) were collected and the tubes containing the 
peak of interest were pooled and concentrated.  SDS-PAGE analysis was used 
to determine the protein purity and concentration was determined using the BCA 
assay.  
 
3.2.8.2  Gel filtration chromatography 
In order to further purify the C-terminal His•Tagged™ protein, it was passed 
through a HiLoad™ 26/60 Superdex™ 75 pg gel filtration chromatography 
column as described in section 3.2.7.1. 
 
3.2.9  PURIFICATION OF β-GALACTOSIDASE 
All pET vectors include an induction control, in the form of a glycerol stock of the 
appropriate vector containing the E. coli β-galactosidase gene as an insert.  The 
pET-28 (b) system includes a glycerol stock of E. coli BL21(DE3) cells with the 
pET-28 vector containing a His•Tagged™ sequence of the β-galactosidase gene.  
These induction controls are used for confirmation of bacterial expression and to 
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verify affinity purification under native and denaturing conditions (Novagen, 
2003). 
 
Large amounts of the 119 kDa protein accumulate in the soluble fraction using 
standard induction conditions, thus it is relatively quick and simple to obtain large 
amounts of pure protein, as the presence of the affinity tag allows for single step 
purification in many cases. 
 
In this study β-galactosidase was expressed from the pET-28 induction control 
and purified using nickel affinity chromatography to obtain a negative control 
protein, containing a His•Tag™, for use in IgE binding studies. 
 
3.2.9.1  β-galactosidase expression 
A 10 ml overnight LB culture with 15 µg/ml kanamycin was grown from a single 
colony inoculated from a streak plate of the frozen glycerol stock of the induction 
control.  This culture was grown at 37°C with shaking at 180 rpm on an orbital 
shaker.  The overnight culture (5 ml) was used to inoculate 250 ml LB-kanamycin 
at 37°C, 180 rpm, until the OD600 value of roughly 0.6 was obtained.  IPTG was 
added to a final concentration of 0.4 mM to induce expression.  After three hours 
of expression the cells were harvested by centrifugation at 5 000 x g for 30 
minutes at 4 °C.  The cells were resuspended in lysis buffer (50 mM NaH2PO4, 
300 mM NaCl and 5 mM imidazole at pH 8) and frozen and stored at -80°C. 
 
3.2.9.2  β-galactosidase purification 
The frozen cells were thawed and treated with lysozyme, spinning end-over-end 
for 30 minutes at room temperature.  They were then sonicated for six cycles of 
30 seconds each, pulsing at 50% duty cycle and 40% power.  At least one 
minute was allowed between bursts for the cells to cool, with the cells kept on ice 
at all times.  After sonification, the lysate was centrifuged for 15 minutes at 5 000 
x g at 4°C.  The supernatant was filtered through a 0.45 µm acetate sterile 
syringe filter (Osmonics) and loaded onto an FPLC system for purification. 
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The supernatant (10 ml injections) was loaded onto a 1 ml HiTrap™ Chelating 
HP affinity column, charged with 0.1 M NiSO4.  The column was developed as 
described in section 3.2.7.3.  The fractions containing the desired pure protein 
were concentrated down to approximately 2 ml and stored at -20°C. 
 
A second β-galactosidase purification was attempted using a similar method to 
that described above.  The filtered supernatant was injected (10 ml injections) 
onto a 1 ml HiTrap™ Chelating HP affinity column, charged with 0.1 M NiSO4 as 
described previously.  The column was equilibrated in equilibration buffer (50 mM 
Tris, 250 mM NaCl at pH 8) and once a stable baseline was achieved the protein 
solution was injected onto the column.  A wash step was performed to remove 
any non-specifically bound proteins using a gradient of 50 mM imidazole (20% of 
the elution buffer containing 50 mM Tris, 250 mM NaCl, 250 mM imidazole at pH 
8) over ten minutes at a flow rate of 1 ml/min.  The His•Tagged™ β-
galactosidase was eluted from the column with a step up to 100% of the elution 
buffer.  Fractions (3 ml) were collected and the tubes containing the peaks of 
interest were pooled and analysed by SDS-PAGE.  The FPLC fractions 
containing the protein of interest were pooled and dialysed against various 
buffers to remove the imidazole from the protein solution. 
 
In an attempt to purify β-galactosidase without the use of imidazole, a 
competitive elution was attempted using the 1 ml HiTrap™ Chelating HP affinity 
column charged with NiSO4 and 1 M NH4Cl for elution.  The column was charged 
as described before and equilibrated in a 0.02 M sodium phosphate binding 
buffer containing 250 mM NaCl at pH 7.2, and the filtered supernatant (5 ml) was 
injected onto the column.  The bound protein was eluted from the column using a 
ten minute gradient of the elution buffer (1 M NH4Cl, 250 mM NaCl and 0.02 M 
sodium phosphate at pH 7.2) at a flow rate of 1 ml/min.  Fractions (3 ml) were 
collected and analysed using SDS-PAGE. 
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3.2.10  THROMBIN CLEAVAGE 
The introduction of a protease or chemical agent recognition sequence between 
the fusion tag and the target protein allows for the removal of the affinity fusion 
partner by site-specific cleavage (Nilsson et al., 1997).  This is important as for 
certain applications it is necessary to remove the affinity fusion partner.  
Chemical cleavage methods are relatively economical, but the reaction 
conditions are harsh and may lead to protein degradation or modification of the 
amino acid chains.  In addition, these methods are relatively unspecific and can 
result in unwanted cleavage within the target protein (Nilsson et al., 1997).  The 
alternative is the use of enzymatic cleavage methods, which are preferable to the 
chemical methods as they are generally more specific and can be performed 
under milder conditions.   
 
After cleavage, the released affinity tag can be captured by passing the cleavage 
mixture over an affinity matrix, with the cleaved target protein collected in the 
flowthrough (Nilsson et al., 1997).  However, the protease remains in solution 
with the target protein and must be removed in order to obtain pure target 
protein.  To avoid such problems affinity-tagging of the protease has been used 
to easily remove the enzyme after cleavage (Nilsson et al., 1997). 
 
In this experiment biotinylated thrombin was used for removal of the affinity 
fusion tag, which was separated from the reaction mixture with streptavidin 
agarose beads.  The strong binding between biotin and streptavidin (Kd ~ 10-15 
M) is frequently used in biochemistry and molecular biology (Nilsson et al., 1997).  
In this case, the tagged enzyme was removed from the reaction mixture by 
strongly binding to the streptavidin agarose, and separated by centrifugation to 
release the target protein into the filtrate.  Since the cleaved His•tag™ could not 
be purified from the target protein by affinity chromatography, as the protein 
contained another poly-histidine tag on the C-terminal side, it was removed from 
the solution during concentration using Amicon Ultra centrifugal filters, with a 
molecular weight cut off of 5 000 Da.  The small cleaved tag would not have 
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been retained by these filters, and thus by concentrating, the target protein was 
purified from the cleaved affinity tag.      
 
A thrombin kit (Novagen, USA) was used to remove the N-terminal His•tag™ 
from the recombinant double His•tagged™ protein, leaving only a C-terminal tag.  
This was carried out according to the manufacturer’s instructions.  Briefly, a small 
scale experiment was performed using 10 µg of the target protein and four 
different thrombin concentrations (25X, 50X, 100X and 200X dilutions of the 
commercial enzyme).  The reaction was allowed to proceed overnight at room 
temperature, with the success of the cleavage determined using SDS-PAGE 
analysis.  Once the conditions for successful cleavage were established, the 
reaction was proportionately scaled up to cleave all the target protein.  After 
overnight cleavage using the lowest thrombin concentration (0.005 U/µl), the 
biotinylated enzyme was removed with streptavidin agarose as described and 
supplied in the Novagen Thrombin Cleavage/Capture Kit.  A ratio of 32 µl of the 
slurry was used per unit of enzyme.  The cleaved target protein was recovered 
by spin-filtration, the protein collected in the filtrate.     
 
3.2.11  ENDOTOXIN REMOVAL 
Lipopolysaccharide (LPS or endotoxin) is a major component of the outer 
membrane of gram-negative bacteria.  It consists of a hydrophobic lipid A portion 
and a hydrophilic oligosaccharide core, either with or without O-specific 
polysaccharides (Adam et al., 1995).  LPS, and more specifically the lipid A 
moiety, shows a wide range of biological activities including toxicity, even in the 
sub-nanogram range (Adam et al., 1995).  Detoxi-Gel™ AffinityPak™ Pre-
packed 1 ml Endotoxin Removal Gel columns (Pierce, USA) were used to 
remove bacterial endotoxins from the purified protein samples.  This endotoxin 
removing gel uses polymyxin B immobilised on agarose to bind and remove 
pyrogens from solution.  Polymyxin B belongs to a family of antibiotics, the 
polymyxins, containing a cationic cyclopeptide with a fatty acid chain.  Removal 
of the endotoxin is achieved by binding of the polymyxin B to the lipid A portion of 
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bacterial lipopolysaccharide (Issekutz, 1983).  This neutralises the biological 
activity of the endotoxins, although not all endotoxins are effectively neutralised 
in this way (Kluger et al., 1985). 
 
The immobilised polymyxin B gel is a stable affinity matrix that prevents leaching 
of the ligand into the sample.  Sodium deoxycholate is used to strip the bound 
endotoxins from the gel, thus regenerating the column.  This is the most efficient 
method for stripping the gel of endotoxins (Adam et al., 1995).  The column was 
regenerated using 5 column volumes (5 ml) of 1% sodium deoxycholate in 
pyrogen-free water, followed by five column volumes of pyrogen-free water to 
remove the detergent.  The column was equilibrated with 5 column volumes 
pyrogen-free buffer (100 mM Tris, 150 mM sodium chloride and 10 mM calcium 
chloride).  The sample was then applied to the column and incubated for an hour, 
with the top and bottom of the column capped.  The sample was eluted from the 
column by removing the top and bottom caps sequentially and adding pyrogen-
free buffer to elute the sample.  The sample was collected by gravity flow through 
the column using aliquots of the pyrogen-free buffer for elution.  The protein 
concentration of the collected aliquots was determined using the BCA assay, and 
the protein rich aliquots were pooled and concentrated in an Amicon Ultra 
centrifugal filter. 
 
3.2.12  ENDOTOXIN DETECTION AND QUANTIFICATION 
The most sensitive and specific method available to detect and measure 
bacterial endotoxins is the LAL assay (Petsch et al., 1998).  This test utilises the 
blood corpuscle extracted from horseshoe crabs, Limulus, and is known as the 
Limulus amebocyte lysate (LAL) test.  The assay is based on the formation of a 
firm gel after the reaction of endotoxin with various endotoxin-sensitive clotting 
factors involved in the LAL enzymatic cascade (Haishima et al., 2003).  The 
strength of the gel clotting reaction is proportional to the endotoxin concentration, 
allowing for detection, and moreover, quantification of the endotoxin (Haishima et 
al., 2003).  It was initially discovered, in 1956, that gram negative bacterial 
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endotoxin caused limulus blood to clot, a powerful defence used by the crabs 
against bacterial infection (Ding and Ho, 2001).  But today, the components of 
the endotoxin-induced coagulation cascade have been well characterised, and a 
synthetic substrate, able to release a chromophore at the end of the cascade 
reaction, can be incorporated into the LAL reagent, allowing for colourimetric 
determination of the amount of endotoxin present, as the absorbance of the 
chromophore can be related to the endotoxin concentration (Haishima et al., 
2003).  The coagulation cascade is shown in figure 3.2.  
 
In the coagulation cascade, endotoxin activates both forms of Factor C, which is 
the endotoxin-sensitive serine protease responsible for the initiation of the 
clotting reaction (Ding and Ho, 2001).  Single-chain Factor C exhibits a reversible 
activation reaction, indicating a form of feedback in the coagulation cascade 
(Ding and Ho, 2001).  An alternative pathway to clot formation involves an 
endotoxin-independent mechanism, and is shown in figure 3.2 in dashed arrows. 
 
                  
Figure 3.2 - The coagulation cascade reaction in the horseshoe crab 
amoebocyte lysate, used in the LAL assay for endotoxin detection and 
quantification (taken from Ding and Ho, 2001). 
 
A Charles River Endosafe (USA) Limulus amebocyte lysate kit was used for the 
quantitative detection of bacterial endotoxin in the protein samples to be used for 
cell culture.  This end point chromogenic test is a simple, reproducible test that 
monitors the appearance of a yellow colour, where the colour intensity is directly 
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related to the endotoxin concentration in the sample.  Endotoxin levels in 
unknown samples are quantitatively determined by comparison to a standard 
curve.  Endotoxin testing was carried out according to the manufacturer’s 
instructions. 
 
3.2.13  IgE BINDING  
The advantages of an affinity fusion tag have already been discussed in section 
3.1.1.3, but an additional advantage to those previously mentioned, is the strong 
interaction between polyhistidine tags and immobilised Ni2+ ions resulting in 
direct immobilisation of tagged proteins, allowing protein-protein or protein-DNA 
interaction studies (Nilsson et al., 1997).  In the study of different biological 
interactions, it is really convenient to have the interacting protein immobilised in a 
direct manner through an affinity tag.  This allows proper orientation of the 
protein molecule, in a controlled and expected manner, in contrast to non-specific 
binding, where the orientation is never certain. 
 
In this study, His select Ni2+ coated 96 well plates (Sigma, USA) were used to 
immobilise the recombinant CD23 through the His•Tag™ onto the plate, and then 
study binding of the protein to IgE.  The protein (20 µg of each, in a total assay 
volume of 100 µl) was coated onto the wells of the microtitre plate and allowed to 
bind overnight at 4°C.  All the wells were washed three times, for five minutes 
each, with 300 µl TBS-T (TBS containing 0.05% Tween 20).  The wells were then 
filled with blocking solution (250 µl, 0.5% BSA in TBS-T) at 4°C overnight.  
Another three, five minute, washing steps with TBS-T were performed.  Human 
myeloma IgE (OEM Concepts, USA) was added to the wells (100 µl) in various 
concentrations ranging from 1 µM to 0.0625 µM, diluted in TBS, and incubated 
for one hour at room temperature.  The plate was then washed five times, for five 
minutes each, with 300 µl TBS-T.  Horse radish peroxidase conjugated mouse 
anti-human IgE (Zymed, USA) was then added to the wells and incubated for an 
hour at room temperature.  The secondary antibody (0.5 mg/ml) was diluted 1:1 
000 in TBS and 100 µl was added to each well.  After the hour incubation, the 
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wells were washed seven times for 30 seconds each, with 300 µl TBS-T.  
Detector solution (3, 3’, 5, 5’ – tetramethyl benzidine, TMB, from Sigma) was 
added to each well (100 µl), and colour development was allowed to proceed to 3 
minutes.  Stop solution (50 µl 2 M H2SO4, Sigma) was then added and the 
absorbance was read at 450 nm in a BioTek PowerWave XS multiplate reader, 
using BioTek KC4 software. 
 
3.3  RESULTS AND DISCUSSION 
3.3.1  INCLUSION BODY ISOLATION 
The target proteins were not present in the soluble fraction of the E. coli cell 
lysate, and were expressed in inclusion bodies.  Isolation of the recombinant 
CD23 therefore involved inclusion body preparation and subsequent refolding 
and renaturation of the denatured protein, followed by further purification through 
chromatography. 
 
A large amount of relatively pure recombinant protein was obtained from the 
inclusion bodies, as figure 3.3 shows.  The expected size of the target protein is 
approximately 37 kDa, and as can be seen in figure 3.3, the protein band 
obtained in the inclusion body preparation is in the correct size range, present 
between the 30 kDa and 40 kDa markers.  The protein band of interest falls just 
below the 40 kDa marker, corresponding to a molecular mass in the region of 37 
kDa.  Although a small amount of the target protein was lost in each washing 
step, it was not much and was tolerable as each wash step improved the purity of 
the final preparation.  The first few washing steps were more effective than 
subsequent steps, as seen in figure 3.3, with the first two washing steps 
removing the majority of the contaminating E. coli proteins.  The subsequent 
washes did not remove large amounts of host protein and in the final step, the 
eighth wash, it appears that very little, if any, contaminants were removed. 
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Figure 3.3 – Inclusion body preparation for the double His•Tagged™ 
protein.  The labelled lanes contain the following: (M) protein marker with 
the 40 kDa and 30 kDa sizes shown on the gel, (1) the supernatant after the 
1st wash step, (2) the supernatant after the 2nd wash step etc to the 8th wash 
step in the lane marked (8).  The inclusion body preparation is present in 
the lane marked ‘IB’. 
 
The amount of recombinant protein obtained in the inclusion body isolation was 
dependant on the volume of bacterial culture used for expression, as table 3.1 
shows.  More C-terminal His•Tagged™ protein was needed than N-terminal 
His•Tagged™ protein, as it was required for cell work in addition to binding 
studies, therefore a larger culture was used, and resulted in more than double 
the amount of protein present in the inclusion body preparation. 
 
Table 3.1 – Protein concentrations of the inclusion body preparations, 
determined using the BCA assay 
Protein Volume of 
culture 
Protein concentration 
(mg/ml) 
Total protein  
(mg) 
N-Terminal 
His•Tagged™ CD23 1 ℓ 22 ~132 
C-Terminal 
His•Tagged™ CD23 2 ℓ 51.82 ~311 
 
 
 
M 1 2 3 4 6 8 IB
40
30
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3.3.2  N-TERMINAL HIS•TAGGED™ exCD23 
The inclusion body preparation was refolded using the rapid dilution method and 
the large volume was concentrated down to approximately 10 ml in order to carry 
out gel filtration chromatography.  Relatively pure refolded protein was obtained 
after gel filtration, although some contaminating proteins were still present in the 
sample as the SDS-PAGE results show in figure 3.4.  The majority of the 
collected protein fraction obtained after gel filtration chromatography was 
approximately 37 kDa in size, as determined from SDS-PAGE analysis.  The 
protein band of interest was found between the 30 and 40 kDa protein markers, 
which corresponds to the expected size of the target recombinant exCD23. 
 
The first peak obtained from the gel filtration column, labelled ‘1’ in figure 3.4, is 
the same protein as that seen in the larger second peak (labelled ‘2’), as shown 
in the SDS-PAGE analysis.  Peak 1 represents the unfolded aggregated 
recombinant protein obtained in the preceding refolding step.  The third peak (‘3’) 
contains the GSH and GSSG present in the refolding buffer, and these 
components are not visible on the acrylamide gel, stained with Coomasie Brilliant 
Blue.  The largest peak, ‘2’, contains the refolded recombinant protein in a fairly 
pure preparation. 
 
 
 
 
 
 
 
 
Figure 3.4 – Chromatogram obtained after gel filtration chromatography of 
the N-Terminal His•Tagged™ exCD23.  The SDS-PAGE analysis of the 
separate peaks is shown as an inset.  The numbers above each peak show 
the lanes in which they were loaded on the acrylamide gel.  The lane 
marked with ‘M’ contains the protein marker (peqGOLD Protein Marker II). 
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In an attempt to further purify the N-Terminal His•Tagged™ exCD23, an anion 
exchange column was used.  The results of this procedure are shown in figure 
3.5. 
 
As the acrylamide gel in figure 3.5 shows, no significant improvement in purity 
was seen in the protein sample after ion exchange chromatography was used.  
The protein is relatively pure, but contains small amounts of contaminating 
protein of a similar size.  The salt gradient used for elution was not effective in 
resolving the recombinant protein from the contaminating proteins and therefore 
no further significant purification was achieved with this column.  
 
 
    
 
 
 
 
 
 
 
 
 
Figure 3.5 – Chromatogram obtained after ion exchange chromatography of 
the N-Terminal His•Tagged™ exCD23.  The SDS-PAGE analysis of the 
separate peaks is shown as an inset.  The lane marked with ‘M’ contains 
the protein marker (peqGOLD Protein Marker II), while the other lanes of the 
gel contain fractions collected through the peak. 
 
Since the protein contained a His•Tag™, and Ni2+ has been shown to interact 
strongly with polyhistidine residues, an affinity column charged with nickel ions 
was used to selectively bind the tagged recombinant protein.  The results of this 
experiment are shown in figure 3.6. 
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The first peak shown in figure 3.6 (unlabelled) was the flow through peak, and 
hence contained all the proteins in the sample that did not bind to the nickel 
column.  This fraction is fairly large, and represents the contaminating proteins 
that were present in the previous protein preparations obtained after gel filtration 
and ion exchange chromatography.  An imidazole wash step was used during the 
affinity chromatography to remove any non-specifically bound proteins from the 
nickel column.  This fraction is shown in peak 1, and the gel lane marked ‘1’.  As 
the acrylamide gel shows, this fraction does not contain the recombinant protein 
of interest, but two protein bands of a similar size to the target protein are 
present, clearly the contaminating proteins seen in figures 3.4 and 3.5.  The 
peaks labelled ‘2’ and ‘3’ in figure 3.6 contain very pure target protein, as the 
acrylamide gel indicates.  Two peaks containing the N-Terminal His•Tagged™ 
exCD23 are seen in the chromatogram, although SDS-PAGE analysis revealed 
that both peaks consisted of the same protein.  The reason for this anomaly is 
not known. 
 
   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 – Chromatogram obtained from nickel affinity chromatography 
of the N-Terminal His•Tagged™ exCD23.  The inset shows the resultant 
SDS-PAGE gel, with the numbered lanes containing aliquots of the peaks 
numbered with the corresponding numbers.  The lane labelled ‘M’ contains 
the protein marker.  
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Regardless of the presence of two separate peaks, the fractions were pooled and 
an extremely pure protein preparation was achieved using this method.  As table 
3.2 shows, approximately 1.11 mg of pure recombinant protein was obtained 
after the affinity chromatography purification procedure.  Although this step 
resulted in a relatively poor recovery of protein from the previous step, 31%, no 
specific assay for the protein of interest is available.  Therefore the loss of protein 
in successive purification steps not only represents the loss of target protein but 
also the decrease in contaminating proteins present in the sample.  Thus, the 
lower the yield from the previous step, the greater the purity of the preparation of 
the protein of interest.  And as the first, unlabelled, peak obtained in figure 3.6 
suggests, a large amount of contaminating protein was removed from the 
sample, and thus a large decrease in total protein is expected.  
 
Table 3.2 – Purification table for the N-Terminal His•Tagged™ exCD23.  
Only 50 mg of the inclusion body preparation was used for refolding and 
further purification. 
Procedure Protein 
concentration 
(mg/ml) 
Volume 
(ml) 
Total 
protein 
(mg) 
Yield 
(%) 
IB preparation 22 6 132 - 
After refold 4.8 10 48 96 
After gel filtration 3.5 1.5 5.3 11 
After anion exchange 1.8 2 3.6 7.5 
After affinity 
chromatography 0.6 2 1.1 2.3 
 
3.3.3  C-TERMINAL HIS•TAGGED™ exCD23 
Since the Ni2+ affinity column provided such excellent results for the N-Terminal 
His•Tagged™ protein purification, it was used for the purification of the C-
Terminal His•Tagged™ protein too.  The concentrated refolded protein solution 
was loaded directly onto the Ni2+ affinity column.  The results of this experiment 
are shown in figure 3.7. 
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As figure 3.7 shows, the components of the refolding buffer had no influence on 
the affinity chromatography system used for the purification.  A single peak was 
obtained using imidazole elution, which contained purely the target recombinant 
protein, as the SDS-PAGE gel shows.  The first, large unlabelled peak in figure 
3.7 was the flow through peak, and this fraction is expected to be large, with a 
high protein concentration, as it contains all the contaminating proteins present in 
the refold mixture.  Good separation was achieved in this system, with no non-
specific binding on the column, as no protein was eluted in the imidazole wash 
step.  Thus the eluted fraction contained pure recombinant CD23. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 – Chromatogram obtained from nickel affinity chromatography 
of the C-Terminal His•Tagged™ exCD23.  The inset shows the resultant 
SDS-PAGE gel, with the lane labelled with the arrow containing the 
similarly labelled peak in the elution profile.  The lane labelled ‘M’ contains 
the protein marker.  
 
In order to remove the imidazole from the protein sample and separate refolded 
recombinant protein from the aggregated form from the refold reaction, the 
sample was run through a gel filtration system.  The results of this method are 
shown in figure 3.8. 
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The IMAC method did not separate the aggregates from the successfully 
refolded protein.  This is seen by the two peaks, first and second, in figure 3.8.  
This is entirely expected as the aggregated protein would also be His•Tagged™ 
and therefore would also bind to the affinity column.  However, good separation 
of these two protein species was achieved with the gel filtration column, as 
shown by the high purity seen in the acrylamide gel.  The third peak obtained in 
figure 3.8 was not a protein fraction, but rather the imidazole used in the buffer 
for elution from the nickel column. 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 – Chromatogram obtained from gel filtration chromatography of 
the C-Terminal His•Tagged™ exCD23.  The SDS-PAGE analysis of the 
fractions is shown in the inset.  The lane labeled with ‘M’ contains the 
protein marker, while the lane labeled with an arrow contains the protein 
fraction similarly labeled in the chromatogram. 
 
The purification process for His•Tagged™ proteins developed here is effective, 
resulting in pure protein preparations using a relatively simple and rapid method.  
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No buffer changing steps between the chromatographic steps are necessary and 
the resultant purity and yield of the target protein is good.  The incorporation of a 
His•Tag™, which is easily removable after purification, offers a definite 
improvement for recombinant CD23 purification to that described by Askew 
(2006). 
 
Almost exactly double the amount of C-Terminal His•Tagged™ exCD23 (2.2 mg) 
was obtained after the purification than N-Terminal His•Tagged™ protein (1.11 
mg) (see tables 3.2 and 3.3).  This is expected as double the amount of bacterial 
culture was used for the C-Terminal His•Tagged™ protein expression.  As 
before, the decrease in total protein is due to the loss of contaminating E. coli 
proteins from the sample, and is not entirely loss of target protein.  Thus the low 
yields after successive purification steps do not indicate merely loss of target 
protein, but also decreases in the amount of contaminating proteins, and hence 
increasing purity of the sample.  The C-Terminal His•Tagged™ protein 
underwent an additional purification step to the N-Terminal His•Tagged™ protein, 
namely endotoxin removal, which is usually accompanied by a large expected 
loss in protein yield.  Therefore in comparison, the purification method developed 
for the C-Terminal His•Tagged™ protein was effective and resulted in a good 
yield of pure protein.    
 
Table 3.3 – Protein purification table for the C-Terminal His•Tagged™ 
protein.  Only 150 mg of the inclusion body preparation was used in the 
refold reaction. 
Procedure Protein 
concentration 
(mg/ml) 
Volume 
(ml) 
Total 
protein 
(mg) 
Yield 
(%) 
IB preparation 51.8 6 311 - 
After refold 10 8 80 53 
After affinity 
chromatography 2.7 2 5.4 3.6 
After gel filtration 1.8 2 3.6 2.4 
After endotoxin 
removal 3.2 0.7 2.2 1.5 
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The recombinant proteins did not appear to be very stable upon storage.  Even 
after protease inhibitor cocktail was added to the protein preparations, and 
storage at -20°C, there appeared to be a slow degradation of the protein, seen as 
bands of a similar but smaller size on acrylamide gels.  The amount of protein 
cleavage appeared to increase with increased storage time.  Letellier et al. 
(1990) also noted the instability of recombinant purified 37 kDa sCD23.  The 
authors noticed that after purification to homogeneity, 45 kDa CD23 molecules 
were unstable and degraded into 37, 33, 29, and 25 kDa fragments, as illustrated 
in figure 3.9 by Bailey et al. (1998).  
 
 
 
 
 
 
Figure 3.9 – Cleavage pattern of intact CD23 (taken from Bailey et al., 1998). 
 
Due to the difficulty in obtaining convincingly pure preparations of 45 kDa CD23, 
the proteolytic activity of soluble CD23 fragments was examined.  The instability 
of the 37 kDa sCD23 molecule suggested that it might be capable of such 
activity, and in fact proved capable of cleaving radiolabelled 45 kDa and 37 kDa 
CD23 into 25 kDa fragments (Letellier et al. 1990).  Three such observations 
were made which argued against the possibility of the presence of a co-purified 
protease and led the authors to suggest that an autoproteolytic mechanism was 
involved. 
 
It is now widely accepted that the cleavage of membrane bound 45 kDa CD23 is 
as a result of the proteolytic action of an as yet partially characterized 
metalloprotease (Marolewski et al., 1998, Bailey et al., 1998, Bailey et al., 1999, 
Lampert et al., 1999, Cabrera et al., 2003).  However, the instability of the 37 kDa 
sCD23 fragment has been documented, and consequently so has the difficulty in 
obtaining entirely pure preparations of this protein.  The instability of this 
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molecule may be inherent in its structure.  The amino acid substitutions in the 
DNA sequence, discussed in chapter 2, may appear to influence the stability of 
the proteins.  However, both the N-Terminal His•Tagged™ protein, with no amino 
acid substitutions, and the C-Terminal His•Tagged™ protein showed degradation 
over time.  Thus the amino acid substitutions can not be the cause of the 
instability, and it would be interesting to further investigate the degradation of the 
recombinant proteins upon storage.   
 
3.3.4  THROMBIN CLEAVAGE 
In order to obtain one C-terminally tagged protein and one N-terminally tagged, 
the expressed and purified double His•Tagged™ protein (C-Terminal 
His•Tagged™ exCD23) was exposed to thrombin in order to cleave the additional 
N-terminal tag.  The results of this cleavage reaction are shown in figure 3.10. 
 
 
 
 
 
 
 
 
 
Figure 3.10 – SDS-PAGE analysis of the overnight thrombin cleavage 
reaction of the C-Terminal His•Tagged™ exCD23 using various dilutions of 
the enzyme.  The lane marker ‘M’ contains the protein marker, the ‘NC’ lane 
contains the negative control sample, in which no enzyme was present, 
and the other four lanes contain the cleavage reaction products with 
various thrombin dilutions, shown above each lane. 
 
Even the lowest thrombin concentration (approximately 0.005 U/µl in the 200X 
dilution) resulted in successful cleavage when the reaction was allowed to 
proceed overnight.  This is clearly shown in figure 3.10, where all thrombin 
dilutions resulted in a shift in the banding pattern on an SDS-PAGE gel, 
M NC 25X 50X 100X 200X
  99 
compared to the negative control.  It can therefore be concluded that all the 
thrombin concentrations tested resulted in successful specific cleavage and from 
these results it was decided to use the lowest thrombin concentration in an 
overnight cleavage reaction in order to cleave the double His•Tagged™ protein, 
resulting in the singly tagged C-Terminal His•Tagged™ exCD23. 
 
3.3.5  ENDOTOXIN REMOVAL AND DETECTION 
The C-Terminal His•Tagged™ protein was needed for cell work in addition to 
binding studies.  For this reason the removal of endotoxin from the protein 
sample was essential.  The amount of endotoxin remaining in the sample after 
the use of an endotoxin removing column was tested and compared to a 
standard curve constructed using control standard endotoxin supplied with the 
LAL assay kit.  The standard curves used for analysis are shown in figure 3.11.  
From these standard curves the endotoxin level present in the protein 
preparation was determined; these results are shown in table 3.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 – Endotoxin standard curve.  (a) shows the standard curve for 
the high range of endotoxin standards, and (b) is the standard curve used 
for the low range of standards.  Each point represents the mean (n = 3), and 
the error bars show the standard deviation.  The equations for the linear 
regression lines and the R2 values are shown on the graphs. 
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Table 3.4 – Endotoxin levels in C-Terminal His•Tagged™ exCD23.  The first 
endotoxin determination was eluted from the endotoxin removal column in 
distilled water, while the second was eluted in endotoxin free PBS. 
 EU/ml ng LPS/ml pg LPS/mg protein Maximal LPS given to cells 
1st 0.464 0.0464 9.28 74 pg 
2nd 0.17 0.017 0.44 0.04 pg 
 
Two endotoxin removal experiments were performed on the C-Terminal 
His•Tagged™ protein.  The first was eluted from the endotoxin removal column in 
distilled water, but this water was tested along with the protein sample, and was 
found to contain high levels of LPS.  Therefore, the protein sample was passed 
through the column a second time, and eluted in endotoxin free PBS.  This 
sample is referred to as the second endotoxin free sample, and the low range 
toxin standard curve was used for the calculation of the endotoxin levels.  For the 
first sample, which was eluted in water, the high range standard curve was used.  
As table 3.4 shows, the endotoxin level for the first sample is higher than that for 
the second, which is expected as it was eluted in water rich in endotoxin.  For 
this sample, the amount of endotoxin in the purified C-Terminal His•Tagged™ 
protein was determined to be 0.464 EU/ml by the Limulus assay.  It has been 
suggested that 1 endotoxin unit equals approximately 0.1 ng of endotoxin (Webb 
et al., 1998).  The recombinant protein was used at a maximum concentration of 
1 mg/ml for cell culture experiments, which translates into approximately 74 pg of 
endotoxin to which the cells were exposed.  This is the maximal concentration to 
which the cells were exposed, as the second sample contained a lower 
endotoxin level.  Previous authors have used endotoxin levels of less than 1 ng 
LPS/mg protein for immunological work with recombinant protein expressed in E. 
coli (Pollock et al., 2003).  Thus the levels of LPS used in this study were well 
within the established range for similar experiments.     
 
3.3.6  β-GALACTOSIDASE HIS•TAGGED™ PROTEIN 
The purification of recombinant His•Tagged™ β-galactosidase proved more 
difficult than expected.  Since this Novagen induction control protein is expressed 
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in the soluble fraction, purification of the recombinant protein from the 
supernatant using the Ni2+ affinity column was expected to be rapid and simple.  
However, whenever purified fractions were obtained and further experimentation 
was conducted, the protein appeared to precipitate out of solution leaving a fine 
white precipitate.  The actual process of acquiring pure protein was not the 
challenging part of the procedure as figures 3.12 and 3.13 show, but maintaining 
the protein in solution proved difficult. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 – Chromatogram obtained from the first attempt at β-
galactosidase purification.  The SDS-PAGE analysis of the numbered peaks 
is shown as an inset, with the numbered lanes corresponding to the 
numbered peaks.  The lane marked ‘M’ contained the protein marker.  
 
Initially the purification of β-galactosidase was attempted using a step wise 
increase in imidazole concentration in order to remove any non-specifically 
bound proteins from the affinity column before elution of the target protein.  As 
the inset in figure 3.12 shows, this method worked well, with large amounts of 
pure protein obtained in the eluted fraction as shown by the single, large band in 
the lanes marked ‘3’.  This fraction was stored at -20°C until further analysis 
could be performed and when the sample was thawed, a viscous white 
precipitate had formed and the protein concentration in the supernatant after 
centrifugation had dropped considerably (table 3.5).  Although the protein 
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concentration was low, only a small amount of protein was required as the 
negative control for IgE binding, so additional preparation was undertaken to 
complete its purification for use in the binding study.  This involved changing the 
buffer that the sample was in and removing the imidazole from the solution.  A 
NAP-5 desalting column was used for this purpose, but once the protein was 
eluted from the column, the concentration determined by BCA assay was found 
to be very low, only 0.1 mg of protein remaining (table 3.5). 
 
Therefore a second expression was conducted and the purification was 
attempted again, this time using an imidazole gradient washing step in an 
attempt to prevent the loss of target protein in that step.  The chromatogram 
obtained from this procedure is shown in figure 3.13. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 – Chromatogram obtained from the second attempt of β-
galactosidase purification.  The SDS-PAGE analysis of the numbered peaks 
is shown as an inset, with the numbered lanes corresponding to the 
numbered peaks.  The lane marked ‘M’ contained the protein marker.  
 
As the SDS-PAGE gel in figure 3.13 shows, the initial flow through peak 
contained large amounts of contaminating E. coli protein that did not bind to the 
affinity column.  The imidazole wash step removed a fair amount of non-
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specifically bound contaminating proteins, while a large amount of target protein 
was achieved by eluting with 250 mM imidazole.  The β-galactosidase fraction 
was not stored as previously described but all the tubes containing the target 
protein were pooled and dialysed against the equilibration buffer (50 mM Tris, 
250 mM NaCl at pH 8) in order to remove the imidazole from the protein sample.  
This procedure, however, resulted in the formation of a white precipitate, an 
indication that the protein was once again aggregating out of solution.  In an 
attempt to get the protein back into solution, the dialysis buffer was changed to 
one with a lower pH and lower salt concentration (50 mM Tris, 25 mM NaCl at pH 
7.5) in an attempt to stabilise the protein and prevent aggregation, but this was 
ineffective in solubilising the recombinant protein, and the white precipitate 
remained. 
 
A number of authors have noted a tendency of β-galactosidase to precipitate out 
of solution, forming large aggregates after purification and storage, a 
characteristic exacerbated by the presence of imidazole (Kim et al., 2003; 
Pessela et al., 2003).  These authors also over-expressed poly-His-tagged β-
galactosidase enzymes in E. coli.  Thus a purification procedure without 
imidazole was needed, and a competitive elution from the affinity column was 
decided upon, using an elution buffer of 1 M NH4Cl in a 0.02 M phosphate buffer, 
at a lower pH (7.2) at which the protein was more stable (Phan Tran et al., 1998).  
The results of this chromatographic procedure are shown in figure 3.14. 
 
The chromatogram obtained using this method gave excellent separation with a 
large flow through peak and a single peak eluted in the ammonium chloride 
gradient.  However, the SDS-PAGE analysis, seen in figure 3.14, showed that it 
was the completely incorrect protein obtained in the eluate, with a molecular 
mass of just below 15 kDa, while the β-galactosidase protein had an expected 
mass of approximately 120 kDa.  The protein obtained in the ‘eluted’ fraction was 
present in both of the previous flow-through peaks, and was present in a 
significantly high concentration in both, see figures 3.12 and 3.13.  The change in 
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pH appears to have favoured the non-specific binding of this protein to the 
column.  The target protein is not present in the flow-through peak in figure 3.14, 
and is definitely not present in the eluted fraction.  Thus it appears that the NH4Cl 
gradient was not strong enough to elute the protein from the affinity column. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 – Chromatogram obtained from the third attempt of β-
galactosidase purification.  The SDS-PAGE analysis of the numbered peaks 
is shown as an inset, with the numbered lanes corresponding to aliquots 
taken from the numbered peaks.  The lane marked ‘M’ contained the protein 
marker.  
 
The supernatant of the second purification attempt of β-galactosidase, with the 
large amount of white precipitate present, was tested for protein concentration 
and purity by SDS-PAGE analysis.  The protein content was estimated to be 0.4 
mg/ml by BCA, with a total protein content of 6.4 mg, more than enough required 
for the binding studies.  In addition, the target protein appeared to make up the 
majority of the protein material in the solution, as figure 3.15 shows.  The 
purification attempts for β-galactosidase are summarised in table 3.5. 
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Figure 3.15 – SDS-PAGE analysis of the β-galactosidase sample used for 
IgE binding studies.  The protein marker was loaded into the first lane, with 
the sizes shown in kDa, and the protein sample was loaded next to it. 
 
Table 3.5 – Attempts at purifying β-galactosidase 
Attempt Protein concentration (mg/ml) Total protein (mg) 
After expression 1.8 27 
After affinity column 0.3 0.5 
1st 
After NAP-5 desalting 
column 
0.2 0.1 
2nd After affinity column and 
dialysis 0.4 6.4 
3rd After affinity column INCORRECT 
PROTEIN 
INCORRECT 
PROTEIN 
 
3.3.7  IgE BINDING 
The ability of the recombinant CD23 proteins to bind IgE was investigated in an 
enzyme-linked immunosorbent assay (ELISA).  The results of this binding study 
are shown in figure 3.16. 
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Figure 3.16 – Binding curves obtained for IgE binding to the purified 
recombinant CD23 proteins.  (a) shows the initial response of increasing 
IgE concentrations binding to the immobilised recombinant proteins.  A 
hyperbola, for one site binding, was fitted to the curve.  (b) shows the 
manipulated data in a double reciprocal plot in order to obtain a straight 
line.  Linear regression best fit analysis was applied to this data.  Each 
point shows the mean (n = 2). 
 
In this study, the recombinant proteins were immobilised onto a plate, and 
increasing IgE concentrations were used as the free ligand in the binding 
experiment.  The unmanipulated data in figure 3.16 (a) shows an increase in 
response with increasing IgE concentrations up to a point, after which the 
response appears to level off.  The curve obtained shows the classical 
rectangular hyperbolic curve characteristic of ligand binding.  GraphPad Prism, 
version 4.01, software was used for the analysis of the binding data.  The 
resultant equation for the fitted hyperbola was Y=Bmax*X/(Kd+X), with the values 
for the two different proteins shown in table 3.6.  As figure 3.16 (a) shows, the 
binding of IgE to the two differently tagged proteins appears very similar.  When 
the double reciprocal plot, shown in figure 3.16 (b), was analysed for statistical 
significance, it was found that there was no significant difference in the slopes of 
the two lines, and no significant difference in the elevations.  Thus the Y-
intercepts for the two curves are not significantly different either.  These data 
appear to show that regardless of the position of the tag, and hence the 
orientation of the immobilised protein, the binding to IgE is unaffected.  
Membrane bound CD23 is orientated with the extracellular lectin domain 
available for IgE binding, thus the same orientation as the N-terminal 
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His•Tagged™ exCD23 bound to the plate.  The binding of this protein to IgE 
would be expected to be similar to natural CD23 and IgE binding.  But the results 
of this experiment show that even in the opposite orientation (bound to the plate 
through the C-terminal His•Tag™), the binding results are the same.  Thus the 
orientation of the protein does not affect the IgE binding ability. 
 
Table 3.6 – Statistical values obtained for the IgE binding curves of the two 
recombinant proteins (statistical values calculated using GraphPad Prism 
version 4.01 software). 
Hyperbola Double reciprocal 
Value C-Terminal 
His•Tag 
N-Terminal 
His•Tag 
Value C-Terminal 
His•Tag 
N-Terminal 
His•Tag 
Bmax 4.259 4.219 Slope 0.023 0.022 
R2 0.9325 0.9580 R2 0.9962 0.9714 
Kd 8.98 x 10-8 M 7.98 x 10-8 M Kd 9.69 x 10-8 M 9.67 x 10-8 M 
Ka 1.1 x 107 M-1 1.3 x 107 M-1 Ka 1.0 x 107 M-1 1.0 x 107 M-1 
 
In order to determine whether biologically active recombinant CD23 was 
obtained, the binding to IgE must be compared to published values.  Gould et al. 
(2003) cite Ka values between 2 and 7 x 107 M-1 for murine CD23.  Other binding 
experiments using CD23 expressed on different cell types report Ka values of 5.3 
x 107 M-1 (Sato et al., 1997), 4.15 x 107 M-1 (Anderson and Spiegelberg, 1981), 
and 7 x 107 M-1 (Bettler et al., 1989).  As table 3.6 shows, the Ka calculated from 
our binding study is approximately 1.1 x 107 M-1.  This is very close to the 
expected published range, and when taking into account the sensitivity of the 
assay and the use of only duplicate values, the results appear to correspond very 
well with the accepted range.  In this study, human IgE was available only in 
limited quantity, as it is very costly and scarce.  For this reason, the experiment 
was only performed once, using duplicate wells for each concentration of the 
proteins.  It is therefore strongly recommended that, in order to make more 
definite conclusions, the experiment should be repeated, using a higher 
concentration range of IgE, up to at least 40 µM IgE to cover a log range of 
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concentrations.  Because 20 µg of protein was immobilised onto the plate, at 
least 2 – 200 µg of IgE should be used to determine the Ka value.  Ideally, more 
sensitive binding studies should be investigated using Quartz Crystal 
Microbalance and Dissipation (QCMD) or Surface Plasmon Resonance (SPR) 
technology.  However, because the experimental values for Ka obtained using 
this ELISA method are so similar to the expected values, it can be assumed that 
the recombinant protein produced in this experiment is biologically active.  
 
The effect of the amino acid substitutions, brought about by errors in the DNA 
amplification could possibly influence the tertiary structure and binding ability of 
the recombinant proteins.  But since the N-terminal His•Tagged™ exCD23 had 
no amino acid differences to CD23, and its binding is the same as the C-terminal 
His•Tagged™ protein, the differences in amino acid sequence clearly had no 
effect on the structure and function of the recombinant proteins. 
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CHAPTER FOUR – EOSINOPHIL RESPONSES TO CD23 
 
4.1  INTRODUCTION 
4.1.1  THE EOSINOPHILIC CELL LINE, EoL-1 
Eosinophils are polymorphonuclear leukocytes with characteristic cytoplasmic 
granules that stain with eosin dyes (Hansel et al., 1990).  This cell type has long 
been recognised as part of the inflammatory response in parasitic and allergic 
disease, but only recently has their role as effector cells and their 
pathophysiological role been elucidated.  The characteristic eosinophilic granules 
contain highly cytotoxic compounds, like ECP, MBP, and EPO.  Activated 
eosinophils are able to produce large amounts of cytotoxic oxygen radicals, in 
addition to bronchoconstricting compounds like LTC4 and platelet activating 
factor, which are believed to play a role in the etiology of asthma, a disease 
characterised pathologically by an infiltration of eosinophils into the airway 
submucosa (Coyle et al., 1996).  The association between eosinophils and 
asthma has been extensively documented.  The release of these eosinophil 
derived cytotoxic products induces damage to the airway epithelium and 
generates pro-inflammatory mediators (Coyle et al., 1996). 
 
For research purposes purified eosinophils need to be studied.  However, 
purification of enough eosinophils for the study of allergic inflammation is difficult 
because eosinophils comprise only a small percentage of the circulating 
leukocytes, 1 – 4%, and have a short in vitro life span (Wong et al., 1999).  
Peripheral blood is a readily available source of eosinophils, but blood from 
healthy donors contains very low numbers of these cells (Hansel et al., 1990), 
thus large amounts of blood are required to obtain adequate numbers of cells.  In 
addition, eosinophil purification methods are time consuming (Thurau et al., 
1996), and although a purity of greater than 95% can be achieved for separated 
eosinophils (Malm-Erjefält et al., 2004), other lymphocytes are always present in 
the eosinophil preparations, which may affect results.  For these reasons an 
eosinophilic cell line is often used as a model, namely EoL-1. 
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EoL-1 is a human eosinophilic leukaemia cell line established by Saito et al. 
(1985), from the peripheral blood of a patient with Philadelphia chromosome-
negative eosinophilic leukaemia.  This is the only known human eosinophilic cell 
line that has cytological features of myeloblasts under normal culture conditions 
(Ohyama et al., 1998).  Under normal culture conditions, a small percentage of 
the cells with more typical eosinophil characteristics, like cytoplasmic granules 
and eosinophil peroxidase, were present.  However, under culture conditions 
used to induce maturation of myeloid cells, the frequency of cells with typical 
eosinophilic features increased to about 40% (Saito et al., 1985).  
 
EoL-1 cells differentiate phenotypically and functionally into eosinophils in 
response to a number of stimuli.  Differentiation into mature, eosinophilic granule 
containing cells has been induced in response to prostaglandin E2, forskolin, 
dibutyryl cyclic AMP (dbcAMP), cytokines and butyric acid (Lung et al., 2002; 
Wong et al., 1999). 
 
The induction of EoL-1 differentiation by butyrate has been well documented 
(Kodama et al., 2004), and has also been shown to differentiate other cell types 
(Fischkoff et al., 1984).  The mechanism of butyrate differentiation is thought to 
be through the inhibition of nuclear deacetylase which results in hyperacetylation 
of the histone proteins, and ultimately gene transcription and differentiation 
(Patnaik et al., 2002).  Wong et al. (1999) showed differentiation of EoL-1 cells by 
dbcAMP, which is metabolised into butyrate and cAMP in the cells. 
 
The typical functions of eosinophils characterised by the release of their granular 
proteins is dependent on the state of activation of the cell.  Activated eosinophils 
release their granules and associated cytotoxic compounds more readily.  
Activation occurs in response to chemotactic agents, cytokines and microbial 
factors, with activated cells having distinctive morphological, physical, 
biochemical and functional properties (Hansel et al., 1990).  Activated 
eosinophils have a lower density than their unstimulated counterparts and are 
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referred to as hypodense.  The differentiation of EoL-1 cells induces the 
formation of activated hypodense eosinophils (Wong et al., 1999).    
 
The EoL-1 cell line has been established and partially characterised for years.  
Wong et al. (1999) describe EoL-1 cells as a suitable in vivo eosinophilic model 
for studying eosinophilic functions, making this immortalised cell line useful for 
studying human eosinophilic functions and their regulation.  
 
4.1.2  CYTOKINES   
Cytokines are important protein mediators of the immune response (Duramad et 
al., 2004).  They are low molecular weight soluble proteins produced and 
secreted by cells and act as immune mediators, affecting the biological behaviour 
of target cells and constituting the communication network for the immune 
system (DuPont et al., 2005).  Cytokines can be defined as any protein that 
affects the growth or differentiation of the same or another cell type (Lawrence 
2000).  They produce their effects on the same cells that produce them, on cells 
nearby, or on cells distant in the body from the cells producing the cytokines, by 
binding to specific receptors on target cells (Hickman et al., 1997).  This binding 
triggers signal transduction pathways that effect biological activities such as 
stimulation or inhibition of cell activation, proliferation, and differentiation.  The 
affinity of cytokines for their receptors is very high and they can therefore exert a 
biological effect at very low concentrations.  Production and secretion of 
cytokines is well regulated and usually occurs after cell stimulation and may be 
short lived.  On the other hand, cytokines may induce a cascade effect in which 
the action of one cytokine causes the target cell to produce one or more 
additional cytokines, which then affect other cells and the cascade continues 
(Hickman et al., 1997). 
 
It has been demonstrated that T cell clones could be divided into subsets based 
on the production of distinct patterns of cytokines (Carter and Swain, 1997).  T 
cell responses can be either Th1-type or Th2-type.  The Th1-type response is 
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dominated by the production of IFN-γ, IL-12 and TNF-α/β, associated with cell 
mediated immunity.  The Th2-type response is characterised by the production of 
IL-4 and IL-5 and associated with humoral immunity.  The Th1/Th2 nomenclature 
has now been generalised to Type 1/Type 2 responses to reflect the role of non-
T-derived cytokines (Carter and Swain, 1997).  Type 1 cytokines, IFN-γ, IL-12 
and TNF-α/β promote pro-inflammatory immune responses, whereas type 2 
cytokines, IL-4, IL-5, IL-10 and IL-13, promote anti-inflammatory, antibody-
dependent immune responses (Mosmann and Coffman, 1989).  Allergy results 
from an imbalance in favour of a Th2 response, and is negatively regulated by 
Th1 cells (van Oosterhout and Motta, 2005).  
 
Eosinophils were initially considered ‘end cells’, incapable of producing novel 
proteins, but have been shown to be important effector cells capable of 
synthesising and releasing a number of regulatory cytokines (Moqbel, 1996).  
Eosinophils are known as potent pro-inflammatory cells (Rothenberg et al., 
1997), and have been shown to spontaneously release TNFα from atopic 
individuals (Moqbel, 1996).  Woerly et al. (1999a) showed the secretion of IL-2 
and IFN-γ from eosinophils after CD28 ligation.  However, the synthesis and 
release of IL-4, IL-5 and IL-10 from eosinophils suggested that they could also 
participate in the regulation of the Th2 pathway of the immune response 
(Nakajima et al., 1996; Woerly et al., 1999b).  These results suggest that 
eosinophils can function as immunoregulatory cells involved in the release of 
both Type 1 and Type 2 cytokines. 
 
IL-5 regulates the development and function of eosinophils.  It stimulates the 
expansion of eosinophil precursors in the bone marrow and is a late 
differentiation factor for eosinophils (Palframan et al., 1998).  IL-5 has the ability 
to prime eosinophils, increasing their responsiveness to mediators that stimulate 
degranulation, the respiratory burst and chemotaxis.  It is also an important 
survival factor for eosinophils as it inhibits their apoptosis (Yamaguchi et al., 
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1991).  Dubucquoi et al. (1994) showed that under physiological stimulation, 
eosinophils released significant amounts of IL-5. 
 
Eosinophils have also been shown to release physiological concentrations of IL-
4, confirming that these cells synthesise and secrete this important Type 2 
cytokine, possibly playing an important role in the development and maintenance 
of the allergic inflammatory response (Moqbel, 1996). 
 
IL-8 appears to be a very abundant eosinophil cytokine, but its precise role in 
allergic inflammation remains unknown (Moqbel, 1996).  Steube et al. (2000) 
reported that EoL-1 cells constitutively produced IL-8, with secretion strongly 
enhanced by tetradecanoyl phorbol acetate (TPA).  The authors found the same 
for MCP-1, a potent chemoattractant.  MCP-1 has been reported to enhance the 
cytostatic activity of monocytes against several tumour cell lines and to increase 
tumour-specificity of the host (Steube et al., 1999). IL-8 and MCP-1 are two 
‘prototype’ members of the CXC and CC chemokine subfamilies, respectively 
(Steube et al., 2000).  Eosinophils have also been shown to synthesise and 
release IL-10 after IgA immune complex stimulation (Nakajima et al., 1996; 
Woerly et al., 1999b). 
 
4.1.3  FLOW CYTOMETRY 
Throughout the field of immunology, flow cytometry remains a defining 
technology (Pala et al., 2000).  Flow cytometry is a technique used for counting 
cells and differentiating cell types in a mixed population.  A stream of 
fluorescently labelled cells is run through a fluorescence detector, which counts 
the number of cells of each type (Lawrence, 2000).  The cells passing through 
the laser beam impart two types of light scatter.  Forward scatter (FS) is laser 
light diffracted around the cell and is proportional to the size or volume of the cell.  
Light scattered at a 90° angle, side scatter (SS), is proportional to the internal 
complexity or granularity of the cell (Wilkerson, 2004). 
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Apart from cells, microspheres can also be analysed by flow cytometry.  In fact, 
microsphere-based flow cytometric assays have been introduced as alternatives 
to solid based immunoassays like ELISA.  The most popular method for 
quantifying secreted cytokines is the ELISA, due to its high specificity and 
sensitivity.  These assays involve sandwiching a cytokine between two cytokine 
specific antibodies that bind to mutually exclusive sites on the cytokine.  The 
capture antibody secures the cytokine to a solid support, while the detection 
antibody is biotinylated in order to link the cytokine to an avidin-conjugated 
detection system (Vignali, 2000).  There are limitations to this technique 
however, including the need for significant sample volumes for each analyte, 
single analyte analysis preventing multiplexing, and the labour intensive nature of 
this method (duPont et al., 2005).    
 
An alternative method is the use of a flow cytometry based system, which has 
become the most widely used multiplex analysis technology (DuPont et al., 
2005).  The principle is essentially the same as an ELISA, but the capture 
antibody is coupled to a microsphere, and does not secure the cytokine to a solid 
base.  The antibody coated beads therefore capture analytes in the solution.  The 
microspheres act as a solid matrix producing a light scatter signal when passing 
through the laser.  The fluorescence emitted by the capture antibody detects the 
analyte and provides a quantifiable fluorescent signal (Wilkerson, 2004).  The 
advantages of these assays are clear.  Multiple analytes can be independently 
and quantitatively assayed simultaneously, very small volumes of sample are 
required, collection of data from numerous beads provides statistical rigor, in 
addition to time and cost savings (Elshal and McCoy, 2006).  Accurate evaluation 
of multiple immune mediators has been problematic due to a lack of validated 
multiplex analysis methodology, however, several commercial kits are now 
available.  DuPont et al. (2005) found essentially identical results between 
multiplex cytokine kits and ELISA based methods and Elshal and McCoy (2006) 
state that it should be possible to use multiplex bead array assays in lieu of 
ELISA in studies requiring high throughput analysis of multiple analytes. 
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Cytokine production by normal resting cells is minimal, therefore most published 
techniques make use of a strong stimulatory effector in order to demonstrate the 
cytokine producing potential of the cells (Sewell et al., 1997).  Phorbol myristate 
acetate (PMA), also known as phorbol-12-myristate-13-acetate or tetradecanoyl 
phorbol acetate (TPA), is commonly used as the stimulus in concentrations 
ranging between 10 ng/ml (16.2 nM) and 100 nM.  
 
4.2  MATERIALS AND METHODS 
4.2.1  ROUTINE CELL CULTURE 
EoL-1 cells were obtained from the European Collection of Cell Cultures 
(Salisbury, UK) and were maintained in BioWhittaker RPMI 1640 with 25 mM 
Hepes and 2 mM L-glutamine (Cambrex, USA), supplemented with 15% heat 
inactivated fetal bovine serum, (HI FBS) from Delta Bioproducts, RSA, and 
antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin, Highveld Biological, 
RSA).  The cell cultures were mycoplasma free and were cultivated at 37°C in a 
humidified atmosphere containing 5% CO2.  The growth of EoL-1 cells is similar 
in suspension and stationary conditions (Ohyama et al., 1998), and thus they 
were cultured in 25 ml suspension culture flasks.  When larger volumes were 
required, the cells were initially grown in the small 25 ml flasks, and then 
transferred into larger 250 ml culture flasks.  Depending on the cell density and 
the rate of growth, fresh medium was added to the cells every two to three days.   
 
4.2.2  CRYOPRESERVATION 
Excess cells were carefully frozen and stored at cryogenic temperatures until 
required.  A variety of methods was attempted for cryopreservation but viability of 
the cells after thawing was very low.  Eventually a suitable cryopreservation 
method was established which involved freezing the cells at high density 
(between 4 and 6 million cells), in 1 ml fetal bovine serum, containing 10% 
DMSO.  The freezing process was allowed to proceed slowly, under controlled 
conditions, using a device known as Mr Frosty (Nalgene, USA), which was filled 
with isopropanol, and stored at -80°C.  This freezing container provides a simple 
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system designed to achieve a rate of cooling very close to 1°C per minute.  The 
rate of cooling is extremely important as it affects the rate of formation and size 
of ice crystals, as well as the solution effects that occur during freezing.  Mazur et 
al. (1972) suggest that ice crystal formation and solution effects play a role in cell 
activation and that an optimum cooling rate minimises the effect of each.  With 
few exceptions, a uniform rate of cooling of 1°C per minute from ambient 
temperature is preferred. 
 
After remaining at -80°C overnight, the vials were transferred to liquid nitrogen for 
indefinite storage.  When required the cells were rapidly thawed and immediately 
transferred to 1 ml of pre-warmed medium.  Cells were then slowly and 
sequentially diluted with medium to a total volume of 5 ml.  The cells were 
harvested by centrifugation at 1000 rpm for 2 minutes in an Eppendorf 5804 R 
centrifuge, using the A-4-44 rotor, the supernatant discarded, in order to remove 
the remaining DMSO from the solution, and replaced by growth medium.  The 
cells were then incubated at 37°C as described above. 
 
4.2.3  CELL VIABILITY 
Cell cultures were examined daily to observe the morphology of the cells, colour 
of the medium and cell density in order to asses the viability of the cells and 
check for contamination.  This was achieved using a Nikon TMS-F inverted 
phase contrast microscope at a 100X magnification, monitoring any changes in 
the general appearance of the cultures. 
 
Viability can be assessed quantitatively using the dye Trypan Blue.  This dye is 
excluded by live cells but accumulates in dead cells due to the loss of integrity of 
the membrane structure (Traore and Meyer, 2002).  Therefore live cells will 
appear clear, as the dye is excluded from the cells because the cell membrane is 
impermeable to it, while dead cells appear blue.  In order to count the cells and 
thereby estimate the total cell number, equal volumes of cell suspension and 
0.4% (m/v) Trypan Blue in PBS were mixed and added to a haemocytometer, 
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where cells were counted and dead cells could be differentiated from living ones.  
Each large square of the haemocytometer represents 0.1 mm3.  Since 1 cm3 is 
approximately 1 ml, the total number of cells can be determined from the 
following equation: 
  Cells/ml = average cell count per square x dilution factor x 104 
The total number of cells was therefore obtained by multiplying the number of 
cells per ml by the volume of culture from which the cell sample was removed.  
The cell viability was expressed as the percentage of the total viable, unstained 
cells over the total number of cells present.   
 
Another method used to estimate cell viability is the CellTitre-Blue® Cell Viability 
Assay (Promega, USA).  This method provides a homogeneous, fluorometric 
method for estimating the number of viable cells present in a multiwell plate 
format.  The assay is based on the conversion of the indicator dye, resazurin, 
into resorufin, a highly fluorescent compound.  Essentially, the metabolic capacity 
of the cells is measured, which is an indicator of cell viability.  Viable cells are 
able to reduce resazurin to resorufin, while nonviable cells are not able to reduce 
the indicator dye, due to a loss in metabolic capacity, and thus do not generate a 
fluorescent signal (O’Brien et al., 2000).   
 
Resazurin is dark blue in colour and has little intrinsic fluorescence until it is 
reduced to resorufin, which is pink in colour and is highly fluorescent using an 
excitation wavelength of 560 nm and an emission wavelength of 590 nm.  
Resazurin is reduced to resorufin inside living cells, probably as a result of the 
actions of several different redox enzymes, possibly mitochondrial, cytosolic and 
microsomal enzymes.  The reduction reaction is shown in figure 4.1.  The 
fluorescent signal from CellTitre-Blue® Reagent is proportional to the number of 
metabolically active, viable cells.  A good linear relationship exists between the 
cell number and the fluorescent signal produced. 
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Figure 4.1 – Conversion of resazurin to highly fluorescent resorufin by 
metabolically active cells.  The fluorescent signal is proportional to the 
number of viable cells (Promega, USA). 
 
The CellTitre-Blue® Cell Viability Assay was carried out by incubating 100 µl of 
the cell suspension with 20 µl of the reagent in a black 96 well plate.  The plate 
was then protected from light, and incubated at 37°C for 2 hours.  The 
fluorescence was read on a Fluoroskan Ascent FL fluorimeter (Thermo Lab 
Systems, USA) equipped with Ascent Software version 2.6, using an excitation 
wavelength of 544 nm and an emission wavelength of 590 nm.  A standard curve 
was constructed, to estimate the viability, by adding 20 µl of the reagent to each 
well of a 96 well plate, containing increasing numbers of cells, which was then 
covered in foil and incubated at 37ºC for two hours.  After incubation the 
fluorescence was recorded.   
 
4.2.4  DIFFERENTIATION 
It has been reported that EoL-1 cells can be induced to differentiate into not only 
phenotypically but also functionally mature eosinophilic granule containing cells 
in response to a number of stimuli, including cytokines (Shintaku et al., 1994), 
butyric acid (Saito et al., 1993), dbcAMP (Tai et al., 1996; Wong et al., 1999) and 
even the green tea catechin epigallocatechin-3-gallate (EGCG) (Lung et al., 
2002).  However, the European Collection of Cell Cultures recommends 
differentiation with butyrate.  It has been shown that sCD23 promotes 
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differentiation of germinal centre B cells into plasma cells in vitro, possibly 
interacting with CD21 and thus extending the lifetime and capacity of these cells 
to proliferate.  It also promotes the growth and differentiation of basophils and T 
cells from their respective precursor cells (Gould et al., 2003). 
  
It was therefore decided to differentiate the EoL-1 cells using butyrate as 
described by Kodama et al. (2004) and to investigate the influence of the 
recombinant CD23 protein on the differentiation of the cells.  This was achieved 
by culturing the EoL-1 cells in the presence of various compounds for 12 days.  
The cells were suspended at a density of 5 x 105 cells/ml in medium containing 
the various inducers.  Cell viability was assessed every three days using the 
Trypan Blue exclusion test, and cell number was adjusted to the original seeding 
density with fresh differentiation medium.  Cell viability was also estimated using 
the CellTitre-Blue® Cell Viability Assay. 
 
Normal blood eosinophils express cytokine receptors, adhesion molecules for 
migration through tissue, CD95 for the induction of apoptosis by the Fas ligand, 
as well as cytotoxic granular proteins (Wong et al., 1999).  These are important 
characteristics of eosinophils in allergic inflammation and indicate their mature, 
activated state.  Differentiation of EoL-1 cells by butyrate is accompanied by the 
formation of eosinophilic granules, expression of peptide receptors, cell adhesion 
molecules and CD14 amongst others (Kodama et al., 2004).  Secretory products 
from the eosinophilic granules include cytotoxic substances such as MBP, EPO, 
ECP, LTC4, platelet-activating factor and substance P (Wong et al., 1999).  Since 
EoL-1 cells can be induced to differentiate into mature granular eosinophilic cells, 
it follows that the progress of the differentiation process can be monitored by 
detection of the eosinophil-specific proteins contained in these granules.    
 
Thus, the progress of differentiation was monitored by observing any 
morphological changes in the cells, in addition to using flow cytometry for 
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eosinophil-specific protein detection and an enzymatic assay for the detection of 
myeloperoxidase (MPO). 
 
4.2.4.1  Flow cytometry of intracellular MBP and MPO   
In a previous study, the differentiation-inducing activity of EGCG on EoL-1 cells 
was investigated by observing the morphological changes in the cells, as well as 
the expression of the eosinophil-specific proteins, including MBP and EPO (Lung 
et al., 2002).  However, according to the findings of Kodama et al. (2004), EPO is 
not expressed by EoL-1 cells differentiated with butyrate.  In contrast, induction 
of MPO was clearly shown in this study.  The expression of MBP and MPO by 
butyrate differentiated EoL-1 cells was therefore analysed by flow cytometry. 
 
IntraPrep™ Permeabilization Reagent (Beckman Coulter, Switzerland) was used 
for fixing and staining the EoL-1 cells.  The IntraPrep™ Reagent kit consists of 
two reagents, Reagent 1 for fixing the cells, which contains 5.5% formaldehyde, 
and Reagent 2, for permeabilizing the cells, which consists of a saponin-based 
permeabilizing and lysing medium, containing 0.1% sodium azide.  This kit is 
designed for the immunological detection of intracellular leukocyte antigens by 
flow cytometry.  The reagents create holes in the membrane without affecting the 
gross morphology of the cell, thereby preserving the flow cytometric light 
scattering properties.  Kappelmayer et al. (2000) investigated the effects of 
various commercial fixation/permeabilization methods, including IntraPrep™.  
The authors reported that IntraPrep™, amongst others, provided specific staining 
of the markers tested, one of which was MPO, in sufficient intensities.   The 
permeabilization and staining procedure was carried out as described by the 
manufacturer.  Briefly, approximately 5 x 105 cells were aliquoted into a tube, and 
100 µl of Reagent 1 was added.  The tube was vigorously vortexed and 
incubated at room temperature for 15 minutes.  PBS (4 ml) was added and the 
tube was centrifuged at 300 x g at room temperature for 5 minutes.  The 
supernatant was discarded by aspiration and 100 µl reagent 2 was added.  The 
mixture was incubated for 5 minutes at room temperature and gently agitated for 
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two seconds.  The conjugated intracellular specific antibody, monoclonal mouse 
anti-human MPO, labelled with FITC (BD Biosciences, USA) was added.  A 5X 
dilution of the 12.5 µg/ml stock solution was made, and 20 µl was added to each 
tube.  The appropriate conjugated irrelevant isotypic specific antibody controls, 
20 µl, (mouse IgG1-FITC and mouse IgG1-APC, both from Immunotech, France) 
were added to the control tubes.  For MBP detection, 20 µl of a 200X dilution of 
the 0.5 mg/ml stock, of the intracellular unconjugated mouse anti-human 
eosinophil major basic protein monoclonal antibody (BD Pharmingen, USA) was 
added.  Each tube was gently vortexed and incubated at room temperature for 15 
minutes in the dark.  PBS (4 ml) was added and the tube was centrifuged at 300 
x g at room temperature for 5 minutes.  The supernatant was discarded by 
aspiration, and the cells were resuspended in 500 µl PBS containing 0.5% 
formaldehyde.  For the MBP staining, the conjugated secondary antibody, APC-
conjugated rat anti-mouse IgG1 monoclonal antibody (BD Pharmingen, USA) 
was added (20 µl of a 50X dilution of the 0.2 mg/ml stock), and incubated for 15 
minutes at room temperature in the dark.  PBS (4 ml) was added, the tube was 
centrifuged as before, and the supernatant discarded.  The stained cells were 
resuspended in 500 µl PBS containing 0.5% formaldehyde.  Flow cytometry 
analysis was then carried out. 
 
Within two hours of fixation, the samples were run on a Cytomics FC 500 flow 
cytometer (Beckman Coulter, Switzerland) using CXP acquisition software, 
version 2.0.  Dot plots of FS versus SS were recorded.  FS relates to cell size 
while SS relates to cell complexity.  Protocols were set up using unstained cells, 
ensuring that the samples fell within a detectable range.  The fluorescence 
channels specific to the fluorescent conjugates were monitored, namely FL1 for 
FITC and FL4 for APC.  In each sample at least 10 000 events were acquired.   
 
4.2.4.2  Measurement of peroxidase activity 
The activity of MPO was assayed using a modified version of the methods 
described by Schneider and Issekutz (1996) and Kodama et al. (2004).  Cells (80 
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µl of culture per replicate to be analysed) were harvested by centrifugation at 14 
100 rpm (Eppendorf miniSpin plus) at room temperature for 2 minutes.  The 
culture supernatant was removed and the cells were resuspended in an equal 
volume of 0.25% sucrose containing 0.22% cetyltrimethyl-ammonium bromide.  
After a freeze-thaw cycle, the cell suspensions were centrifuged at 10 000 x g for 
10 minutes at 4°C.  The supernatant was transferred to a 96 well plate (80 µl per 
well), and incubated for 30 minutes at room temperature with the same volume of 
50 mM Hepes buffer (pH 8) containing 6 mM potassium bromide, 3 mM o-
phenylene diamine and 8.8 mM H2O2.  The reaction was stopped by adding 2 
volumes of a cold stop solution containing 4 N H2SO4 and 2 mM resorcinol.  The 
absorbance was measured at 490 nm using a BioTek (USA) PowerWave XS 
multiplate reader. 
   
4.2.5  EXTRACELLULAR CYTOKINE PRODUCTION 
Changes in the cytokine profiles after various treatments were investigated using 
a FlowCytomix human basic kit (Bender MedSystems, Austria).  Aliquots of cell-
free cell culture supernatant were removed from the culture flask and stored at -
80°C until analysis was performed.   
 
The FlowCytomix human basic kit is used to perform a fluorescent bead 
immunoassay for quantitative detection of soluble human analytes in cell culture 
supernatants by flow cytometry.  The analytes investigated in this study were IL-
4, IL-5, IL-8, IL-10, IFN-γ, in a 5plex kit, and MCP-1, in a simplex kit.  The 6 
cytokines could not be combined and analysed simultaneously as the bead 
identities overlapped, therefore MCP-1 analysis had to be performed separately.  
FlowCytomix technology uses a sandwich immunoassay that couples the capture 
antibody with two different sized microspheres (4.4 and 5.5 µm). Individual 
microsphere sets are coded using different internal fluorescent intensities. The 
assay uses the same principles as an ELISA, but assesses multiple cytokines or 
analytes per sample.  The microspheres are coated with antibodies specific to 
each of the analytes to be detected by the system.  The beads can be 
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differentiated by their sizes and distinct spectral addresses.  A mixture of the 
coated beads is incubated with the samples or standard mixture.  The analytes 
present then bind to the antibodies linked to the fluorescent beads.  A biotin-
conjugated secondary antibody mixture is added, which is specific to the analytes 
being investigated.  Streptavidin-Phycoerythrin (PE) is added, which binds to the 
biotin conjugate and emits a fluorescent signal.  The amount of fluorescence 
emitted for each bead is proportional to the analyte concentration being detected 
by that bead population.  Figure 4.2 shows a pictorial representation of the 
reagents used in this assay. 
    
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 – Pictorial representation of the principle of the fluorescent bead 
immunoassay used for cytokine detection.  The wavy blue lines represent 
the excitation light beam, while the straight coloured lines show the 
emission beams, with the fluorescence channel used for detection on a 
Cytomics FC 500 flow cytometer (Beckman Coulter, Switzerland).  Picture 
modified from Vignali (2000). 
 
The standards, beads, biotin conjugates and Streptavidin-PE were prepared 
according to the manufacturers instructions.  The assay was carried out without 
the use of the 96-well filter plate provided, and instead incubations were 
performed in tubes.  The test procedure outlined by the manufacturers was 
followed.  Briefly, 25 µl of standard or sample was added to each tube.  The bead 
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mixture (25 µl) was added, followed by the biotin-conjugate mixture (50 µl).  Each 
tube was mixed and incubated at room temperature for 2 hours in the dark.  
Assay buffer (1 ml) was added to each tube, centrifuged at 200 x g for 5 minutes 
at room temperature, and the supernatant was carefully removed by aspiration, 
leaving approximately 100 µl of liquid in each tube.  Another washing step was 
performed before the addition of 50 µl Streptavidin-PE.  The tubes were mixed 
and incubated for one hour at room temperature in the dark.  Each tube was 
washed twice as before, 500 µl assay buffer was added, and the samples were 
analysed by flow cytometry.   
 
Detection of the cytokine concentrations in the sample or standards was 
performed using a Cytomics FC 500 flow cytometer (Beckman Coulter, 
Switzerland).  The cytometer was calibrated using the setup beads provided 
according to the manual and no less than 3 000 events were acquired for the 
5plex kit, i.e. 600 events per analyte, and no less than 500 events for the MCP-1 
simplex kit.  Dedicated analysis software, FlowCytomix Pro 1.0.4.2 (Bender 
MedSystems, Austria), was supplied with the kit and was used to analyse the 
data after acquisition.  Standard curves, ranging from 0 to 10 000 pg/ml, for the 
assay system were obtained from dilutions of the standards supplied with the kit, 
reconstituted and diluted as described by the manufacturer.  The concentration of 
each cytokine in the cell culture supernatants was determined by extrapolation 
from the corresponding standard curve using the FlowCytomix Software.    
 
4.3  RESULTS AND DISCUSSION 
4.3.1  ROUTINE CELL CULTURE AND CRYOPRESERVATION 
 The EoL-1 cells were received from the United Kingdom, and shipped in a frozen 
state.  After arrival they were rapidly thawed and diluted slowly and sequentially 
into 10 ml warm medium containing 10% HI FBS.  The viability of the thawed 
cells was low, approximately only 50%, and this value steadily dropped over time 
until very few, if any, cells remained viable.  A second vial of EoL-1 cells was 
received, and it proved more successful to dilute the cells to an initial volume of 5 
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ml medium, containing 15% HI FBS.  The initial viability was above 90%, clearly 
much improved to the first vial.  EoL-1 cells grow slowly, taking up to five days to 
reach a suitable level to subculture (Atkin, Information scientist at the European 
Collection of Cell Cultures, England, personal communication, 2006), with a 
doubling time of 48 hours (Saito et al., 1985), and it was recommended that they 
be left to grow without any more agitation than necessary.  This proved accurate, 
as after two days in culture with no agitation the cells appeared to be healthy and 
growing, and large cell clumps had formed, typical cluster formation 
characterised by proliferation of leukocyte cell lines (Militi et al., 2005), and the 
medium had changed colour slightly indicating metabolic activity.  Thus it was 
established that the cells preferred little agitation and subculturing only when high 
cell densities were reached.  Subculturing consisted of dilution, i.e. increasing the 
volume of the culture with fresh medium. 
 
Once the ideal culture conditions for the EoL-1 cells had been established, they 
flourished and high cell numbers were obtained.  The surplus cells needed to be 
carefully frozen and stored at cryogenic temperatures until they were needed 
again.  However, no literature was available on the cryopreservation of EoL-1 
cells.  Freezing can be lethal to cells due to damage caused by ice crystals, 
changes in the concentrations of electrolytes, dehydration and pH changes.  To 
minimise these damaging effects the cells need to be treated with a cryo-
protective agent, like DMSO or glycerol, which lowers the freezing point of the 
water and thus protects the cells (Freshney, 1994).  Cell lines are routinely frozen 
in medium containing 10% HI FBS and 10% DMSO, and this was initially 
attempted with the EoL-1 cells, resuspended in 10 ml warm medium after 
thawing.  The viability of the cells was extremely low after thawing and 
progressively decreased until all the cells had died.  Freezing and thawing may 
be detrimental to cells (Freshney, 1994) thus it was essential that an appropriate 
method for cryopreservation be established to minimise the damaging effects of 
this procedure.  A number of variables were changed in order to optimise the 
cryopreservation method, and these are summarised in table 4.1. 
  126 
Table 4.1 – Attempts at establishing a successful cryopreservation method 
for the EoL-1 cells. 
Treatment Volume Viability 
Medium : HI FBS : DMSO 
(80 : 10 : 10 v/v)  
Resuspended in 10 ml 0% 
Medium : HI FBS : DMSO 
(80 : 10 : 10 v/v) 
Resuspended in 5 ml 0% 
Warm serum : DMSO  
(90 : 10 v/v) 
Resuspended in 5 ml 0% 
Cold serum : DMSO  
(90 : 10 v/v) 
Resuspended in 5 ml, DMSO 
removed after thawing >80% 
 
Initially the thawed cells were resuspended in 10 ml medium, but since the cells 
appeared to prefer smaller volumes, they were resuspended in 5 ml medium.  
This had no effect on increasing the viability and all the cells eventually died.  A 
different cryopreservation medium was tried, 10% DMSO in serum as opposed to 
medium, but once again after thawing the viability decreased to 0%.  The DMSO 
was then removed after thawing by harvesting the cells and resuspending them 
in fresh medium, and this proved to be very successful, resulting in a cell viability 
of more than 80%.  Thus the cryopreservation method established for the EoL-1 
cells consisted of freezing them in 10% DMSO, 90% serum at a rate of 1°C per 
minute to -80°C.  The viability of the thawed cells appeared higher when cold 
serum was used.  The cells were then transferred to liquid nitrogen where they 
could be preserved for extended periods of time.  To thaw them, the cells were 
rapidly defrosted and immediately diluted with pre-warmed medium.  The cells 
were then collected by centrifugation, the supernatant removed and replaced 
with fresh medium.  The cells were transferred to a suspension culture flask and 
incubated at 37°C.   
 
4.3.2  DIFFERENTIATION OF EoL-1 CELLS 
The differentiation of the EoL-1 cells was monitored by observing any 
morphological changes as well as performing assays for intracellular eosinophil 
marker proteins MBP and MPO, while monitoring cell viability over a 12 day 
period. 
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4.3.2.1  Morphological markers of differentiation 
Differences in morphological appearance are expected with differentiation.  The 
cells were examined under 400X magnification (Zeiss Axioplan microscope and 
Imaplan V 2.06, IMATEC Electronische, 2004 software), and photographs were 
taken of the untreated and differentiated cells.  These are shown in figure 4.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 – Morphological changes in EoL-1 cells after 12 days of butyrate 
treatment.  (a) Untreated cells, (b) cells treated with 0.5 mM butyrate.  Cell 
diameters are indicated above and below the cells.   
 
As figure 4.3 indicates, no significant change in cell size is seen after butyrate 
treatment, but there does appear to be a definite increase in cell complexity, with 
the treated cells appearing more granular.  Some of the untreated cells do seem 
somewhat grainy, but this is expected as a small percentage of the cells cultured 
under standard conditions contain cytoplasmic granules and has more typical 
eosinophilic characteristics (Saito et al., 1985).  The characteristic eosinophilic 
cell appearance, with irregular cytoplasm, rich in granules, is seen in the butyrate 
treated cells.   
 
(a)
(b)
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4.3.2.2  Intracellular MBP and MPO markers of differentiation 
The effect of two different butyrate concentrations (0.5 and 400 mM) on the 
differentiation of the EoL-1 cells was investigated over 12 days.  Figure 4.4 
shows the effects of butyrate on the expression of intracellular MPO and MBP by 
EoL-1 cells after 12 days of treatment, as detected by flow cytometry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 – The effects of butyrate on the expression of intracellular MPO 
and MBP in EoL-1 cells, as detected by flow cytometry.  EoL-1 cells were 
treated with (a) 400 mM butyrate and (b) 0.5 mM butyrate for 12 days, with 
untreated cells used as the control.  Cells were incubated with either 
mouse anti-human MPO or MBP monoclonal antibody.  The red line 
indicates the fluorescence profile obtained at day 0, while the blue line 
shows the profile at day 12.  Overlay histograms are representative results 
obtained in quadruplicate, all of which were similar to those shown.     
MPO MBP
MPO MBP
(a)
(b)
Ev
e
n
ts
Fluorescence intensity
  129 
As figure 4.4 shows treatment with butyrate had a definite effect on the EoL-1 
cells.  The higher butyrate concentration (400 mM) showed greater MPO and 
MBP expression, when compared to the lower concentration (0.5 mM).  
However, even the lower concentration of butyrate resulted in an increase in the 
expression of the eosinophil specific proteins.  Since the expression of these 
proteins characterises mature eosinophilic cells, the presence of the proteins 
indicates the differentiated state of the cells. 
 
The effect of exCD23 on the differentiation of the EoL-1 cells was also 
investigated.  Three protein concentrations were used, and the results of 12 days 
of culture in the presence of exCD23 are shown in figure 4.5. 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 – Effect of 12 days of exCD23 treatment on EoL-1 cells.  
Intracellular MPO (a) and MBP (b) expression were analysed by flow 
cytometry.  The blue line shows the overlay histogram for untreated EoL-1 
cells representing the control in this experiment.  The red, orange and 
yellow profiles indicate EoL-1 cells incubated with 10, 100 and 1000 ng/ml 
exCD23, respectively.    
 
The exCD23 appeared to have the opposite effect to butyrate on the EoL-1 cells.  
The histograms shifted to the left of the untreated cells, not to the right as seen 
for the butyrate treatment.  These results suggest that the recombinant protein is 
in fact not differentiating the cells, like butyrate, into more complex and granular 
cells, but is instead moving the cells away from the control towards less 
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complexity, with less MPO and MBP expressed than in the control cells.  These 
results appear to support the proliferative effect by exCD23 seen in figures 4.8 
and 4.9.  This shift also appears to be concentration dependent, with the lowest 
exCD23 concentration, 10 ng/ml, showing the greatest shift from the control, 
while the highest concentration, 1 000 ng/ml, showed the profile most similar to 
the untreated cells.  The histograms obtained for 10 ng/ml and 100 ng/ml 
exCD23 are very similar.  Daniels et al. (2005) reported a dose-dependant 
secretion of cytokines from PBMCs after incubation with recombinant sCD23, 
with maximal cytokine production at 100 ng/ml.  Thus there appears to be a 
CD23 concentration dependent effect on leukocytes.   
 
In addition to detection by flow cytometry, an enzymatic assay for MPO was used 
to monitor the expression of this eosinophil specific protein over the time course 
of differentiation of the EoL-1 cells.  Figure 4.6 shows these results. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 – Effect of butyrate and exCD23 treatment on the activity of MPO, 
expressed by EoL-1 cells.  Cells were cultured for 12 days in the presence 
of the various substances and MPO activity was analysed enzymatically 
over the 12 day period.  Cell number was accounted for by dividing the 
response by the viable cell numbers, determined using the CellTitre-Blue® 
Cell Viability Assay.  Values represent the means from independent 
experiments ± SD (n=4) for the 0.5 mM butyrate and exCD23 treatments.  
For the 400 mM butyrate treatment, values from eight replicates from only 
one experiment are shown, values represent means ± SD (n=8).  
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The enzymatic assay for MPO is expected to show an increase in activity with 
increasing time, as more cells differentiate into mature eosinophilic-like cells after 
increasing exposure to butyrate.  However, the results in figure 4.6 do not show 
this expected trend.  EoL-1 cells exposed to 400 mM butyrate do appear to show 
increasing peroxidase activity with time, but a maximum is reached at 9 days 
which declines at day 12.  The trend seen for the 0.5 mM butyrate treatment, 
excluding time 0, appears to increase with time, peaking at day 12, although the 
increase is not statistically significant.  The peroxidase activity detected in these 
cells is much lower (approximately 100-fold at day 12) than for the 400 mM 
butyrate treatment.  exCD23 (10 ng/ml) was also used to investigate the 
differentiation of the cells, but as figure 4.6 shows, there is a steady decrease in 
activity over time after the peak at day 3, although the values are significantly 
higher than the 0.5 mM butyrate treatment for all the time points (P<0.05, 
determined using Students t test).   
 
The results obtained from this experiment suggest that the assay used was not 
sensitive enough to detect the low levels of MPO expressed by the EoL-1 cells.  
In order to overcome this problem, more cells could be used in the initial cell lysis 
procedure, ensuring higher enzyme concentrations, allowing for accurate 
detection and quantification.  The 400 mM butyrate treatment resulted in a 
marked decline in viable cell numbers (see figure 4.7), worst at day 12, thus at 
this point the assay may not be able to accurately detect the MPO activity, due to 
insufficient cells, and hence a decrease is seen at this time point.  The accuracy 
of the enzymatic activity determined by this assay for the other two treatments is 
therefore uncertain, and no conclusive statements regarding the effect of these 
treatments on the differentiation of the EoL-1 cells, determined by MPO activity, 
can be made.  However, these results do suggest that the higher butyrate 
concentration resulted in a higher number of differentiated cells after 12 days, 
and these results are confirmed by the flow cytometry analysis.  Figure 4.4 
clearly shows a large shift in MPO expression when 400 mM butyrate was used 
for differentiation, but only a marginal shift is seen with 0.5 mM butyrate.  Thus a 
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smaller percentage of the entire cell population is differentiated after 12 days of 
0.5 mM butyrate treatment, than with 400 mM butyrate, and a lower enzyme 
concentration is expressed in total.  In addition, the enzymatic results suggest 
that the recombinant protein was not able to differentiate the EoL-1 cells, as a 
decrease in enzyme activity is seen over time.  These results are confirmed by 
the flow cytometry results showing decreased MPO expression with exCD23 
treatment, seen in figure 4.5. 
 
Terakawa et al. (2005) used 0.5 mM butyrate for the differentiation of EoL-1 cells 
over 12 days, and incubation of the cells with butyric acid increased the content 
of eosinophil-derived neurotoxin, a marker for mature eosinophils in a time 
dependent manner. Kodama et al. (2004) also used 0.5 mM butyrate treatment 
for 12 days to differentiate EoL-1 cells, following the progress of the process by 
measuring peroxidase activity.  The authors concluded that butyrate induced 
differentiation of the EoL-1 cells into eosinophil-like cells.  
 
4.3.2.3  Cell viability during differentiation 
The substances used in the treatments for differentiation had a significant effect 
on the cell number and viability during the course of the experiment (figure 4.7).        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 – Effect of butyrate on the viability of EoL-1 cells over 12 days.  
Results are from one count only, but all experiments showed very similar 
results to those shown here.   
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As figure 4.7 shows, cell viability of untreated cells remains fairly constant over 
the 12 days.  Initially the lower butyrate concentration (0.5 mM) appears to 
increase the cell viability, but after 12 days there is a drop in viability to 
approximately 60%.  The high butyrate concentration has a marked detrimental 
effect on the cells, with only 34% remaining viable after the 12 days of treatment.  
This is not surprising as in addition to differentiation, butyrate has been shown to 
have a variety of effects such as anti-proliferating activity, modulation of gene 
expression, regulation of cell cycle protein and induction of apoptosis (Patnaik et 
al., 2002).  Thus the higher butyrate concentration has a greater apoptotic effect, 
resulting in greatly reduced cell viability.  So, although the higher butyrate 
concentration showed a greater effect on MPO and MBP expression, the 
decrease in cell viability made this experiment non-feasible.  Thus a balance 
needs to be achieved between successful differentiation and maintenance of 
adequate numbers of viable cells, this balance is obtained by using 0.5 mM 
butyrate for differentiation. 
 
Induction of cellular differentiation is one means of suppression of cell growth.  
Although treatment of the cells with 0.5 mM butyrate did not significantly 
decrease the total number of viable cells when compared to untreated cells 
(figure 4.8), it did influence the ratio of viable to non-viable cells.  Butyrate 
treatment significantly increased the number of non-viable cells in the sample, as 
shown in figure 4.7. 
 
While butyrate had no significant effect on the cell number after 12 days of 
treatment, the cells incubated with 10 ng/ml exCD23 for 12 days showed a 
significant increase in cell number compared to the untreated cells (P=0.00486).  
TPA significantly decreased the cell number (P=0.00596 for TPA, P=0.00607 for 
the TPA/CD23 combination).  As figure 4.8 shows, the addition of CD23 to the 
TPA treatment was not able to counteract the negative effect of TPA on the cell 
numbers and resulted in significantly reduced cell numbers, compared to the 
untreated cells. 
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Figure 4.8 – Effect of various substances on the growth of EoL-1 cells.  
Cells were cultured in the presence of the various compounds (0.5 mM 
butyrate, 10 ng/ml exCD23 and 100 nM TPA) for 12 days, after which they 
were counted using the Trypan Blue exclusion test.  Values represent the 
mean ± SD (n=4).  Asterisks show significant differences to the untreated 
cells, determined using a two-tailed Students t test for unequal variance, 
P<0.05).  
 
As shown in figure 4.8, exCD23 had a significant effect on the cell number, when 
compared to untreated cells.  In order to investigate this apparent proliferative 
effect further, differentiated EoL-1 cells (grown in the presence of 0.5 mM 
butyrate for 12 days) were exposed to 10 ng/ml exCD23, 100 nM TPA or a 
combination of the two for 24 hours.  Figure 4.9 shows the results of this 
experiment. 
 
 
 
 
 
 
 
Figure 4.9 – Effect of exCD23 and TPA on the number of differentiated EoL-
1 cells (12 days of 0.5 mM butyrate treatment) after 24 hour exposure.  Cell 
numbers were determined using the CellTitre-Blue® Cell Viability Assay.  
Results are means ± SD (n=4).  The asterisk shows significant differences 
between treatments, (P<0.05) using a two-tailed Students t test for unequal 
variance. 
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Exposure of the differentiated EoL-1 cells to exCD23 had a significant effect on 
the cell number, compared to the TPA treatments.  The number of viable cells 
present after TPA treatment was significantly lower than those exposed to 
exCD23, and when these two substances were used in combination, no 
significant difference was seen between the TPA treatment, and the TPA and 
exCD23 combined treatment.  These results suggest that the recombinant 
protein had a proliferative effect on the EoL-1 cells, but when combined with 
TPA, it could not compensate for the reduction in cell number brought about by 
the TPA (refer to figure 4.8).  All three 24 hour exposure treatments started with 
the same number of cells, as equal volumes were aliquoted from the culture, to 
start the experiment.  The TPA treatment appears to decrease the cell number, 
but not statistically significantly.  On the other hand, the exCD23 treated cells 
show an almost two-fold increase in cell number, compared to the cell number 
after 12 days of butyrate treatment, after only 24 hours of exposure.  Thus it can 
be seen that exCD23 caused an increase in EoL-1 proliferation. 
 
These findings indicate that exposure of EoL-1 cells to recombinant CD23 results 
in proliferation and not differentiation, with a significant increase in cell number 
compared to untreated cells. 
 
4.3.3  EXTRACELLULAR CYTOKINE PRODUCTION 
A representative plot of the flow cytometric bead analysis of the five cytokines 
analysed in the cell culture supernatants is shown in figure 4.10.  When gated on 
one of the microsphere populations, beads 4.4 or 5.5 µm, the dot plot Y-axis 
indicates the bead populations with distinct fluorescence intensities on the FL4 
channel giving a total of five different cytokines, as figure 4.10(b) shows.  For 
MCP-1, only one bead population will be shown as only one analyte is detected 
using the simplex kit (figure 4.10d).  The X-axis indicates the fluorescence 
intensities of the PE-conjugated detection antibody for each bead population.  
The fluorescence of each particular cytokine was calculated from a standard 
curve constructed and run within the same experiment (Annexure F, Figure F.1).    
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Figure 4.10 – Representative plot of the flow cytometric analysis of five 
cytokines (a and b) and MCP-1 (c and d) using a cytokine bead assay.  
Gating using a FS vs SS dot plot (a, c) could easily differentiate between 
the two different sizes of microspheres.  Each group of microsopheres (4.4 
and 5.5 µm) contained different bead populations internally dyed with 
different intensities of a fluorescent dye (b), while in the simplex kit only 
one bead population was used for the detection of MCP-1 (d).  The 
fluorochrome for bead differentiation was identified on channel FL4, while 
the specific cytokine of interest for each bead population was quantified by 
detection of mean fluorescence intensity on channel FL2, detecting the PE 
fluorochrome linked to the detection antibody. 
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The cytokines assayed in the extracellular bead assay kit included the Th1 
cytokine IFN-γ, the Th2 cytokines IL-4, IL-5 and IL-10, IL-8 which is neither a Th1 
nor Th2 cytokine, and MCP-1, a potent leukocyte chemoattractant.  A 24 hour 
study was performed, where undifferentiated cells were exposed to different 
treatments for 24 hours, with cytokine detection performed at 0, 4 and 24 hours 
using an aliquot of the culture supernatant for analysis.  The results of this 
experiment are shown in figure 4.11.   
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Figure 4.11 – Cytokine secretion by EoL-1 cells after 24 hour culture with 
CD23.  0.5 mM butyrate and 10 ng/ml exCD23 were used in the treatments.  
Cytokine concentrations were determined using a flow cytometric bead 
assay, and divided by the number of viable cells in the sample determined 
using the CellTitre-Blue® Cell Viability Assay.  Results are the mean of two 
independent samples.  The numbers next to the treatment name indicate 
the time, in hours, at which the sample was assayed. 
 
As figure 4.11 shows, the change in cytokine production by the viable cells was 
influenced by time.  After 4 hours of culture, there appeared to be an increase in 
all the cytokines for all the treatments compared to 0 hours and 24 hours.  The 
cytokine production after 24 hours appeared lower than the initial production at 
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time 0.  This change in secreted cytokine concentration over time is unusual, and 
may represent a cyclical pattern.  Hoffman et al. (2002) found that NF-κB 
production should be monitored at various time intervals and not at a single time 
point due to oscillations in the production of this nuclear factor.   Thus the 
cytokine production by EoL-1 cells may follow a similar pattern and needs to be 
further investigated. 
 
Unfortunately very few studies have reported the secretion of various cytokines 
by eosinophils, and most of the published results of this nature use purified 
human eosinophils.  The only available data for cytokine secretion from EoL-1 
cells deals with IL-8 and MCP-1, and is in a comparable range to the results 
obtained in this study. 
 
Figure 4.11 indicates that untreated EoL-1 cells constitutively produce a 
significant amount of the cytokines tested, with more IFN-γ produced by 
untreated cells than any of the treatments.  IL-10 was produced in small amounts 
but IL-8, IL-4, IL-5 and MCP-1 all appear to be significantly produced by the 
untreated cells over 24 hours.  These results are expected as Steube et al. 
(2000) reported the constitutive expression of IL-8 and MCP-1 by EoL-1 cells 
over a 24 hour period.  They published values between 50 and 100 pg/ml for 106 
cells.  Equivalent cell numbers and time period equate to values of approximately 
1260 pg/ml of constitutively expressed IL-8 in this experiment, and 290 pg/ml 
MCP-1, for 106 cells.  The results obtained in this study are higher than those 
published by Steube et al. (2000), but are still in a comparable range and can 
thus be expected.  The production of IFN-γ is, however, considerably greater 
than the other cytokines.  Woerly et al. (1999a) reported a production of low 
amounts of IFN-γ (10 pg/ml) from unstimulated human eosinophils.  IFN-γ 
production increased to a maximum of 180 pg/ml by CD28 ligation after 18 hours 
of treatment.  When equivalent cell numbers are used, a mean of approximately 
3000 pg/ml IFN-γ is obtained in this study with untreated cells.  This is much 
higher than that reported by Woerly et al. (1999a) for stimulated human 
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eosinophils, and the difference could lie in the use of the eosinophilic cell line 
EoL-1 in this study as Stuebe et al. (2000) suggest that cytokine production may 
be a common feature of malignant cells.  Eosinophils have been reported to 
release an average of 75 pg/ml IL-4 per 106 cells (Moqbel, 1996) for unstimulated 
cells.  This value is much lower than that obtained here, approximately 700 pg/ml 
for 106 EoL-1 cells.   
 
Dubucquoi et al. (1994) report a maximal production of 300 pg/ml of IL-5 after 18 
hours of stimulation of human eosinophils.  Unfortunately no cell numbers are 
reported so no direct comparisons can be made.  But the results of this study, for 
106 cells, give a mean of approximately 1000 pg/ml IL-5 production after 24 
hours of no treatment.  Human eosinophils stimulated for 18 hours with IgA-anti-
IgA complexes were found to produce IL-10 at a concentration of approximately 
35 pg/ml (Woerly et al., 1999a).  When equivalent cell numbers are compared, 
the untreated EoL-1 cells in this study produced approximately 160 pg/ml IL-10. 
 
The use of 0.5 mM butyrate, 10 ng/ml exCD23 and a combination of the two had 
no stimulatory effect on the cytokine production of the cells, and in fact appear to 
suppress the cytokine secretion by the EoL-1 cells.  All three treatments showed 
very similar results, with an increase at 4 hours, compared to 0 and 24 hours, 
and all treatments produced lower cytokine concentrations than the untreated 
control.        
 
A second cytokine secretion study was performed, culturing the EoL-1 cells 
under various conditions for 12 days.  The cells were cultured with different 
substances and cytokine analysis was performed after 12 days.  A further 
experiment involved the culture of the EoL-1 cells with butyrate to induce 
differentiation; followed by 24 hour treatment with various substances and 
subsequent cytokine analysis.  The results of these experiments are shown in 
figure 4.12. 
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Figure 4.12 – Cytokine secretion by differentiated EoL-1 cells.  Cytokine 
concentrations were determined using a flow cytometric bead assay, and 
divided by the number of viable cells in the sample determined using the 
CellTitre-Blue® Cell Viability Assay.  Results are the mean of two 
independent samples.  ª indicates the cytokine production at time 0, ¹ 
indicates the cytokine production after 12 days of treatment (MCP-1 
secretion was not analysed in this experiment), ² indicates 24 hour 
exposure of 12 day butyrate differentiated cells to the various substances. 
 
As figure 4.12 shows, the general trends seen in the 24 hour experiment (figure 
4.11) continue in the 12 day experiment.  These include the decrease in cytokine 
production after the peak at 4 hours, the insignificant role of exCD23 and 
butyrate on the production of cytokines from the EoL-1 cells when used alone or 
in combination, the prominence of IFN-γ as a secretory product from the cells, 
the low concentration of secreted IL-10, and with IL-4 and IL-5 showing similar 
trends to those seen in figure 4.11.  However, an interesting difference is clear in 
the untreated cells.  The IFN-γ concentration has decreased markedly from time 
0, while IL-8 production has increased noticeably, the same is seen for the TPA 
treated cells.   
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The 12 day treatment of EoL-1 cells with 10 ng/ml exCD23 and 0.5 mM butyrate 
appears to decrease the amount of cytokines secreted, especially IFN-γ and IL-8, 
when compared to the untreated cells, cultured for 12 days.  Both these 
treatments also reduced the cytokine secretion in the 24 hour experiment (figure 
4.11), when compared to the untreated control cells.  The effect of both exCD23 
and butyrate, and their combined effect, appears to be very similar. 
 
Twelve days of TPA treatment resulted in a significant increase in IFN-γ, IL-8, IL-
4 and IL-5 secretion by the EoL-1 cells.  In the cells treated with TPA for both 12 
days and over a 24 hour exposure period, the IL-8 concentration is very high 
when compared to the other cytokines analysed, although IFN-γ is also elevated.  
IL-8 has been reported to be a very abundant eosinophil cytokine (Moqbel, 
1996), thus the presence of this cytokine in such elevated concentrations is not 
surprising, especially after TPA treatment.  Steube et al. (2000) reported that 
TPA strongly enhanced or induced secretion of IL-8 from EoL-1 cells, indicating 
the involvement of protein kinase C activation in this process.  TPA also reduced 
the rate of cell proliferation throughout the time period (24 hours) of their 
experiment (Stuebe et al., 2000), and these results are confirmed in figure 4.8, 
with TPA significantly decreasing the cell numbers after 12 days of treatment 
(P=0.00596 for TPA treatment compared to untreated cells, and P=0.00607 for 
TPA and CD23 treatment, compared to untreated cells).  These authors 
concluded that EoL-1 cells may represent a very useful model to study cytokine 
gene induction, due to the high stimulation index obtained after TPA treatment.  
The results shown in figure 4.12 confirm this as TPA exposure increased 
production of all the cytokines analysed, when compared to the butyrate 
differentiated cells (pre-TPA treatment).  Although TPA treatment resulted in 
significantly reduced cell numbers, enormous cell clumps were observed when 
counting the cells.  The cytokine production after TPA treatment therefore 
originates from these huge clumps of healthy cells. 
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The large increase in cytokine production after 12 days of culture in the presence 
of TPA is expected as it is frequently used (Prussin and Metcalfe, 1995; Mascher 
et al., 1999; Pala et al., 2000; Baran et al., 2001; Duramad et al., 2004) as a 
strong supra-physiological stimulus in culture to demonstrate the potential of cells 
to synthesise cytokines (Sewell et al., 1997). 
 
The 24 hour exposure of the butyrate differentiated EoL-1 cells to exCD23 
appears to decrease the IFN-γ and IL-8 secretion compared to untreated cells, 
but the recombinant protein appears to have no effect on cytokine secretion 
when compared to the 12 day butyrate treated cells (i.e. pre-exCD23 treatment).   
 
The 12 day butyrate treated cells act as the control when comparing the 24 hour 
exposure treatments.  TPA appears to increase IFN-γ, IL-8, IL-4 and IL-5 when 
compared to this control.  Twenty four hour exposure of the differentiated cells to 
a combination of TPA and exCD23 resulted in the highest IL-8 and IFN-γ 
production of the three post-differentiation treatments.  Thus, the presence of the 
recombinant protein appears to have caused a synergistic effect with the TPA on 
cytokine production, in terms of IL-8 and IFN-γ.  Twelve day exposure of the EoL-
1 cells to the TPA and exCD23 combination also resulted in high cytokine 
concentrations, but not higher than TPA acting alone.  Thus the recombinant 
protein appears to counteract the stimulatory effect of the TPA, especially 
regarding IL-8, with IFN-γ secretion also lower than the TPA treatment alone.  
The cytokine producing effect of the exCD23 may therefore be short lived. 
 
Unfortunately, due to the limited reagents and hence inadequate number of 
replicates, no statistically significant relationships can be elucidated from these 
data.  This study can therefore be seen as a preliminary investigation into the 
cytokine production of EoL-1 cells, especially in response to exCD23.  
 
In order to simplify the data for ease of comparison, the results were converted 
into a Th1/Th2 ratio (figures 4.13 and 4.14).  Th1/Th2 ratios have been used 
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before in cytokine studies, with the IFN-γ/IL-10 ratio (Whetzel et al., 2007; 
Redwine et al., 2005; Sobue et al., 2001) and the IFN-γ/IL-4 ratio (Rachmiel et 
al., 2006; Myint et al., 2005; Dimitrov et al., 2004; Koarada et al., 2002) used 
extensively for comparisons.  In this study the IL-10 concentrations were very 
low, so the IFN-γ/IL-4 ratio was used, and this ratio is generally used as the most 
representative of a Th1 or Th2 profile (Girón-González et al., 2000). 
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Figure 4.13 – Effect of various treatments on the IFN-γ/IL-4 ratio secreted 
by EoL-1 cells after 24 hours of culture.  exCD23 was added at 10 ng/ml, 
while 0.5 mM butyrate was used.  Results are the means of two 
independent samples.  The numbers next to the treatment name indicate 
the time, in hours, at which the sample was assayed. 
           
Twenty four hour culture of the EoL-1 cells, with various substances, shows a 
change in the Th1/Th2 ratio over time, although the changes are fairly small and 
probably insignificant.  As figure 4.13 shows, untreated cells appear to have a 
cycle in which the ratio increases slightly from 0 hours to 4, then drops at 24 
hours.  Treatment with CD23 shows a similar pattern, but it is more pronounced, 
with a higher peak at 4 hours compared to 0 and 24 hours.  Treatment with 0.5 
mM butyrate appears to reverse this effect, with a peak at 24 hours, while the 
ratio at 4 hours is the lowest.  And when the recombinant protein and butyrate 
are used in combination, a different trend is seen, with the ratio decreasing from 
0 hours to 24 hours.  This decreasing Th1/Th2 ratio appears not to apply to the 
  144 
12 day treatment with the two substances (figure 4.14), as the butyrate and 
exCD23 treated cells show the highest ratio compared to the untreated, butyrate 
treated and exCD23 treated EoL-1 cells.  
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Figure 4.14 – Effect of various treatments on the IFN-γ/IL-4 ratio secreted 
by differentiated EoL-1 cells after 12 days of culture.  exCD23 was added at 
10 ng/ml, while 0.5 mM butyrate and 100 nM TPA were used.  Results are 
the mean of two independent samples.  ª indicates the cytokine production 
at time 0, ¹ indicates the cytokine production after 12 days of treatment, ² 
indicates 24 hour exposure of 12 day butyrate differentiated cells to the 
various substances. 
 
 TPA appears to decrease the Th1/Th2 ratio, with decreases seen for both the 12 
day treatment, compared to untreated cells, and for the 24 hour exposure of the 
differentiated cells, when compared to the butyrate treated cells.  The TPA and 
exCD23 combination, however, does not follow the same trend, and fairly high 
values are obtained for these treatments, compared to TPA alone, although 
these values are not as high as the recombinant protein acting alone.  Thus the 
exCD23 appears to counteract the effect of TPA, as seen in figure 4.12. 
 
It is difficult to see correct correlations of Th1/Th2 negative feedback 
mechanisms in extracellular assays since the collection of cytokines in the 
supernatant is analysed, and this may be affected by the half-life of a particular 
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protein and/or the amount of cytokine bound to receptors on the surface of target 
cells (Breen, 2002).  Thus, no truly significant relationships can be revealed from 
this Th1/Th2 data, but general trends can be elucidated.   
 
In summary, EoL-1 cells constitutively express a number of cytokines, in an 
apparent cyclical manner.  Treatment with TPA shows that these cells are 
capable of secreting large amounts of both Th1 and Th2 cytokines, establishing 
them as a useful model for the study of cytokine secretion and cytokine gene 
induction.  TPA treatment results in the highest cytokine secretion but also in the 
lowest Th1/Th2 ratio, suggesting a preferential increase in Th2 cytokines after 
TPA exposure.   
 
exCD23 appeared to counteract the stimulatory effect of TPA on cytokine 
secretion from the cells, although a short term synergistic effect on the secretion 
of IL-8, and possibly IFN-γ, was seen.  The protein could not however counteract 
the negative effect of TPA on cell number.  Treatment of the cells with the 
exCD23 and TPA combination resulted in a change in the Th1/Th2 ratios, 
compared to TPA alone, suggesting that it counteracts the effect of TPA on the 
Th1/Th2 ratios, possibly by suppressing the Th2 increase brought about by TPA.  
Treatment of the cells with the recombinant protein alone appeared to suppress 
the secretion of IL-8 and IFN-γ from the EoL-1 cells.   
 
Treatment with butyrate had a similar effect to exCD23 on the cytokine profiles, 
but a difference in the Th1/Th2 ratios for these two treatments was seen.  The 
recombinant protein and butyrate treatments had opposite effects on the 
differentiation of the cells, with butyrate treatment resulting in differentiated EoL-1 
cells and reduced cell number and viability, while exCD23 treatment favoured 
proliferation.  
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CHAPTER FIVE – CONCLUSIONS AND RECOMMENDATIONS 
 
The DNA for the low affinity IgE receptor, CD23, was successfully cloned into two 
bacterial expression vectors (pET 28 and pET 42), allowing expression of the 
ectodomain of this protein.  Although the use of Taq polymerase resulted in the 
misincorporation of two nucleotide bases, the resultant protein was not 
significantly different from the known sequence in terms of folding and activity, as 
determined by IgE binding. 
 
The addition of a GST•Tag™ on the N-terminal end of the exCD23 protein did 
not achieve the desired increase in solubility.  The ability to produce soluble, 
refolded recombinant CD23 would be extremely beneficial, and would save both 
time and reagents.  However, an improved method for CD23 purification was 
developed, using His•Tag™s, allowing for simple and rapid purification using Ni2+ 
IMAC.  The resultant protein preparation had a high purity, which was increased 
by the subsequent use of a gel filtration column to remove unfolded or misfolded 
aggregates.  The method established here is valuable as no buffer changes are 
required between chromatographic procedures, with good purity and yield of 
target protein.  In addition, the position of the His•Tag™ (i.e. N-terminal or C-
terminal) has no influence on IgE binding, thus simplifying planning of the cloning 
scheme. 
 
Although the purification method yielded pure recombinant protein, the 37 kDa 
exCD23 was unstable upon storage and showed degradation even after storage 
at -20°C in the presence of protease inhibitors.  The reason for this instability is 
unclear, and further investigations into this phenomenon would offer interesting 
results, and possibly shed some light on the formation of sCD23 from the 
membrane bound form.    
 
The effect of recombinant exCD23 on the human eosinophilic cell line, EoL-1, 
was investigated, in conjunction with butyrate and TPA.  Results indicated that 
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exCD23 was not able to differentiate the cells into mature eosinophil-like cells, 
although sCD23 has been reported to differentiate germinal centre B cells into 
plasma cells (Liu et al., 1991), as well as basophils and T cells from their 
respective precursors (Gould et al., 2003).  Mossalayi et al. (1997) report that 
sCD23 results in the differentiation of CD7+/CD3- thymic/bone marrow 
precursors.  But the results obtained in this study show clearly that exCD23 did 
not favour differentiation of the EoL-1 cells.  In contrast, it had a marked effect on 
the proliferation of the cells.  sCD23 has been shown to influence myeloid cells in 
a number of ways, and results not only in the differentiation of these cells, but 
also in proliferation (Mossalayi et al., 1997).  Treatment of differentiated EoL-1 
cells with exCD23 for only 24 hours caused a significant increase in cell 
numbers, while 12 day treatment of undifferentiated EoL-1 cells resulted in an 
almost two-fold increase in cell number, compared to untreated cells.  Thus the 
proliferative effect of exCD23 on EoL-1 cells is clear.    
 
exCD23 also affected the cytokine secretion of the EoL-1 cells, appearing to 
suppress cytokine secretion, especially IL-8 and IFN-γ secretion, when compared 
with untreated cells.  During an inflammatory reaction, eosinophils are attracted 
to the site of inflammation and infiltrate the tissues.  These activated cells then 
undergo degranulation and release their cytotoxic products and other 
inflammatory mediators.  Since exCD23 appeared to suppress the release of 
cytokines from the differentiated, hypodense eosinophilic cells, it is possible that 
this protein might be able to alleviate the harmful effects brought about by 
eosinophilic degranulation in allergic reactions.  However, this needs to be further 
investigated and future studies should include research into the effect of sCD23 
on the release of the cytotoxic proteins like MBP, ECP, EPO and EDN.  The 
cytokine assays were only performed in duplicate due to limited reagents, and 
thus need to be supplemented with further data to confirm the trends shown 
here, and to elucidate statistically significant relationships.  In addition, further 
investigation into the mechanism of this apparent cytokine suppression is 
strongly recommended. 
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Lynch et al. (1999) reported that human eosinophils did not release their 
cytotoxic products in suspension, and needed to be attached to a plate before 
the respiratory burst occurred.  Thus, it would be interesting to see if cell 
adhesion had any influence on the release of the cytokines measured in this 
study.  
 
The nuclear factor, NF-κB, is a major regulator of inflammatory mediators 
including a variety of adhesion molecules, acute-phase proteins and cytokines 
(Clifton et al., 2005).  Thus the apparent cyclical pattern of cytokine secretion 
seen in this study is not surprising, since it is regulated by NF-κB, which itself 
shows an oscillating concentration pattern (Hoffman et al., 2002)  In addition, a 
series of promoter mutation studies have shown that an NF-κB binding site acts 
as a predominant cis-acting element in IL-8 gene expression (Roebuck, 1999).  
Thus in order to investigate the mechanism of cytokine suppression in EoL-1 
cells by exCD23, further studies should explore the role of NF-κB in this process. 
 
NF-κB is activated by many factors that increase the inflammatory response, 
including cytokines, viral infection, oxidants and antigens (Kehlen et al., 1999).  
This activation leads to the coordinated expression of many genes that encode 
proteins involved in mediator synthesis and further amplification and perpetuation 
of the inflammatory response (Kehlen et al., 1999).  NF-κB is therefore an 
obvious target for anti-inflammatory treatment (Barnes and Karin, 1997). 
 
The close association of IL-8 and IFN-γ seen in this study is expected, as IFN-γ 
is known to influence IL-8 secretion from human cells including bronchial 
epithelial cells (Saunders et al., 1994) and macrophages (Sorimachi et al., 2003).  
The results obtained here suggest that IFN-γ augments IL-8 secretion in EoL-1 
cells, since when the IFN-γ concentration is high, so too is the IL-8 concentration.  
Higher concentrations of IFN-γ (>2 500 pg/ml/106 viable cells) strongly enhanced 
the production of IL-8 from the eosinophilic cells.  This relationship should also 
be further explored. 
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The results obtained in this study indicate that EoL-1 cells constitutively produce 
significant amounts of IFN-γ, IL-8, IL-4, IL-5 and MCP-1, and to a lesser degree 
IL-10.  This confirms their suitability as a useful model for cytokine studies, 
especially regarding the dramatic increase in cytokine secretion after TPA 
stimulation.  The possible secretion of other cytokines and mediators should also 
be further investigated. 
 
The butyrate differentiation experiments should be repeated with other 
concentrations tested for efficacy on EoL-1 cell differentiation.  Concentrations 
ranging between 0.5 mM and 400 mM are recommended, in order to find the 
optimum balance between maintaining the cell viability over 12 days of the 
experiment and allowing for sufficient differentiation with subsequent expression 
of the eosinophil-specific proteins.  A butyrate concentration slightly higher than 
0.5 mM is expected to achieve differentiation of a larger portion of the cell 
population, while maintaining suitably high viability over the course of the 
experiment. 
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ANNEXURE A – DNA and protein sequences of human CD23, and vector 
maps showing the recombinant plasmids 
 
atggaggaaggtcaatattcagagatcgaggagcttcccaggaggcggtgttgcaggcgtggg 
 M  E  E  G  Q  Y  S  E  I  E  E  L  P  R  R  R  C  C  R  R  G 
actcagatcgtgctgctggggctggtgaccgccgctctgtgggctgggctgctgactctgctt 
 T  Q  I  V  L  L  G  L  V  T  A  A  L  W  A  G  L  L  T  L  L 
ctcctgtggcactgggacaccacacagagtctaaaacagctggaagagagggctgcccggaac 
 L  L  W  H  W* D  T  T  Q  S  L  K  Q  L  E  E  R  A  A  R  N 
gtctctcaagtttccaagaacttggaaagccaccacggtgaccagatggcgcagaaatcccag 
 V  S  Q  V  S  K  N  L  E  S  H  H  G  D  Q  M  A  Q  K  S  Q 
tccacgcagatttcacaggaactggaggaacttcgagctgaacagcagagattgaaatctcag 
 S  T  Q  I  S  Q  E  L  E  E  L  R  A  E  Q  Q  R  L  K  S  Q 
gacttggagctgtcctggaacctgaacgggcttcaagcagatctgagcagcttcaagtcccag 
 D  L  E  L  S  W  N  L  N  G  L  Q  A  D  L  S  S  F  K  S  Q 
gaattgaacgagaggaacgaagcttcagatttgctggaaagactccgggaggaggtgacaaag 
 E  L  N  E  R  N  E  A  S  D  L  L  E  R  L  R  E  E  V  T  K 
ctaaggatggagttgcaggtgtccagcggctttgtgtgcaacacgtgccctgaaaagtggatc 
 L  R  M  E  L  Q  V  S  S  G  F  V  C  N  T  C  P  E  K  W  I 
aatttccaacggaagtgctactacttcggcaagggcaccaagcagtgggtccacgcccggtat 
 N  F  Q  R  K  C  Y  Y  F  G  K  G  T  K  Q  W  V  H  A  R  Y 
gcctgtgacgacatggaagggcagctggtcagcatccacagcccggaggagcaggacttcctg 
 A  C  D  D  M  E  G  Q  L  V  S  I  H  S  P  E  E  Q  D  F  L 
accaagcatgccagccacaccggctcctggattggccttcggaacttggacctgaagggggag 
 T  K  H  A  S  H  T  G  S  W  I  G  L  R  N  L  D  L  K  G  E 
tttatctgggtggatgggagccacgtggactacagcaactgggctccaggggagcccaccagc 
 F  I  W  V  D  G  S  H  V  D  Y  S  N  W  A  P  G  E  P  T  S 
cggagccagggcgaggactgcgtgatgatgcggggctccggtcgctggaacgacgccttctgc 
 R  S  Q  G  E  D  C  V  M  M  R  G  S  G  R  W  N  D  A  F  C 
gaccgtaagctgggcgcctgggtgtgcgaccggctggccacatgcacgccgccagccagcgaa 
 D  R  K  L  G  A  W  V  C  D  R  L  A  T  C  T  P  P  A  S  E   
ggttccgcggagtccatgggacctgattcaagaccagaccctgacggccgcctgcccaccccc 
 G  S  A  E  S  M  G  P  D  S  R  P  D  P  D  G  R  L  P  T  P 
tctgcccctctccactcttga 
 S  A  P  L  H  S  - 
 
Figure A.1 – Nucleotide and amino acid sequence of human CD23 (obtained 
from an NCBI Blast search (http://130.14.29.110/BLAST/index.shtml), 
accession number NM_002002).  The fist amino acid residue present in the 
cloned protein construct is shown as bold and underlined, while the 
modified amino acid residue, changed from tryptophan to methionine in the 
cloning scheme, is marked with an asterisk.  The codon modified to a start 
codon is underlined and italicised, while the primer binding sites are 
shown as underlined.  
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Figure A.2 – Vector map used for construction of the recombinant plasmid 
for expression of the GST•Tagged™ exCD23.  The restriction sites used for 
cloning are shown, in addition to the position of the tag and the DNA insert, 
relative to the position of the various other sequence landmarks present on 
the vector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.3 – Vector map used for construction of the recombinant plasmid 
for expression of the N-terminal His•Tagged™ exCD23.  The restriction 
sites used for cloning and the position of the tag and the DNA insert 
relative to the position of the various other sequence landmarks present on 
the vector are shown. 
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Figure A.4 – Vector map used for construction of the recombinant plasmid 
for expression of the C-terminal His•Tagged™ exCD23.  The restriction 
sites used for cloning are shown, in addition to the position of the tag and 
the DNA insert, relative to the position of the various other sequence 
landmarks present on the vector. 
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ANNEXURE B – Sequencing results and alignment for the N-terminal 
GST•Tagged™ protein 
 
 
GST    CTGGAAGAGAGGGCTGCCCGGAACGTCTCTCAAGTTTCCAAGAACTTGGAAAGCCACCAC 60 
CD23   CTGGAAGAGAGGGCTGCCCGGAACGTCTCTCAAGTTTCCAAGAACTTGGAAAGCCACCAC 720 
       ************************************************************ 
GST    GGTGACCAGATGACGCAGAAATCCCAGTCCACGCAGATTTCACAGGAACTGGAGGAACTT 120 
CD23   GGTGACCAGATGGCGCAGAAATCCCAGTCCACGCAGATTTCACAGGAACTGGAGGAACTT 780 
       ************ *********************************************** 
GST    CGAGCTGAACAGCAGAGATTGAAATCTCAGGACTTGGAGCTGTCCTGGAACCTGAACGGG 180 
CD23   CGAGCTGAACAGCAGAGATTGAAATCTCAGGACTTGGAGCTGTCCTGGAACCTGAACGGG 840 
       ************************************************************ 
GST    CTTCAAGCAGATCTGAGCAGCTTCAAGTCCCAGGAATTGAACGAGAGGAACGAAGCTTCA 240 
CD23   CTTCAAGCAGATCTGAGCAGCTTCAAGTCCCAGGAATTGAACGAGAGGAACGAAGCTTCA 900 
       ************************************************************ 
GST    GATTTGCTGGAAAGACTCCGGGAGGAGGTGACAAAGCTAAGGATGGAGTTGCAGGTGTCC 300 
CD23   GATTTGCTGGAAAGACTCCGGGAGGAGGTGACAAAGCTAAGGATGGAGTTGCAGGTGTCC 960 
       ************************************************************ 
GST    AGCGGCTTTGTGTGCAACACGTGCCCTGAAAAGTGGATCAATTTCCAACGGAAGTGCTAC 360 
CD23   AGCGGCTTTGTGTGCAACACGTGCCCTGAAAAGTGGATCAATTTCCAACGGAAGTGCTAC 1020 
       ************************************************************ 
GST    TACTTCGGCAAGGGCACCAAGCAGTGGGTCCACGCCCGGTATGCCTGTGACGACATGGAA 420 
CD23   TACTTCGGCAAGGGCACCAAGCAGTGGGTCCACGCCCGGTATGCCTGTGACGACATGGAA 1080 
       ************************************************************ 
GST    GGGCAGCTGGTCAGCATCCACAGCCCGGAGGAGCAGGACTTCCTGACCAAGCATGCCAGC 480 
CD23   GGGCAGCTGGTCAGCATCCACAGCCCGGAGGAGCAGGACTTCCTGACCAAGCATGCCAGC 1140 
       ************************************************************ 
GST    CACACCGGCTCCTGGATTGGCCTTCGGAACTTGGACCTGAAGGGGGAGTTTATCTGGGTG 540 
CD23   CACACCGGCTCCTGGATTGGCCTTCGGAACTTGGACCTGAAGGGGGAGTTTATCTGGGTG 1200 
       ************************************************************ 
GST    GATGGGAGCCACGTGGACTACAGCAACTGGGCTCCAGGGGAGCCCACCAGCCGGAGCCAG 600 
CD23   GATGGGAGCCACGTGGACTACAGCAACTGGGCTCCAGGGGAGCCCACCAGCCGGAGCCAG 1260 
       ************************************************************ 
GST    GGCGAGGACTGCGTGATGATGCGGGGCTCCGGTCGCTGGAACGACGCCTTCTGCGACCGT 660 
CD23   GGCGAGGACTGCGTGATGATGCGGGGCTCCGGTCGCTGGAACGACGCCTTCTGCGACCGT 1320 
       ************************************************************ 
GST    AAGCTGGGCGCCTGGGTGTGCGACCGGCTGGCCACATGCACGCCGCCAGCCAGCGAAGGT 720 
CD23   AAGCTGGGCGCCTGGGTGTGCGACCGGCTGGCCACATGCACGCCGCCAGCCAGCGAAGGT 1380 
       ************************************************************ 
GST    TCCGCGGAGTCCATGGGACCTGATTCAAGACCAGACCCTGACGGCCGCCTGCCCACCCCC 780 
CD23   TCCGCGGAGTCCATGGGACCTGATTCAAGACCAGACCCTGACGGCCGCCTGCCCACCCCC 1440 
       ************************************************************ 
GST    TC---------------------------------------------------------- 782 
CD23   TCTGCCCCTCTCCACTCTTGAGCATGGATACAGCCAGGCCCAGAGCAAGACCCTGAAGAC 1500 
       **                                                           
Figure B.1 – DNA sequencing results aligned with a published CD23 
sequence, accession number BC064417.  GST indicates the N-terminal 
GST•Tagged™ protein DNA sequence, CD23 indicates the published 
sequence, the numbers on the right show the position in the sequence, and 
the asterisks indicate proper alignment.   
 
 
 
 
 
 
  174 
 
GST    ----------------------------------------------IDTTQS???LEERA 5 
CD23   MEEGQYSEIEELPRRRCCRRGTQIVLLGLVTAALWAGLLTLLLLWHWDTTQSLKQLEERA 60 
                                                      *****   ***** 
GST    ARNVSQVSKNLESHHGDQMTQKSQSTQISQELEELRAEQQRLKSQDLELSWNLNGLQADL 65 
CD23   ARNVSQVSKNLESHHGDQMAQKSQSTQISQELEELRAEQQRLKSQDLELSWNLNGLQADL 120 
       ******************* **************************************** 
GST    SSFKSQELNERNEASDLLERLREEVTKLRMELQVSSGFVCNTCPEKWINFQRKCYYFGKG 125 
CD23   SSFKSQELNERNEASDLLERLREEVTKLRMELQVSSGFVCNTCPEKWINFQRKCYYFGKG 180 
       ************************************************************ 
GST    TKQWVHARYACDDMEGQLVSIHSPEEQDFLTKHASHTGSWIGLRNLDLKGEFIWVDGSHV 185 
CD23   TKQWVHARYACDDMEGQLVSIHSPEEQDFLTKHASHTGSWIGLRNLDLKGEFIWVDGSHV 240 
       ************************************************************ 
GST    DYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFCDRKLGAWVCDRLATCTPPASEGSAESM 245 
CD23   DYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFCDRKLGAWVCDRLATCTPPASEGSAESM 300 
       ************************************************************ 
GST    GPDSRPDPDGRLPTPSAPLHS* 266 
CD23   GPDSRPDPDGRLPTPSAPLHS  321 
       *********************       
Figure B.2 – Translated DNA sequence showing the exCD23 sequence, 
aligned with a published CD23 protein sequence, accession number 
AAH62591.  GST indicates the N-terminal GST•Tagged™ protein sequence, 
CD23 indicates the published sequence, the numbers on the right show the 
position in the sequence, and the asterisks indicate correct alignment.  The 
start codon is not shown as it is present in the tag sequence, N-terminal to 
the protein sequence, but the first amino acid present in the recombinant 
CD23 sequence is shown as bold and underlined.  The stop codon is 
shown by a bold asterisk.  The question marks show amino acid residues 
that could not be elucidated as the sequencing primers did not overlap. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  175 
ANNEXURE C – Sequencing results and alignment for the N-terminal 
His•Tagged™ protein 
 
 
N-term   ---------------------------------ATGGGCAGCAGCCATCATCATCATCAT 75 
CD23     AGACCTCCATCCCCAGCTGGGAGGTGGGGTGCAGGCAGGTGGGGGCACTGACAATCCCCC 600 
                                              *  *  * **    **        
N-term   CACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGACACCACACAGAGTCTAAAACAG 135 
CD23     CTCTCCACTCCTCTTCTCTCCCCCTCCCCAGACTGGGACACCACACAGAGTCTAAAACAG 660 
         * *  **     **  *  * * *  *    *   ************************* 
N-term   CTGGAAGAGAGGGCTGCCCGGAACGTCTCTCAAGTTTCCAAGAACTTGGAAAGCCACCAC 195 
CD23     CTGGAAGAGAGGGCTGCCCGGAACGTCTCTCAAGTTTCCAAGAACTTGGAAAGCCACCAC 720 
         ************************************************************ 
N-term   GGTGACCAGATGACGCAGAAATCCCAGTCCACGCAGATTTCACAGGAACTGGAGGAACTT 255 
CD23     GGTGACCAGATGGCGCAGAAATCCCAGTCCACGCAGATTTCACAGGAACTGGAGGAACTT 780 
         ************ *********************************************** 
N-term   CGAGCTGAACAGCAGAGATTGAAATCTCAGGACTTGGAGCTGTCCTGGAACCTGAACGGG 315 
CD23     CGAGCTGAACAGCAGAGATTGAAATCTCAGGACTTGGAGCTGTCCTGGAACCTGAACGGG 840 
         ************************************************************ 
N-term   CTTCAAGCAGATCTGAGCAGCTTCAAGTCCCAGGAATTGAACGAGAGGAACGAAGCTTCA 375 
CD23     CTTCAAGCAGATCTGAGCAGCTTCAAGTCCCAGGAATTGAACGAGAGGAACGAAGCTTCA 900 
         ************************************************************ 
N-term   GATTTGCTGGAAAGACTCCGGGAGGAGGTGACAAAGCTAAGGATGGAGTTGCAGGTGTCC 435 
CD23     GATTTGCTGGAAAGACTCCGGGAGGAGGTGACAAAGCTAAGGATGGAGTTGCAGGTGTCC 960 
         ************************************************************ 
N-term   AGCGGCTTTGTGTGCAACACGTGCCCTGAAAAGTGGATCAATTTCCAACGGAAGTGCTAC 495 
CD23     AGCGGCTTTGTGTGCAACACGTGCCCTGAAAAGTGGATCAATTTCCAACGGAAGTGCTAC 1020 
         ************************************************************ 
N-term   TACTTCGGCAAGGGCACCAAGCAGTGGGTCCACGCCCGGTATGCCTGTGACGACATGGAA 555 
CD23     TACTTCGGCAAGGGCACCAAGCAGTGGGTCCACGCCCGGTATGCCTGTGACGACATGGAA 1080 
         ************************************************************ 
N-term   GGGCAGCTGGTCAGCATCCACAGCCCGGAGGAGCAGGACTTCCTGACCAAGCATGCCAGC 615 
CD23     GGGCAGCTGGTCAGCATCCACAGCCCGGAGGAGCAGGACTTCCTGACCAAGCATGCCAGC 1140 
         ************************************************************ 
N-term   CACACCGGCTCCTGGATTGGCCTTCGGAACTTGGACCTGAAGGGGGAGTTTATCTGGGTG 675 
CD23     CACACCGGCTCCTGGATTGGCCTTCGGAACTTGGACCTGAAGGGGGAGTTTATCTGGGTG 1200 
         ************************************************************ 
N-term   GATGGGAGCCACGTGGACTACAGCAACTGGGCTCCAGGGGAGCCCACCAGCCGGAGCCAG 735 
CD23     GATGGGAGCCACGTGGACTACAGCAACTGGGCTCCAGGGGAGCCCACCAGCCGGAGCCAG 1260 
         ************************************************************ 
N-term   GGCGAGGACTGCGTGATGATGCGGGGCTCCGGTCGCTGGAACGACGCCTTCTGCGACCGT 795 
CD23     GGCGAGGACTGCGTGATGATGCGGGGCTCCGGTCGCTGGAACGACGCCTTCTGCGACCGT 1320 
         ************************************************************ 
N-term   AAGC*------------------------------------------------------- 799 
CD23     AAGCTGGGCGCCTGGGTGTGCGACCGGCTGGCCACATGCACGCCGCCAGCCAGCGAAGGT 1380 
         ****  
Figure C.1 – DNA sequencing results aligned with a published CD23 
sequence, accession number BC064417.  N-term indicates the N-terminal 
His•Tagged™ protein DNA sequence, CD23 indicates the published 
sequence, the numbers on the right show the position in the sequence, and 
the asterisks indicate proper alignment.  The start codon is shown in bold 
and underlined, while the tag sequence is italicised and underlined.  The 
stop codon is shown by a bold asterisk.  The codon for the internal 
methionine residue, the first amino acid in the exCD23 sequence, is shown 
as bold and underlined. 
 
 
 
 
  176 
 
N-term                             MGSSHHHHHHSSGLVPRGSHMDTTQSLKQLEERA 56 
CD23     MEEGQYSEIEELPRRRCCRRGTQIVLLGLVTAALWAGLLTLLLLWHWDTTQSLKQLEERA 60 
                                                        ************* 
N-term   ARNVSQVSKNLESHHGDQMAQKSQSTQISQELEELRAEQQRLKSQDLELSWNLNGLQADL 116 
CD23     ARNVSQVSKNLESHHGDQMAQKSQSTQISQELEELRAEQQRLKSQDLELSWNLNGLQADL 120 
         ************************************************************ 
N-term   SSFKSQELNERNEASDLLERLREEVTKLRMELQVSSGFVCNTCPEKWINFQRKCYYFGKG 176 
CD23     SSFKSQELNERNEASDLLERLREEVTKLRMELQVSSGFVCNTCPEKWINFQRKCYYFGKG 180 
         ************************************************************ 
N-term   TKQWVHARYACDDMEGQLVSIHSPEEQDFLTKHASHTGSWIGLRNLDLKGEFIWVDGSHV 236 
CD23     TKQWVHARYACDDMEGQLVSIHSPEEQDFLTKHASHTGSWIGLRNLDLKGEFIWVDGSHV 240 
         ************************************************************ 
N-term   DYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFCDRKLGAWVCDRLATCTPPASEGSAESM 296 
CD23     DYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFCDRKLGAWVCDRLATCTPPASEGSAESM 300 
         ************************************************************ 
N-term   GPDSRPDPDGRLPTPSAPLHS*                                       317 
CD23     GPDSRPDPDGRLPTPSAPLHS--------------------------------------- 321 
         *********************  
Figure C.2 – Translated DNA sequence showing the exCD23 sequence, 
aligned with a published CD23 protein sequence, accession number 
AAH62591.  N-term indicates the N-terminal His•Tagged™ protein 
sequence, CD23 indicates the published sequence, the numbers on the 
right show the position in the sequence, and the asterisks indicate correct 
alignment.  The start codon is shown in bold and underlined, while the tag 
sequence is italicised and underlined.  The stop codon is shown by a bold 
asterisk.  The first amino acid in the exCD23 sequence, an internal 
methionine, is shown as bold and underlined. 
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ANNEXURE D – Sequencing results and alignment for the C-terminal 
His•Tagged™ protein 
 
 
C-term   --------------------------------------ATGGGCAGCAGCCATCATCATC 266 
CD23     CCCAAGACC-TCCATCCCCAGCTGGGAGGTGGGGTGCAGGCAGGTGGGGGCACTGACAAT 595 
                                                   *  *  * **    **    
C-term   ATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGACACCACACAGAGTCTAA 326 
CD23     CCCCCCTCTCCACTCCTCTTCTCTCCCCCTCCCCAGACTGGGACACCACACAGAGTCTAA 655 
           *  * *  **     **  *  * * *  *    *   ******************** 
C-term   AACAGCTGGAAGAGAGGGCTGCCCGGAACGTCTCTCAAGTTTCCAAGAACTTGGAAAGCC 386 
CD23     AACAGCTGGAAGAGAGGGCTGCCCGGAACGTCTCTCAAGTTTCCAAGAACTTGGAAAGCC 715 
         ************************************************************ 
C-term   ACCACGGTGACCAGATGACGCAGAAATCCCAGTCCACGCAGATTTCACAGGAACTGGAGG 446 
CD23     ACCACGGTGACCAGATGGCGCAGAAATCCCAGTCCACGCAGATTTCACAGGAACTGGAGG 775 
         ***************** ****************************************** 
C-term   AACTTCGAGCTGAACAGCAGAGATTGAAATCTCAGGACTTGGAGCTGTCCTGGAACCTGA 506 
CD23     AACTTCGAGCTGAACAGCAGAGATTGAAATCTCAGGACTTGGAGCTGTCCTGGAACCTGA 835 
         ************************************************************ 
C-term   ACGGGCTTCAAGCAGATCTGAGCAGCTTCAAGTCCCAGGAATTGAACGAGAGGAACGAAG 566 
CD23     ACGGGCTTCAAGCAGATCTGAGCAGCTTCAAGTCCCAGGAATTGAACGAGAGGAACGAAG 895 
         ************************************************************ 
C-term   CTTCAGATTTGCTGGAAAGATTCCGGGAGGAGGTGACAAAGCTAAGGATGGAGTTGCAGG 626 
CD23     CTTCAGATTTGCTGGAAAGACTCCGGGAGGAGGTGACAAAGCTAAGGATGGAGTTGCAGG 955 
         ******************** *************************************** 
C-term   TGTCCAGCGGCTTTGTGTGCAACACGTGCCCTGAAAAGTGGATCAATTTCCAACGGAAGT 686 
CD23     TGTCCAGCGGCTTTGTGTGCAACACGTGCCCTGAAAAGTGGATCAATTTCCAACGGAAGT 1015 
         ************************************************************ 
C-term   GCTACTACTTCGGCAAGGGCACCAAGCAGTGGGTCCACGCCCGGTATGCCTGTGACGACA 746 
CD23     GCTACTACTTCGGCAAGGGCACCAAGCAGTGGGTCCACGCCCGGTATGCCTGTGACGACA 1075 
         ************************************************************ 
C-term   TGGAAGGGCAGCTGGTCAGCATCCACAGCCCGGAGGAGCAGGACTTCCTGACCAAGCATG 806 
CD23     TGGAAGGGCAGCTGGTCAGCATCCACAGCCCGGAGGAGCAGGACTTCCTGACCAAGCATG 1135 
         ************************************************************ 
C-term   CCAGCCACACCGGCTCCTGGATTGGCCTTCGGAACTTGGACCTGAAGGGGGAGTTTATCT 866 
CD23     CCAGCCACACCGGCTCCTGGATTGGCCTTCGGAACTTGGACCTGAAGGGGGAGTTTATCT 1195 
         ************************************************************ 
C-term   GGGTGGATGGGAGCCACGTGGACTACAGCAACTGGGCTCCAGGGGAGCCCACCAGCCGGA 926 
CD23     GGGTGGATGGGAGCCACGTGGACTACAGCAACTGGGCTCCAGGGGAGCCCACCAGCCGGA 1255 
         ************************************************************ 
C-term   GCCAGGGCGAGGACTGCGTGATGATGCGGGGCTCCGGTCGCTGGAACGACGCCTTCTGCG 986 
CD23     GCCAGGGCGAGGACTGCGTGATGATGCGGGGCTCCGGTCGCTGGAACGACGCCTTCTGCG 1315 
         ************************************************************ 
C-term   ACCGTAAGCTGGGCGCCTGGGTGTGCGACCGGCTGGCCACATGCACGCCGCCAGCCAGCG 1046 
CD23     ACCGTAAGCTGGGCGCCTGGGTGTGCGACCGGCTGGCCACATGCACGCCGCCAGCCAGCG 1375 
         ************************************************************ 
C-term   AAGGTTCCGCGGAGTCCATGGGACCTGATTCAAGACCAGACCCTGACGGCCGCCTGCCCA 1106 
CD23     AAGGTTCCGCGGAGTCCATGGGACCTGATTCAAGACCAGACCCTGACGGCCGCCTGCCCA 1435 
         ************************************************************ 
C-term   CCCCCTCTGCCCCTCTCGAGCACCACCACCACCACCACTGA*------------------ 1147 
CD23     CCCCCTCTGCCCCTCTCCACTCTTGAGCATGGATACAGCCAGGCCCAGAGCAAGACCCTG 1495 
         ***************** *                 *   * 
Figure D.1 – DNA sequencing results aligned with a published CD23 
sequence, accession number BC064417.  C-term indicates the C-terminal 
His•Tagged™ protein DNA sequence, CD23 indicates the published 
sequence, the numbers on the right show the position in the sequence, and 
the asterisks indicate proper alignment.  The start codon is shown in bold 
and underlined, while the tag sequences are italicised and underlined.  The 
stop codon is shown by a bold asterisk.  The codon for the internal 
methionine residue, the first amino acid in the exCD23 sequence, is shown 
as bold and underlined. 
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C-term                                 MGSSHHHHHHSSGLVPRGSHMDTTQSLKQL 117 
CD23     ----MEEGQYSEIEELPRRRCCRRGTQIVLLGLVTAALWAGLLTLLLLWHWDTTQSLKQL 56 
                                                            ********* 
C-term   EERAARNVSQVSKNLESHHGDQMTQKSQSTQISQELEELRAEQQRLKSQDLELSWNLNGL 177 
CD23     EERAARNVSQVSKNLESHHGDQMAQKSQSTQISQELEELRAEQQRLKSQDLELSWNLNGL 116 
         *********************** ************************************ 
C-term   QADLSSFKSQELNERNEASDLLERFREEVTKLRMELQVSSGFVCNTCPEKWINFQRKCYY 237 
CD23     QADLSSFKSQELNERNEASDLLERLREEVTKLRMELQVSSGFVCNTCPEKWINFQRKCYY 176 
         ************************ *********************************** 
C-term   FGKGTKQWVHARYACDDMEGQLVSIHSPEEQDFLTKHASHTGSWIGLRNLDLKGEFIWVD 297 
CD23     FGKGTKQWVHARYACDDMEGQLVSIHSPEEQDFLTKHASHTGSWIGLRNLDLKGEFIWVD 236 
         ************************************************************ 
C-term   GSHVDYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFCDRKLGAWVCDRLATCTPPASEGS 357 
CD23     GSHVDYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFCDRKLGAWVCDRLATCTPPASEGS 296 
         ************************************************************ 
C-term   AESMGPDSRPDPDGRLPTPSAPLEHHHHHH*                              387 
CD23     AESMGPDSRPDPDGRLPTPSAPLHS----------------------------------- 321 
         ***********************      
Figure D.2 – Translated DNA sequence showing the exCD23 sequence, 
aligned with a published CD23 protein sequence, accession number 
AAH62591.  C-term indicates the C-terminal His•Tagged™ protein 
sequence, CD23 indicates the published sequence, the numbers on the 
right show the position in the sequence, and the asterisks indicate correct 
alignment.  The start codon is shown in bold and underlined, while the tag 
sequences are italicised and underlined.  The stop codon is shown by a 
bold asterisk.  The first amino acid in the exCD23 sequence, an internal 
methionine, is shown as bold and underlined. 
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ANNEXURE E – BCA standard curve 
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Figure E.1 – Representative standard curve used for BCA protein 
determination.  Values are means ± SD (n=3).  The equation obtained from 
the linear regression analysis is shown on the graph, along with the R2 
value. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  180 
ANNEXURE F – Cytokine standard curves 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure F.1 – Cytokine standard curves used for the quantification of the 
cytokine concentrations in the bead array assay.  The particular cytokine 
being analysed is shown on top of the graph.  The equation obtained from 
linear regression is shown on each graph, along with the R2 value. 
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